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The history of renal transplantation with the use of a kidney from a human cadaver donor 
began in 1933 and many more were performed since then (1-4). Although most of these were 
technically successful, none of the recipients had really benefited from this new approach for 
the treatment of end-stage renal failure. It was with the transplantation of a kidney from a 
monozygotic twin in 1953, that a new phase in the evolution of renal transplantation started 
(5). To date, renal transplantation has become common practice and the best alternative 
amongst other modalities of renal replacement therapy (6). Apart from renal transplantation, 
transplantation of other solid organs, e.g. heart, lung, liver, pancreas, have found their way in 
clinical practice and in recent decades thousands of recipients have substantially benefited 
from this treatment.  
 
1.2 The main problems of organ transplantation 
 
1.2.1 Donor shortage 
 
Organ transplantation is unique among other surgical procedures, in that it critically depends 
on the donation of an organ or a partial organ from another person. Though since 1988 the 
number of organ donors has increased each year with an average of approximately 1100 
organs, the number of patients on the waiting list has increased much more dramatic, resulting 
in an average increase of 5000 patients each year. Worldwide, more than 147,000 patients are 
waiting for a life-saving organ transplant, but only about 40,000 organ transplants are 
performed each year (7).  
The need to bridge the gap between the increasing demand for organ donation and the relative 
stable supply of available organs have forced the transplant community to reevaluate donor 
selection criteria. Over the last decade, the ideal criteria for organ donor selection have been 
abandoned. Hence, more and more organs that would have been considered unsuitable for 
transplantation in the past are currently being used routinely. This has resulted in a new class 
of organ donors termed the "marginal" donors. The so called "expanded" donor pool, i.e. 
donors fulfilling the "extended criteria", consists of older donors or donors who have diabetes 
mellitus, hypertension, and renal insufficiency (8, 9). Today, the average donor is over 50 
year-old and the main cause of death is intracranial hemorrhage (10). The risk factors that are 
associated with poorer transplantation outcome using marginal donors include age, previous 
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diseases with a systemic influence on the vascular system (i.e. arterial hypertension, diabetes 
mellitus), cause of death (cardiovascular or cerebrovascular disease), and brain death (35, 36). 
Another alternative source for organ donors is the non-heart beating donor (NHBD). Death in 
these donors is defined as an irreversible cessation of circulatory and respiratory function. 
Thus, organs procured from NHBDs undergo prolonged hypotension and warm ischemia time. 
Historically, the use of NHBDs has been restricted to kidney donation, but, although limited, 
NHBDs have also been used in liver transplantation (11). A comparison of 377 NHBD kidney 
transplants to 12156 heart beating donor kidney transplants between 1995 and 1998 showed 
that though the NHBD group had inferior initial function, the 1-year and 3-year graft survival 
rates (85% and 73%) were not different from those in the heart beating donor group. Organs 
from NHBD may therefore be appreciated increasing importance for the cadaveric donor pool 
in the future (12). 
1.2.2 Graft rejection 
Vascularized organs, when transplanted into an immunocompetent recipient, are prone to 
immunological damage due to a variety of effector mechanisms. Several types of transplant 
rejection can be distinguished based on their time course of appearance and histological 
manifestation (13-15).  
Hyperacute and acute vascular rejection are both directed against donor endothelial cells, but 
they differ markedly in the onset, histology and mechanisms of destruction of the vasculature. 
Whereas hyperacute rejection immediately starts after reperfusion of the transplant, and is 
mediated by pre-existing antibodies and complement, acute vascular rejection starts within 
days to weeks and the relative importance of antibodies and complement in the pathogenesis 
of vascular rejection is unclear (16, 17). Acute vascular rejection is characterized by a 
profound thrombus formation and focal ischemia often associated with neutrophil and 
mononuclear cell infiltration (18). In contrast, in hyperacute rejection neutrophil infiltration is 
mostly lacking. 
Acute interstitial rejection differs from the former two types, in that it is defined by the 
infiltration of mononuclear cells into the tubuli, also referred to as ‘tubulitis’ (19). In fact, 
tubular cells, as opposed to endothelial cells in hyperacute and acute vascular rejection, are 
the target cells that are destroyed in this type of rejection (20, 21).  Acute interstitial rejection 
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occurs mostly within the first three months after transplantation and is exclusively mediated 
by alloreactive T-cells that recognize donor antigens on tubular cells. 
Chronic rejection is the most prominent factor for graft loss after transplantation. In renal 
allografts, chronic rejection, also termed chronic allograft nephropathy, is characterized by a 
relative slow rate of decline in renal function. The histopathological findings in chronic 
allograft nephropathy are atherosclerosis, glomerular sclerosis, multilayering of the 
peritubular capillaries, interstitial fibrosis and tubular atrophy (22). 
1.3 Relation between pre-transplantation injury and graft survival 
1.3.1 Response to injury hypothesis 
The hypothesis that tissue injury initiates allograft rejection was put forward in 1995 by Lu et 
al (23) and contains two implications. On one hand it postulates that tissue injury of the 
allograft is recognized by the immune system in the recipient. On the other hand it postulates 
that such recognition initiates allograft rejection. It should be noted however, that the 
presence of alloantigens is required to maintain immune reactivity. Several sets of 
observations support this hypothesis. Firstly, it has been demonstrated that in renal biopsies 
from autografts in dogs and allografts from identical twins, a mild inflammatory infiltration is 
still present (24). These grafts are not rejected since no mismatched alloantigens are present 
on the grafts, thus there is no alloimmune reaction in these cases. The observed inflammation 
must be due to injury during the transplant procedure. Secondly, if injury initiates rejection, 
severe injury should result in a greater incidence of rejection. Indeed, ample evidences 
suggest that severe injury makes renal allografts more prone to rejection (25). Thirdly, if 
injury initiates rejection, less injury should result in less rejection. This is also compatible 
with the observation of Terasaki et al (26) that transplant survival of renal allografts from 
living donors is superior to that of cadaver donors. Finally, if tissue injury initiates rejection, 
therapies which decrease injury during transplantation should also decrease the incidence of 
acute rejection. In fact, there are reports showing that the use of human recombinant 
superoxide dismutase and antibodies against intercellular adhesion molecule 1 (ICAM-1) or 
lymphocyte function associated antigen 1 (LFA-1), all of which reduce the extent of ischemia 
and reperfusion injury, can decrease acute rejection episodes (27-29).  
1.3.2 Living donors versus cadaveric donors 
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Based on the kidney transplant data of the United Network of Organ Sharing (UNOS) renal 
transplant registry, Terasaki et al (26) reported that the three-year graft survival of kidneys 
from living donors was much higher than that of kidneys from cadaver donors, despite a 
better HLA matching of the latter. This indicates that poor survival of grafts from cadaver 
donors can not be solely attributed to the difference in immunogenicity. According to the 
response to injury theory, the higher survival rate of renal transplants from living donors 
compared to that of cadaver donors should also be attributed to the fact that the latter suffer 
from more damage. All renal allografts suffer unavoidable injury from the transplant process 
during organ retrieval and the actual transplantation. However, allografts from cadaver donors 
are further injured by hemodynamic instability associated with brain death, trauma or acute 
illness in the donors and by prolonged cold storage while in transit from the donor to the 
recipient (30-33).  
The advantages for the use of a living donor in renal transplantation are summarized as 
follows: less pre-transplantation injury, better long-term patient and allograft survival, lower 
incidence of rejections, less immunosuppression, and reduced need for post-transplantation 
hospital visits and readmissions (34). 
1.3.3 Pre-transplantation injury 
1.3.3.1 Brain death 
Brain death is a dynamic course of events that influences organ allograft quality. At the onset 
of brain death, massive quantities of catecholamines are released within seconds, which 
causes an increase in heart rate and leads to vasoconstriction with increased vascular 
resistance and blood pressure (37-39). The more acutely brain death is imposed, the higher the 
peak catecholamine levels are (39). Already 30 seconds after brain death serum concentration 
of nonadrenaline, adrenaline and dopamine are significantly increased, and fall below baseline 
levels within one hour after brain death (40). Ultimately, a state of hypoperfusion is reached. 
This “autonomic storm” is believed to have important consequences for organ perfusion, 
inflammation and thereby damage to peripheral organs (41-43).  
Since brain death promotes inflammation in end-organs, affects hormone regulation and 
hemodynamic stability, it is generally accepted that it severely influences graft quality (44). 
Moreover, brain death is often associated with ischemia-reperfusion (I/R) injury (45) which 
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can further augment the proinflammatory state of the graft and thus increase graft 
immunogenicity (46, 47). In the sequel of brain death a rapid up-regulation of inflammatory 
mediators like IL-6 and TNFα occurs (48-51). This might in turn result in the upregulation of 
an array of genes including selectins, fibrinogen and kidney injury molecue 1 (KIM-1) (52). 
Brain death is considered to be a risk factor for organ dysfunction (43, 53) and accelerates 
acute rejection episodes (54-56).  
1.3.3.2 Cold preservation   
Allocation of donor organs has been made possible by success of organ preservation. The 
principles of organ preservation are hypothermia, prevention of cell swelling and acidosis 
(57). Hypothermia is an essential mean for slowing down cell metabolism and delaying 
injurious processes provoked by the deficiency of oxygen. Although hypothermic organ 
preservation is common practise in transplantation of solid organs, prolonged cold storage 
may lead to tissue damage and thereby it may have adverse effects on long-term 
transplantation outcome (58, 59).  
There are at least four components that are involved in cold ischemic transplant injury: the 
coupled effect of ischemia and hypothermia during cold storage and the coupled effect of 
reperfusion and rewarming after transplantation (69). The known mechanisms of cold 
ischemic injury are related to perturbations in osmoregulation, energetics, and aerobic 
metabolism (60). During hypothermic preservation, lack of oxygen leads to a rapid decline of 
intracellular ATP concentrations (61). Consequently, energy depletion leads to dissipation of 
ion gradients across the cell membrane as a result of an impaired function of the Na-K 
ATPase. Eventually, intracellular calcium increase (64) which in turn leads to mitochondrial 
calcium overload (66). Ischemia per se stimulates glycogenolyse, most likely via release of 
inosine (87), resulting in production of lactate and initiation of cellular acidosis (61).  
A number of studies have demonstrated that release of intracellular iron plays an important 
role in cell damage during cold preservation (65, 70). However, the intracellular source for 
this release has not clearly been defined. Since free iron leads to the generation of toxic 
hydroxyl radicals, and synthesis of glutathione and intracellular antioxidants are abolished as 
a result of ATP depletion, reactive oxygen species accumulate (62, 63), giving rise to massive 
cell destruction (66, 69).  
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Endothelial injury is a prominent feature of cold ischemia (67). In a rat model, it has been 
reported that renal allografts exposed to cold ischemia exceeding 6 hours develop progressive 
vascular injury and inflammation 24 hours after transplantation. This was characterized by an 
irregular PECAM staining and augmented VCAM-1 expression, accompanied by perivascular 
monocyte infiltration (71).  
Other studies have also demonstrated that prolonged cold ischemia is associated with more 
inflammation (72). Recipients of grafts with long cold ischemia experience early acute 
rejection more often than those with minimal cold ischemia and are at higher risk for delayed 
graft function (68, 73, 74). Thus, prolonged cold preservation severely influences long-term 
graft survival (59, 68). 
1.4 Donor preconditioning  
Because donor factors are important determinants of short and long-term allograft survival 
(75), optimal management of cadaver donors is clearly of high relevance for transplantation 
outcome. In this respect, the value of donor preconditioning has been appreciated and many 
different approaches to achieve this objective were successful. Most, if not all, of these 
strategies were aimed at reducing ischemia reperfusion (I/R) injury, a complex interrelated 
sequence of events that classically involves the vascular endothelium and activated leukocytes 
(76-79).  
It is important to emphasize that donor preconditioning has great advantages because it not 
only might improve transplantation outcome, but can also be achieved cost-efficiently without 
great effort or side effects for the recipient (96). Based on the principle being used, donor 
preconditioning can be divided into ischemic preconditioning and pharmacological 
preconditioning. 
1.4.1 Ischemic preconditioning 
In recent years, extensive studies have expanded the knowledge of the role of preconditioning 
for cardiac protection against IR injury. Exposing the heart to brief episodes of ischemia 
protects the myocardium and vascular endothelium against functional damage and cell death 
caused by subsequent prolonged ischemia, a phenomenon that is called ischemic 
preconditioning (IP) (80). The mechanisms of IP is complex and involves a variety of 
mediators and second messengers such as adenosine, protein kinase C, ATP-dependent 
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potassium channels and oxygen radicals (80-82). In addition to the heart, a beneficial effect of 
IP has been reported for liver, lung and intestinal allografts in experimental models (83-85). 
Both an early and late phase of protection has been identified in IP. In the early phase it is 
believed that IP preserves energy metabolism during sustained ischemia (86). Adenosine 
monophosphate activated protein kinase (AMPK) protects cells by acting as a low-fuel 
warning system that is switched on by ATP depletion (86). Whereas activation of AMPK 
concomitantly reduces ATP depletion, lactate accumulation and cell injury, inhibition hereof 
abrogates the beneficial effect of IP of liver allografts (86). 
The L-arginine nitric oxide (NO) pathway also seems to play a pivotal role in the protective 
effect of IP in both the early and late phase. This is based on the observations that 
preconditioning with inhaled NO protects against IR injury (83) and treatment of animals with 
nitric oxide synthase inhibitor diminishes the effect of IP (85).  
1.4.2 Pharmacological preconditioning 
Pharmacological preconditioning can be accomplished by treating the donor or allograft with 
compounds that can either prevent organ damage due to ischemia or prevent cell activation or 
infiltration of mononuclear cells upon reperfusion.  
As transendothelial migration of inflammatory cells relies on the presence of adhesion 
molecules on the endothelium, such as ICAM, VCAM, selectins, and their ligands on 
leukocytes (76-79), prevention of this particular interaction or expression of adhesion 
molecules is a widely used approach in animal models to limit infiltration of mononuclear 
cells into the allograft. The use of anti-sense ICAM constructs (88), and soluble ligands or 
antibodies against adhesion molecules have been shown to be successful in IR models (89-91).  
The transcriptional activation of inflammatory genes is tightly regulated by transcription 
factors, including nuclear factor–κB (NF–κB) (92-94). By perfusion a renal allogaft with NF-
қB decoy oligodeoxynucleotides prior to transplantation, a significant decrease in monocyte 
infiltration was observed (95). In addition, other studies have shown that donor pre-treatment 
with steroids significantly decreases tissue and serum expression of proinflammatory 
cytokines in brain dead human donors (97). Recently, carbamylated recombinant human 
erythropoietin (CEPO) was also demonstrated to be neuroprotective and renoprotective in 
experimental models of brain injury (98), cerebral ischemia (99) and brain death (100). 
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Catecholamines are frequently used in donor management to improve blood pressure. In two 
independent studies, Schnuelle et al found that donor catecholamine usage reduced the 
incidence of acute rejection episodes within the first month after transplantation and improved 
long term allograft survival after kidney transplantation of cadaveric allografts (103, 104). In 
rat models, dopamine pre-treatment was found to inhibit tubulitis (105) and to improve both 
short and long term outcome (106) after renal transplantation. Several possible mechanisms 
may account for this phenomenon. Firstly, catecholamines have the propensity to protect 
endothelial cells against cold preservation injury (107). Cold preservation also impairs 
endothelial barrier function, which is restored during rewarming when endothelial cells were 
pre-treated with catecholamines prior to cold storage (108). Therefore, dopamine pre-
treatment can maintain vascular integrity by limiting vascular permeability of solid organs. 
Secondly, catecholamines may mitigate the detrimental effect of acute traumatic brain death 
on the donors. As acute brain death is associated with a profound neuroendocrine 
dysregulation, often leading to hypotension, application of catecholamines may improve 
hemodynamic stability in these donors. Consistent with this is the observation by Schnuelle et 
al that the salutary effect of catecholamines was most pronounced in donors that had suffered 
acute traumatic brain death (103). Thirdly, explosive brain death is associated with cytokine 
production, expression of adhesion molecules and inflammation (41, 97). While 
catecholamines have been shown to be able to reduce the expression of these inflammatory 
mediators, this might contribute to the protective effect of donor catecholamine pre-treatment 
(102, 109). Catecholamines can also induce the production of the anti-inflammatory cytokine 
IL-10 in monocytes (110, 111). Fourthly, dopamine is capable to stimulate the induction of 
protective enzymes HO-1 in renal tubular epithelial and endothelial cells (112, 113). The 
induction of HO-1 has been reported to exert beneficial effects in a number of transplantation 
models (101), rendering the organ more resistant to the insult of ischemia reperfusion and 
inflammation. 
Recently, the use of gaseous agents for donor pre-treatment has gained more interest. Carbon 
monoxide (CO), a byproduct of heme catalysis by heme oxygenase, has shown to be 
cytoprotective as it induces vasorelaxation (114, 115), inhibits cell proliferation (116, 117) 
and apoptosis (118), suppresses inflammation (119, 121), protects organs against I/R injury 
(120, 122), and diminishes graft rejection (123). Low dose CO treatment also ameliorates 
ischemia/reperfusion injury of transplanted lung, liver, intestines and kidney in rat models 
(120, 124-126). As a novel approach to deliver CO, Motterlini et al (127, 128) has recently 
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developed a class of compounds, termed CO releasing molecules (CORMs), which are able to 
release CO in a controllable manner (129). Like CO, CORMs have potent anti-inflammatory 
effects (119), and improve vascular function by exerting significant vasodilation in rat aortas 
precontracted with phenylephrine (130). 
Nitric oxide (NO), normally synthesized from L-arginine by NO synthase, shares at least one 
common mechanism of action with CO, i.e. they both stimulate guanylate cyclase. The 
beneficial effect of NO has been demonstrated in mouse models using eNOS deficient donor 
(131). Cold ischemia/reperfusion injury in liver grafts from wild type donors was significantly 
attenuated compared to eNOS-deficient donors after liver transplantation (131). Although 
eNOS is an important source of NO production, during ischemia the endogenous nitrite pool 
may serve as alternative NO source when eNOS activity is compromised as a result of 
decreased oxygenation and increased acidosis (132). Recently, data from a number of 
experiments showed that nitrite administration before transplantation protects heart, liver and 
kidney against ischemia/reperfusion injury (133). 
Hydrogen sulphide (H2S) is a third gaseous mediator that protects against 
ischemia/reperfusion injury (134). Although these data look promising, more work is required 
for the potential use of H2S as a cytoprotective mediator in organ transplantation.  
1.5 Aims of this study 
Graft immunogenecity is not completely dependent on HLA differences between donor and 
recipient. Although allocation of renal allografts is based on HLA matching, the importance 
of this is often ignored due to the small (10%) difference in graft survival rates between the 
best and worst matched pairs (135). Also in liver transplantation, neither matching for HLA 
class I nor HLA class II has shown to influence transplantation outcome (136). As kidney 
transplants from unrelated living donors are performing exceedingly well despite poor HLA 
compatibility, the concept of tissue injury as important determining factor for long-term 
allograft survival has been more appreciated. Attempts should therefore be undertaken to limit 
tissue injury of the allograft before organ implantation. Cold preservation is a major cause of 
pre-transplantation injury, and hence it represents an important target for intervention. Since 
in retrospective studies the beneficial effect of donor catecholamine usage has been 
demonstrated, the aim of this thesis was to further elucidate in in vitro and in vivo models why 
catecholamines are protective. Emphasis was put on the vasculature because prolonged 
hypothermia is associated with endothelial barrier dysfunction, the endothelium is a major 
 Chapter 1: General introduction  
 
 21
player in inflammation, and above all, the vasculature is severely affected in chronic allograft 
vasculopathy. In particular, we assessed in an isolated ventilated and perfused lung model 
how cold preservation affects oedema formation and inflammation and if this was diminished 
by dopamine treatment. Furthermore, we made use of in vitro models to assess the processes 
that might lead to preservation injury and how these were influenced by dopamine. Efforts 
were also made to identify the structural entities within catecholamines that convey protection. 
Apart from catecholamines we also investigated CO-releasing molecules (CORM) as a mean 
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Endothelial barrier dysfunction severely compromises organ function after reperfusion. Since 
dopamine pre-treatment improves hypothermia-mediated barrier dysfunction, we tested the 
hypothesis that dopamine treatment of lung allografts positively affects tissue damage associated 
with hypothermic preservation and reperfusion.  
Rats were treated for 1 hour with dopamine (5μg/min/kg) or vehicle (NaCl). Thereafter lungs 
were explanted, flushed with Perfadex-solution and stored at 4°C for different time periods. Peak 
inspiratory pressure (PIP), pulmonary arterial pressure (PAP) and lung weight were measured 
online during reperfusion. Inflammatory mediators in the perfusate and the expression of 
adhesion molecules in situ were measured after perfusion.  
Lungs could tolerate a cold ischemia time (CIT) of up to 6 hours with stable PIP, PAP and no 
oedema formation upon reperfusion. CIT above 6 hours significantly increased PIP, PAP and 
pulmonary oedema in untreated but not in dopamine treated lungs (p<0.001 dopamine treated 
vs. untreated). Perfusion and ventilation alone induced a strong upregulation of cytokine-
induced neutrophil chemoattractant-1 (CINC-1) and adhesion molecules in untreated lungs, 
while in dopamine treated lungs significantly lower levels were found. Dopamine treatment 
also inhibited tissue damage associated with hypothermic preservation as measured by NADH 
staining. 
Our study suggests that donor dopamine treatment is a highly effective modality to maintain 
organ quality of lung allograft. These findings are of high clinical relevance because 
prevention of tissue damage might reduce complications associated with lung transplantation 
















Implementation of lung transplantation as treatment modality for patients with end-stage lung 
disease became possible because of significant improvements in surgical techniques, organ 
preservation and immunosuppression. Nevertheless, cold preservation and ischemia/reperfusion 
(I/R) injury still represent a genuine problem that limits the success of lung transplantation. Both 
factors can provoke non-specific alveolar damage, lung oedema and hypoxemia (1). This 
significantly contributes to the high incidence of graft failure (2) and the poor one-year graft 
survival (3) in lung transplant recipients. Because graft failure remains the leading cause for 
morbidity and mortality after lung transplantation, the success of lung transplantation will 
critically depend on successfully reducing the incidence of graft failure. 
In general, cold ischemia time (CIT) is considered to be an important factor for transplantation 
outcome, particularly in heart and lung transplant recipients (4). Deterioration in organ quality 
and function during cold ischemia is mediated by a series of events such as oxidative stress, iron 
release and intracellular calcium overload (4-6). This ultimately leads to cell death and hence to 
organ dysfunction.  
Many clinical complications that are associated with prolonged CIT of lung allografts are 
caused by the loss of endothelial barrier function (7-10). Tissue oedema occurs as a 
consequence of barrier dysfunction and is associated with an increase in pulmonary arterial 
and inspiratory pressure. Because hypothermia also impairs the Na+/K+-ATPase (4, 5), fluid 
homeostasis is dysregulated in the alveolar space during reperfusion and hence oedema 
formation will aggravate (12). Apart from oedema formation, reperfusion induces an 
unspecific inflammatory response (13-16). Endothelial barrier dysfunction and leukocyte 
extravasation often occur together. Although barrier function might contribute to leukocyte 
extravasation it is at present unclear to what extent. 
Previously, we could demonstrate in vitro that dopamine is not only able to prevent cold 
preservation-induced injury of endothelial cells but also promotes barrier function upon 
rewarming (5, 17). These effects were not receptor mediated and did not require de novo protein 
synthesis, but were likely dependent on the reactive oxygen species (ROS) scavenging properties 
of dopamine (5). Also clinical studies (18) and animal models (19) have demonstrated that donor 
dopamine pre-treatment beneficially affects immediate renal function and inflammation 
following warm and cold ischemia.  
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In the present study, we employed an isolated rat lung model to test the hypothesis that dopamine 
treatment of lung allografts positively affects tissue damage associated with hypothermic 
preservation and reperfusion. 
 
Materials and Methods 
 
Animals 
Wistar rats weighing 300-350g were obtained from Janvier, Rennes, France. Animals were 
kept under standard conditions and fed standard rodent chow and water ad libitum. All 
procedures were performed according to the Guide for the Care and Use of Laboratory 
Animals published by the National Academy of Sciences and were approved by German 
federal regulations (RP Karlsruhe, AZ: 35-9185.81/G-66/04). 
 
Anaesthesia and operative techniques 
Animals were anesthetized by intraperitoneal injection of thiopental (60 mg/kg). One group of 
rats (n=9) received dopamine (5μg/min/kg body weight) intravenously for one hour. The dose 
was chosen on the basis of studies performed in a rat model for warm and cold ischemia (19, 
20). Untreated rats served as control group (n=9). In both groups of animals a 14-gauge 
angiocatheter was inserted into the trachea by cervical tracheotomy. The animals were 
ventilated with a small animal respirator, using 95%O2 / 5%CO2 gas, a tidal volume of 2 ml 
and a rate of 60 breaths per min with 2cm H2O of positive end-expiratory pressure. Median 
sternotomy and thymectomy were performed to expose the heart-lung block. After heparin 
injection into the right ventricle (1000U/kg), a canula was placed into the main pulmonary 
artery through the right ventricular outflow tract and secured with 3–0 braided silk sutures. 
The left atrium and ventricle were amputated to vent blood. A warm (37°C) modified Krebs-
Henseleit-Buffer (NaCl: 118 mM, KCl: 4.7 mM, KH2PO4: 1.2 mM, NaHCO3: 24 mM, 
MgSO4: 1.2 mM, glucose: 11.0 mM, CaCl2: 1.7 mM and 2% bovine albumin), containing 
sodium bicarbonate to maintain the pH at 7.3 to 7.4 at 37°C, was used to perfuse the lung. The 
heart-lung block was mounted in a perfusion chamber and maintained at 37°C. Reperfusion 
was performed at a constant flow rate of 5ml/hr.  
 
Experimental Protocol 
Cold preservation was carried out by flushing the lungs with 20ml of cold (4°C) Perfadex 
solution through the main pulmonary artery. Thereafter, the heart-lung block was stored at 
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4°C for 4, 6 and 8 hours and subsequently reperfused at 37°C with warm Krebs-Henseleit-
solution for different time periods. Lungs not subjected to hypothermic preservation were 
directly ventilated and perfused for similar time periods. All groups consisted of at least 9 
animals. During reperfusion, lung oxygenation was assessed at 15, 30 60 90, 120 and 180 
minutes. In each experiment the organ-oxygenation was stable (data not shown). Mean 
pulmonary arterial pressure (PAP) and pulmonary inspiratory pressure (PIP) were measured 
continuously and recorded every ten minutes (MCG, Hottinger-Baldwin-Messtechnik, 
Germany). Lung weight was recorded online to assess oedema formation. The extent of 
pulmonary oedema was also quantified by wet/dry weight (W/D) ratios. To this end, the 
middle right lung lobe was weighted directly before and after drying (72 hours at 70°C). 




At the end of all experiments, lungs were snap frozen in liquid nitrogen. Cryostat sections (3-
5µm) were stained by an indirect immunoperoxidase technique. Briefly, ethanol-fixed 
sections were first incubated with PBS/BSA (5% w/v) and subsequently with 2% H2O2. 
Hereafter, the sections were incubated for 1 hour with ICAM or VCAM primary antibody 
(R&D Systems GmbH, Wiesbaden), followed by extensive washing and finally by incubation 
with a biotine-conjugated secondary IgG antibody for 1 hour. The sections were washed 6 
times in PBS/BSA and incubated with streptavidin-HRP for 30 min. Antibody binding was 
visualized by diaminobenzidine using Vectastain. All sections were counterstained with 
hematoxylin-eosin. ICAM and VCAM were assessed semiquantitatively using a grading scale 
from - to +++ (-: negative, +: weakly positive, ++: positive, +++: strongly positive). More 
than 20 fields of view were blindly evaluated at 40 times.  
 
Nicotinamide adenine dinucleotide (NADH) staining 
The NADH staining was used to assess cellular viability after cold storage (8 hours) and 
warm reperfusion (3 hours). Staining was performed essentially the same as described by 
Gettman et al (21). In brief, cryostat sections (5 µm) were rinsed twice with 0.1 M phosphate 
buffered saline (PBS) pH 7.4 and subsequently incubated for 1 hr at 37ºC with nitro blue 
tetrazolium (NBT) solution and NADH (both from Sigma, St. Louis MO). For 100 ml of 
solution 25 ml NBT, 25 ml of 0.1 M PBS and 50 mg of NADH dissolved in distilled water 
was prepared. The reaction was terminated by rinsing the sections with cold PBS.  
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Cytokine-Induced Neutrophil Chemoattractant-1 (CINC-1) 
CINC-1 concentration was measured in the perfusion solutions by ELISA (R&D Systems 
GmbH, Wiesbaden). Sensitivity of the ELISA was less than 0.08 pg/ml for CINC-1. Each 
experiment was performed at least five times and CINC-1 concentration for each individual 
sample was assessed in triplicate. 
 
RNase Protection assay (RPA) 
Total RNA was isolated from frozen lung tissue using Trizol reagent (Gibco BRL, Eggenstein, 
Germany). RPA was performed with the rCK1 cytokine Multi-Probe Template Set (riboQuant, 
PharMingen, Heidelberg, Germany) as recommended by the manufacturer. Briefly, a set of 
32P-labeled RNA probes were synthesized from DNA templates by T7 polymerase and 
hybridized overnight with 20µg of total RNA. Hereafter free probes and single-stranded RNA 
were digested with RNase H. The samples were loaded on a 5% denaturing polyacrylamide 
gel, dried and exposed to Omat MA Kodak film. The expression of each specific mRNA was 
quantified by densitometry. Two housekeeping genes, i.e. glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and L32 were included in each experiment. 
 
LightCycler Polymerase Chain Reaction (LC-PCR)  
500 ng of total RNA was reversed transcribed into cDNA. C-DNA was diluted in 20 µl DEPC-
treated water and stored at –20°C until analysis. Specific DNA standards were generated by PCR 
amplification of cDNA, purification of the amplified products, and quantification by 
spectrophotometry. LC-PCR of cDNA specimen and DNA standards were performed in a total 
volume of 20 µl, containing 2 µl FastStart DNA Master SYBR Green I, 10 pMol of gene-
specific forward and reverse primers and 2 mM MgCl. The following primers were used: 
VCAM-1: forward: 5’CAGAGATTCAATTCAGTGGCCC3’; reverse: 
5’TGAGACGGTCACCCTTGAACAG3’, ELAM forward: 
5’AGACTCCGGCATGTGGAATGA3’; reverse: 5’AACGCATTCACCACT3’ and S16 
forward: 5’CACCTAACCATACGCCTTGCTT3’; reverse: 5’TGGATCATAGGACAACTG3’. 
Before amplification, each sample was incubated for 2 minutes at 50°C followed by 5 minutes at 
95°C. Amplification of VCAM and ELAM was perfused in 40 and 45 amplification cycles 
respectively. Each cycle consisted of denaturation for 15 seconds at 95°C, annealing for 1 minute 
at 55°C and extention for 1 minute at 72°C. PCR efficiency was assessed from the slopes of the 
standard curves and was found to be between 90% and 100%. Linearity of the assay could be 
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demonstrated by serial dilution of all standards and cDNA. All samples were normalized for an 
equal expression of S16. Each experiment was repeated 3 times. 
 
Statistical analysis  
Data are shown as means ± SD. Comparisons were made using Wilcoxon’s rank sum test, 
one-way ANOVA or the Mann-Whitney U test. Statistical analysis was performed using Stat 
View 4.01 (Abacus Corporation Inc., Berkeley, CA). A p-value of less than 0.05 was 




Influence of cold preservation on PAP, PIP and oedema formation during reperfusion 
To investigate the influence of cold preservation on PAP, PIP and oedema formation, lungs 
from dopamine and vehicle treated rats were stored in Perfadex solution for 4, 6 and 8 hours, 
and subsequently perfused for 180 minutes with warm Krebs-Henseleit solution. Lungs not 
subjected to cold preservation were use for comparison. When cold preservation time was 4 
and 6 hours, the increase in lung weight did not significantly differ between lungs that were 
subjected to cold preservation and lungs that were not. This was irrespective of dopamine 
treatment (Fig. 1A). However, in lungs that were preserved for 8 hours, lung weight increased 
more than 4g within 35 minutes in lungs obtained from vehicle treated rats (n=9). Dopamine 
pre-treatment significantly prolonged the time of perfusion in these lungs, as only in 4 out of 
9 lungs weight increased more than 4g during the reperfusion period (Fig 1B, p<0.003, 

















Perfusion time (minutes) 






Perfusion time (minutes)  








 Chapter 2: DA limits pulmonary oedema and inflammation in lung allografts 
 
 34
























Figure 1 (A and B) Influence of dopamine pre-treatment on pulmonary oedema formation. 
Rats were pre-treated with dopamine (5µg/min/kg body weight) 1 hr before lung explantation 
(n=9; bold line). Untreated rats (n=10; dotted line) served as control. The lungs were 
subjected to cold preservation for 6 hr (A) or 8 hr (B) and subsequently reperfused with warm 
Krebs-Henseleit solution for 180 minutes. Lungs not subjected to cold preservation (n=9; 
striped line) served as additional control Kaplan-Meyer analysis was performed using delta 
(Δ) weight increase more than 4g as endpoint. Significant differences between the groups 
were only observed after 8 hr of cold preservation: dopamine pre-treatment and cold 
preservation vs naïve and no cold preservation *: p<0.05, No dopamine pre-treatment vs 
dopamine pre-treatment #: p<0.01 (by log-rank-test). C: Influence of cold preservation time 
on peak inspiratory pressure (PIP) and pulmonary arterial pressure (PAP). Rats were pre-
treated with dopamine (DA) (filled bars) as described in figure A and B or left untreated 
(open bars). Hereafter, the lungs were subjected to cold preservation for different time 
periods and subsequently ventilated and reperfused with warm Krebs-Henseleit solution for 
180 minutes. Each group consisted of 9 animals. The results are expressed as mean PAP or 
PIP ± SD measured at the end of the reperfusion period. *: p<0.01 no cp vs. 8h cp, #: p<0.05 
DA vs. without DA. 
 
Both, PIP and PAP also remained stable during 180 minutes of warm reperfusion in lungs that 
were preserved for 6 hours or less, but increased significantly when the preservation period 
lasted for 8 hours. Dopamine pre-treatment significantly blunted the increase in PIP and PAP 
during reperfusion (Fig 1C). 
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Figure 2 A: Influence of cold preservation time on CINC-1 production. Rats were treated 
with dopamine (DA) (filled bars) as described in figure 1 or left untreated (no DA) (open 
bars). Hereafter the lungs were either directly ventilated and perfused with warm Krebs-
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Immediately after cold preservation, the lungs were ventilated and perfused. CINC-1 
concentration was measured in the perfusate solution at the end of the reperfusion period. 
Each group consisted of 5 animals. The results are expressed as mean CINC-1 (pg/ml) ± SD. 
* p<0.01 DA vs. no DA, #: p<0.01 0 hours vs. 6 hr of cold preservation. B: Influence of 
dopamine treatment on TNFα mRNA expression. Total RNA was isolated from native lungs 
(n=5), from lungs, with 6 hr of cold preservation (6h cp) and from dopamine pre-treated 
lungs, also subjected to 6 hr of cold preservation (DA + 6h cp). RNA was either isolated 
before (open bars) or after ventilation and warm reperfusion (180 minutes). TNFα mRNA 
expression was measured by means of RPA and standardized for equal expression of GAPDH 
as described in materials All groups consisted of 6 animals. The results are expressed as 
mean TNFα/GAPDH ratio ± SD. * p<0.01 before vs. after reperfusion. 
 
To study if cold preservation might affect the inflammatory response after reperfusion, we 
assessed the production of the neutrophil chemotactic protein CINC-1 in the perfusate of 
lungs. In addition we tested, if dopamine pre-treatment influences CINC-1 production. In 
naïve lungs not subjected to cold storage, CINC-1 was clearly present in the perfusate 3 hours 
after perfusion. This was significantly inhibited by dopamine pre-treatment. In lungs from 
vehicle treated rats, CINC-1 production inversely correlated with the time of cold 
preservation. The production of CINC-1 in dopamine treated lungs remained low, even after 
prolonged 8 hours of cold preservation (Fig 2A). To assess the influence of cold preservation 
and dopamine treatment on other inflammatory mediators, a cytokine multi-probe RNAse 
protection assay was used. After reperfusion TNF α mRNA expression was upregulated. This 
was neither influenced by cold preservation time nor by dopamine pre-treatment (Fig. 2B). 
Similar results were found for IL-1α, IL-1β and IL-6 (data not shown).  
 
Similar as CINC-1 production, mRNA expression of VCAM-1 and ELAM were upregulated 
during warm reperfusion, only in lungs that were not subjected to cold preservation. 
Dopamine pre-treatment significantly inhibited the upregulation of these mRNA`s. 
Upregulation of VCAM and ELAM mRNA during reperfusion was less pronounced after cold 
preservation (Fig. 3). Immunhistological staining for ICAM-1 and VCAM-1 confirmed that 
upregulation of adhesion molecules was clearly more pronounced in naïve lungs, not 
subjected to cold preservation (Fig. 4 and Table 1). 
 
Tissue viability after cold preservation and warm reperfusion 
To study tissue viability after cold storage and reperfusion and if this was influenced by 
dopamine pre-treatment, we made use of the NADH histological staining. Although both 
lungs obtained from untreated and dopamine treated rats clearly showed a positive NADH 
staining after cold storage and subsequent 3 hours of warm reperfusion, the staining intensity 
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of the latter lungs was more prominent (Fig 5). Thus, suggesting that tissue viability was 




























Figure 3 Influence of dopamine treatment on VCAM-1 and ELAM-1 mRNA expression. Rats 
were treated with dopamine (DA) (filled bars) as described in figure 1 or left untreated (no 
DA) (open bars). Hereafter the lungs were either directly ventilated and perfused (vp) with 
warm Krebs-Henseleit solution for 180 minutes or subjected to 6 or 8 hr of cold preservation 
(6hcp and 8hcp respectively). Immediately after cold preservation, the lungs were ventilated 
and perfused for 180 minutes. Total RNA was isolated from the tissue and assessed for 
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normalized for equal S16 mRNA expression. Each group consisted of 5 animals. The results 
are expressed as mean adhesion molecule/S16 ratio ± SD. * p<0.01 DA vs. no DA, #: p<0.05 




Figure 4 Influence of dopamine treatment on ICAM expression. Rats were treated as 
described in Figure 1, with dopamine (A and C) or left untreated (B and D). Hereafter the 
lungs were directly reperfused and ventilated for 3 hr (A and B) or subjected to 8 hr of cold 
preservation before reperfusion and reventilation (3hr) was initiated. The results of a 
representative experiment (n=5) is depicted. Original magnification was Χ40. 
 
Table 1 Immunohistological staining for ICAM-1 and VCAM-1 in lung tissue 
ICAM VCAM 
 
+ DA - DA + DA - DA 
Native a  + + b - - 
No cold preservation c  + +++ ++ +++ 
Cold preservation c 6 hr ++ ++ ++ +++ 
 8 hr ++ ++ ++ +++ 
 
a: no cold preservation and no reperfusion, b: results are expressed semi-quantitatively: (-: 














Figure 5 Influence of dopamine treatment on tissue viability. Rats were treated with 
dopamine (A and C) or left untreated (B and D) as described in figure 1. The lungs were 
explanted and subjected to 8hr of cold preservation. NADH staining of lung tissue was 
performed after 180 minutes of warm reperfusion. Note a more intensive NADH staining in 
dopamine treated lungs. The results of a representative experiment (n=5) is depicted. 




In general, CIT negatively affects graft function and long-term graft survival after organ 
transplantation (22). As CIT increases, the quality of allografts deteriorates (22), which, in view 
of the danger hypothesis, might result in increased tissue immunogenicity. Since we previously 
could show that donor dopamine usage significantly decreased the incidence of delayed graft 
function after renal transplantation (20, 23, 24) and that dopamine improves endothelial barrier 
function after cold storage (17), we tested in the present study the hypothesis that dopamine 
treatment of lung allografts positively affects tissue damage associated with hypothermic 
preservation and reperfusion. 
The major findings of this study are: first, dopamine pre-treatment inhibits oedema formation 
and positively affects PAP and PIP, after cold preservation and warm reperfusion. Second, 
dopamine pre-treatment abrogates CINC-1 production during lung reperfusion. Third, dopamine 
pre-treatment inhibits the upregulation of adhesion molecules, i.e. ICAM-1. VCAM-1, ELAM, 
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during reperfusion, but it does not affect the production of TNFα, IL-1α, IL-1β and IL-6. Fourth, 
tissue viability is better maintained in dopamine pre-treated lungs after cold storage and 
reperfusion.  
Pulmonary oedema (PE) is a common problem in both organ donors and lung transplant 
recipients, contributing significantly to poor donor lung function (25). Implementation of donor 
management strategies to improve fluid handling of the lung, might therefore significantly affect 
immediate graft function and graft survival after lung transplantation. Our data on prevention of 
PE by dopamine pre-treatment are compatible with the findings of Ware et al (26) who showed 
that preharvest administration of dopamine in low to moderate doses was associated with faster 
alveolar fluid clearance and to a lower wet-to-dry ratio. These findings also imply that dopamine 
usage in donor management should not only be restricted to hemodynamic instable donors.  
The Na+/K+-ATPase is ubiquitously expressed and is essential for maintenance of membrane 
potential and cell volume (27) In addition, it is also implicated in lung oedema clearance by 
increasing active Na+ transport (28). Since prolonged cold preservation of lung allografts 
result in severe inhibition of the Na+/K+-ATPase (29), unsurprisingly, our data show that a 
cold preservation time beyond 6 hours results in profound oedema formation. Although 
dopamine inhibits the Na+/K+-ATPase activity in most tissues, e.g. brain (30) and kidney (31), 
there is also evidence that it increases the ability of the lungs to clear oedema via regulation of 
the alveolar epithelial Na+/K+-ATPase function (32, 33). This might explain our findings that 
pre-treatment of lungs with dopamine reduced PE during warm reperfusion in our model. 
Since PAP and PIP will increase as a consequence of PE, it is clear that dopamine also 
beneficially affects these parameters. 
In addition to the role of Na+/K+-ATPase on PE, endothelial barrier dysfunction is likely 
involved in this process. An increase in F-actin stress fibres, concomitantly with redistribution 
of adherence- and tight-junction proteins, leads to an imbalance between contractile and 
tethering forces in favor of barrier dysfunction (34). As the proper function of adherence- and 
tight-junction proteins is ATP dependent, cold preservation is an eligible condition for barrier 
dysfunction because cold preservation leads to ATP depletion (4). Inasmuch as in vitro 
studies show that dopamine pre-treatment cannot completely prevent redistribution of 
junctional proteins during hypothermia of endothelial cells, it does restore normal distribution 
of ZO-1 and VE-cadherin and barrier function upon rewarming (17). Furthermore, dopamine 
and structurally related molecules have the propensity to protect endothelial cells for necrosis 
during cold preservation (5).Therefore, prevention of endothelial damage and restoration of 
barrier function might both contribute to the reduction of PE in dopamine pre-treated lungs. 
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I/R injury is histological characterized by an inflammatory response, reflected by an increase 
in chemokine production, upregulation of adhesion molecules and production of pro-
inflammatory cytokines. De Perrot et al (35) have demonstrated that IL-8, released early 
during reperfusion, predicts graft function in human lung transplantation. In our model, 
dopamine pre-treatment inhibits CINC-1 production during reperfusion, a rat homologue for 
human IL-8. CINC-1 production was also reduced by cold preservation in a time dependent 
fashion. These findings are compatible with previous studies from our group using the same 
model (36) and with in vitro studies on renal epithelial cells (37). Although NADH staining is 
questionable to assess tissue viability, as false positive staining might occur (38), negative 
NADH staining is in general consistent with tissue non-viability. Because we observed a clear 
reduction in NADH staining after cold preservation, this might indicate that tissue viability is 
decreased in these lungs. The observed reduction in CINC-1 production after cold storage 
could therefore be due to tissue damage.  
In contrast to CINC-1 production, dopamine did not influence the upregulation of TNFα 
mRNA expression during reperfusion. The increased TNFα expression is likely originating 
from alveolar macrophages as was demonstrated by Zhao et al (39), Leo et al (40) and Ashish 
et al (41). Activated alveolar macrophages, in turn, can modulate the inflammatory response 
by activating alveolar epithelial cells (41). Although dopamine did not influence TNFα 
mRNA expression, the expression of ICAM-1, VCAM-1 and ELAM was decreased by 
dopamine. Since dopamine delays TNFα mediated upregulation of adhesion molecules (37), 
this might explain why a reduction in the expression of ICAM-1, VCAM-1 and ELAM was 
found in dopamine treated lungs despite no reduction in TNFα mRNA expression. 
In conclusion, our study demonstrates that dopamine pre-treatment significantly limits formation 
of PE during reperfusion of lungs, subjected to prolonged cold preservation. Moreover, 
dopamine might act as anti-inflammatory drug under these conditions, as it inhibits CINC-1 
production and the expression of adhesion molecules. Since poor immediate graft function is 
frequently observed in lung transplant recipients, strategies to maintain donor lung function are 
warranted. Donor dopamine usage has already proven to be beneficial after renal transplantation 
(23, 24) and seems to be an auspicious treatment modality to maintain organ quality of lung 
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Hypothermic injury: the mitochondrial calcium, ATP and 
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Catecholamines prevent hypothermic cell death which accounts for severe tissue damage and 
impaired allograft function after prolonged organ preservation. Here, we identified cellular 
processes which govern hypothermia-mediated cell death in endothelial cells and how they 
are influenced by dopamine. 
Lactate dehydrogenase assay, intracellular ATP, reactive oxygen species and reduced thio-
group measurement, intracellular calcium measurement and mitochondrial calcium staining 
were performed in the study.  
Intracellular ATP was almost completely depleted within 12 hrs of hypothermic preservation 
in untreated human umbilical vein endothelial cells (HUVEC), while dopamine pre-treatment 
significantly delayed ATP depletion. 4 hrs after hypothermia a redox imbalance was observed 
in untreated cells, which increased with the duration of hypothermia. The redox imbalance 
was primarily caused by depletion of SH reduction equivalents and was significantly inhibited 
by dopamine. In addition, hypothermia-induced Ca2+ influx and mitochondrial Ca2+ 
accumulation were both prevented by dopamine. The protective effect of dopamine was 
abrogated by ionomycin and sodium azide and partly by oligomycin and CCCP.  
Our data demonstrated that loss of intracellular ATP, generation of a redox imbalance and 
accumulation of intracellular Ca2+ underlie cold preservation injury. Dopamine improves the 



















Mitochondria are the major sites of ATP synthesis in eukaryotes. ATP is generated via 
oxidative phosphorylation (ox-phos), in which electrons are liberated from reduced substrates 
and finally delivered to O2. Approximately 2% of consumed oxygen is converted into reactive 
oxygen species (ROS). During ox-phos, the respiratory chain complexes (complex I-IV) 
establish an H+ gradient, which is then utilized to drive ATP synthesis via complex V, i.e. 
ATP synthase. ROS production ensues from the activity of the respiratory chain. The 
superoxide anion is produced at two major sites in the respiratory chain, i.e. in the 
ubiquinone- (Q) cycle via the ubisemiquinone radical intermediate (1, 2) and in complex I 
through a backward electron transfer from succinate to NAD+ (3). Manganese superoxide 
dismutase (MnSOD) converts superoxide into hydrogenperoxide which, in turn, is reduced to 
hydroxyl radicals by Fenton chemistry (4). Apart from their role in ATP synthesis, 
mitochondria also play a pivotal role in other cellular processes such as calcium (Ca2+) 
homeostasis (5, 6).  
Under physiological conditions mitochondrial Ca2+, ATP synthesis and ROS production are 
tightly regulated in a discrete balance, designated as the love-hate triangle (7). Ca2+ is a 
physiological stimulator of ox-phos to balance mitochondrial ATP output and cellular ATP 
demand (8-10). However, when mitochondrial Ca2+ overload occurs, Ca2+ becomes patho-
physiologically relevant and is embodied in the regulation of opening of the mitochondrial 
permeability transition (MPT) pore. Opening of the MPT pore is mediated by high 
mitochondrial Ca2+ concentrations [Ca2+]m and is facilitated by ROS. The mitochondrial 
membrane potential completely dissipates at a high open probability (PO) of the MPT pore. 
Unstable membrane potential and redox transitions can occur under a variety of pathological 
conditions, e.g. ischemia/reperfusion injury, and might have negative consequences for 
mitochondrial integrity and cellular survival (11, 12). 
Hypothermia and ischemia are two major hurdles in hypothermic organ preservation as they 
negatively affect mitochondrial function. Although it has been acknowledged that prolonged 
hypothermic preservation of organ allografts is detrimental to organ viability (13), the cellular 
events leading to hypothermic injury have not been elucidated completely. Nevertheless, 
various studies have highlighted the importance of ROS production, impairment of Ca2+ 
homeostasis and ATP depletion in hypothermic injury (14, 15). 
In order to handle cold ischemic conditions, hibernating mammals have developed a number 
of strategies to limit the problems of Ca2+ homeostasis, ATP synthesis and ROS production. A 
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decreased ox-phos (16), the expression of uncoupling proteins in brown adipose tissue (17), 
as well as an increased Ca2+ uptake in the sarco-/ endoplasmic reticulum (18, 19) are amongst 
mechanisms used by hibernating mammals to adapt to long periods of hypothermia and 
reduced oxygen pressure. 
We and others have demonstrated that dihydroxyphenolic compounds (20-22) and iron 
chelators (23, 24) can protect endothelial- and tubular epithelial cells against hypothermia 
mediated cell death. In the present study we hypothesized that these compounds mediate 
protection by balancing the mitochondrial Ca2+ - ATP - ROS love-hate triangle during 
hypothermia. 
 
Materials and methods 
 
Cell isolation and culture 
Human umbilical vein endothelial cells (HUVEC) were isolated from fresh umbilical cords as 
described previously (25). The cells were cultured in endothelial cell growth medium (EGM) 
(Promocell, Heidelberg, Germany) in T25 flasks (Greiner, Frickenhausen, Germany) coated 
with gelatine (1%). Confluent monolayers were passaged by Trypsin/EDTA (Sigma-Aldrich, 
St. Louis, MO). Characterization of endothelial cells was performed on the basis of a positive 
uptake of acetylated LDL, Factor VIII related antigen and PECAM (CD31) expression, and a 




HUVEC were incubated for 2hrs with 25µM of dopamine (DA, Fresenius Kabi Deutschland 
GmbH, Bad Homburg, Germany). The culture flaks were washed 3 times with 1ml of PBS 
(Invitrogen, Karlsruhe, Germany) and stored for 24hrs at 4°C in HTK-, UW-solution or 
phenol-red free medium (Promocell). Since there was no difference between the use of the 
preservation solutions or phenol red free medium with respect to cell damage after 
hypothermic preservation, in all experiments described in this paper, the cells were stored in 
phenol-red free medium. In some experiments EDTA, BAPTA-AM, thapsigargin, 
myxothiazole, Na-azide, oligomycin, ionomycin, CCCP (carbonyl cyanide 3-
chlorophenylhydrazone) (all from Sigma-Aldrich, St. Louis, MO) were added to the medium 
during hypothermia. 
 




Lactate dehydrogenase assays were performed as recommended by the manufacturer (Roche 
Diagnostics, Mannheim, Germany). Briefly, HUVEC were plated in 24-well plates, grown 
until confluence and stimulated with 25µM dopamine (DA) for 2hrs. The plates were washed 
3 times with 1ml of PBS and stored for 24hrs at 4°C in phenol-red free medium. A 100µl 
aliquot of each supernatant was used to determine LDH release. In each experiment 100µl of 
phenol-red free medium was used as blank. The results are expressed as OD490nm, corrected 
for the blank value. 
 
Measurement of reactive oxygen species 
The intracellular formation of reactive oxygen species (ROS) was detected using the 
fluorescent probe CM-H2-DCFDA (Invitrogen, Karlsruhe, Germany) according to the 
manufacturer’s instructions. The formation of superoxide anions and hydroxyl radicals can 
both be assessed by this method. HUVEC grown in 96-well plates were pre-treated with 
25µM DA for 2hrs. Then the cells were loaded with 10µM of CM- H2-DCFDA for 45min at 
37°C. The cells were incubated at 37°C and 4°C respectively and analysed by serial 
measurements in a Spectra Fluor Plus Fluorescent 96-well plate reader (Tecan Deutschland, 
Crailsdorf, Germany). 
 
Assessment of SH reduction equivalents  
Intracellular “-SH groups” were quantified with a standard assay based on the reduction of 
5,5’ Dithiobis-2-Nitrobenzoic acid (DTNB, Sigma). Cells were lysed in 10mM Tris-buffer w/ 
1% Triton X-100 (Sigma), followed by centrifugation at 15,000rpm for 10 minutes. The 
supernatant was incubated with phosphate buffer containing DTNB at room temperature for 
60 minutes. The quantification was conducted at 412nm using a spectrophotometer (Spectra 
Fluor Plus 96-well plate reader, Tecan). 
 
Assessment of intracellular ATP 
Confluent HUVEC monolayers were treated for 2hrs with 25µM dopamine or left untreated. 
Subsequently the cells were washed and stored at 4°C. Intracellular ATP was extracted at 
serial time points and measured by luciferase driven bioluminescence using the ATP 
Bioluminescence Assay Kit CLS II (Roche Diagnostics, Mannheim, Germany). 
 
Confocal microscopy for mitochondrial calcium staining 
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Reduced Rhod-2 AM (Invitrogen, Karlsruhe, Germany) was used to detect mitochondrial 
calcium levels. Rhod-2 AM stock solution dissolved in DMSO (Sigma) was incubated with 
Na-borohydride (NaBH4, Sigma) solution for 10 minutes at room temperature. HUVECs 
cultured on coverslips were incubated with phenol-red free medium containing 5µM 
dihydroRhod-2 AM at 37°C for 40 minutes. The cells were washed with PBY twice and 
subjected to 4°C. In some cases cells were simultaneously co-incubated with MitoTracker 
Green (200nM, Invitrogen, Karlsruhe, Germany). Fluorescence images were obtained by 
confocal microscopy (Leica TCS SP2, Leica Microsystems, Heidelberg, Germany) under 
corresponding excitation and emission wave lengths. Quantification was performed by image 
analysis (Leica confocal software) and the results were expressed as relative levels of 
fluorescence intensity. 
 
Measurements of intracellular Ca2+ concentrations 
Measurements of intracellular Ca2+ concentrations were performed according to Koppel et al. 
(26). HUVEC were incubated with phenol-red free medium containing 4µm Fura-2 AM 
(Invitrogen, Karlsruhe, Germany) at 37°C for 1hr. The cells were washed with PBS twice and 
treated with dopamine for 2hrs. After washing the cells with PBS twice, phenol-red free 
media was added and the cells were subjected to 4°C for 3hrs. Coverslips were then mounted 
into a thermostatically regulated microscope chamber. A Zeiss Axiovert 35 (Zeiss, Hanau, 
Germany) inverted fluorescence microscope, equipped with a fluor 40/1.30 oil immersion 
objective and a charge-coupled device imaging camera (General Scanning, Planegg, 
Germany), was employed to detect fluorescence changes. Dual wavelength excitation at 340 
and 380 nm was performed by an imaging system (Till Photonics, Planegg, Germany).  After 
calibration, the following equation was used to relate the intensity ratios to cytosolic calcium 
levels: cytosolic calcium=Kd Q(R-Rmin)/(Rmax-R). 
 
Statistical analysis 
For statistical analysis unpaired Student’s t-test (Stats Direct 2.2.2) was applied when 




Influence of hypothermia on intracellular ATP concentrations 
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Human umbilical vein endothelial cells (HUVEC) are extremely susceptible to hypothermic 
injury. Nevertheless, resistance can be acquired by appropriate pre-treatment using dopamine 
or related compounds, as evidenced by an inhibition of LDH release. In dopamine pre-treated 
HUVEC, protection against hypothermic injury was transient, lasting for approximately 48hrs 
(fig. 1A).  
To gain further insights into why dopamine pre-treated HUVEC are protected against 
hypothermic injury, we investigated changes in intracellular ATP levels during hypothermia. 
In HUVEC, 90 % of intracellular ATP was rapidly lost during the first 12hrs. Although 
dopamine pre-treatment resulted in a significant retardation of ATP depletion, ATP levels still 
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Figure 1 A: Dopamine pre-treatment renders HUVEC transiently resistant to hypothermia 
induced cell death. Untreated HUVEC (black circles) and dopamine treated (25µM for 2hrs) 
HUVEC (open circles) were subjected to hypothermia for different time periods. Directly 
after cold storage cell viability was assessed by LDH release in supernatants. All 
experimental conditions were performed in triplicate. The results of a representative 
experiment are expressed as mean LDH release ± SD. A total of 4 experiments were 
performed. B: Loss of intracellular ATP during hypothermia in HUVEC. Untreated HUVEC 
(black circles) and dopamine pre-treated (25µM for 2hrs) HUVEC (open circles) were 
subjected to hypothermia as in A. ATP concentrations were assessed before and directly after 
various time points of hypothermia. All experimental conditions were performed in triplicate 
The results are expressed as mean % of ATP ± SD relative to the amount of ATP before 
hypothermia. A total of 5 experiments were performed.  
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We next assessed whether hypothermia is affecting the intracellular redox balance. At early 
time points after hypothermia, ROS production was not significantly different from control 
cells kept at 37°C. Four hours after initiation of hypothermia however, the amount of SH-
reduction equivalents was significantly decreased (fig. 2A). As hypothermia continued, ROS 
production decreased approximately by 50 % while the amount of SH-reduction equivalents 
dropped to less than 10% after 24hrs (fig. 2B). Similarly, in dopamine pre-treated HUVEC, 
ROS production was decreased during hypothermia, but the loss of SH-reduction equivalents 
was significantly lower in these cells (fig. 2A and B). To assess to what extent loss of SH-
reduction equivalents and ROS production affects the redox balance, we calculated the 
ROS/SH ratio. In untreated versus dopamine treated HUVEC, the ROS/SH ratio was 2- and 7-




A                                                                           B 
 
Figure 2 Influence of hypothermia on intracellular redox balance of HUVEC. The amount of 
free SH-reduction equivalents and the production of ROS were assessed in untreated HUVEC 
(black bars) and dopamine pre-treated (25µM for 2hrs) HUVEC (grey bars) 4hrs (A) or 
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24hrs (B) after initiation of hypothermia. SH-reduction equivalents and ROS produced in 
HUVEC kept at 37ºC for 4hrs (in Figure 2A) or for 24hrs (in Figure 2B) (open bars) was 
taken as 100 %. In A and B, the results are expressed as mean % of free SH-reduction 
equivalents or % of ROS ± SD relative to cells kept at 37ºC. All experimental conditions were 
performed in triplicate, a total of 5 experiments were performed. C: The ratio of ROS and free 
SH-reduction equivalents after 4 and 24hrs of hypothermia. The results are expressed as 
mean ROS/SH ratio ± SD for all 5 experiments (*: p<0.01, unpaired t-test). 
 
 
Role of Ca2+ in hypothermia mediated cell death 
The loss of ATP and the redox imbalance during hypothermia can affect calcium homeostasis 
by impairing ATP dependent ion channels. We therefore tested if a calcium influx occurs 
during hypothermia and if this was required for cell death. Our results showed that the 
addition of EDTA to the preservation solution completely prevented hypothermia mediated 
cell death in HUVEC (fig 3A). In time-course experiments, the addition of EDTA could 
Figure 3 A                                                         B                                                                                                
 
Figure 3 Role of Ca2+ in hypothermia mediated cell death. A: Untreated HUVEC were stored 
for 24hrs at 4ºC in the absence (black bar) or presence (open bar) of 10mM EDTA. In 
addition, DA pre-treated (25µM for 2hrs) HUVEC (grey bars) were included in the 
experiments as positive control. Supernatants were collected and assessed for LDH release. B: 
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points after initiation of hypothermia. Supernatants were collected after 24hrs of hypothermia 
and assessed for LDH release. In A and B, results are expressed as mean LDH release ± SD. 
All experimental conditions were performed in triplicate, a total of 4 experiments have been 
performed. C: Cytosolic [Ca2+] was measured in untreated (black bars) and DA pre-treated 
(white bars) HUVEC after 3hrs of hypothermia. Cells were subjected to hypothermia in the 
absence or presence of 10mM EDTA. The results are expressed as mean [Ca2+] ± SD. A total 
of 4 experiments were performed, comprising at least 50 cells for each condition. D: HUVEC were 
pre-treated with 25µM DA for 2hrs and subsequently subjected to hypothermia for 24hrs in the 
absence or presence of thapsigargin (10µM) or ionomycin (10µM). Untreated HUVEC stored 
for 24hrs at 4ºC in the presence or absence of BAPTA (10µM) or in the presence of EDTA 
and thapsigargin (10µM) were also included in these experiments. Supernatants were 
collected and assessed for LDH release. The results are expressed as mean LDH release ± SD. 
All experimental conditions were performed in triplicate, a total of 4 experiments were done (*: 
p<0.01, unpaired t-test).     
 
prevent hypothermia mediated cell death when administered for up to 4hrs after initiation of 
hypothermia. Beyond this time point, addition of EDTA did not protect HUVEC from cell 
death. Similarly, when dopamine was added at different time points after hypothermia it was 
not protective when the cells were already subjected to hypothermia for more than 2hrs (Fig 
3B).  
Intracellular [Ca2+], measured after the first 3hrs of hypothermia, was significantly higher in 
untreated than in dopamine treated HUVEC. When EDTA was added to the preservation 
solution no increase in intracellular [Ca2+] occurred (Fig 3C). While addition of the calcium 
ionophore ionomycin completely abolished the protective effect of dopamine, this was not 
observed in the presence of EDTA. Similarly, addition of thapsigargin to release Ca2+ from 
intracellular stores, only affected dopamine mediated protection but not that of EDTA (Fig 
3D). The intracellular Ca2+ chelator BAPTA-AM was also protective against hypothermia 
mediated cell death.  
To investigate if an increased Ca2+ influx resulted in mitochondrial Ca2+ accumulation, the 
mitochondrial calcium indicator Rhod-2 was used to assess changes in [Ca2+]m. The 
specificity of Rhod-2 for mitochondrial calcium was demonstrated by double labelling with 
Mitotracker green. Because entry of Rhod-2 in the mitochondria is completely dependent on 
the mitochondrial membrane potential, the specificity of Rhod-2 was also tested by adding 
CCCP to destroy the mitochondrial membrane potential. Based on the time-course 
experiments with EDTA, we anticipated that calcium entry would occur within the first 4hrs 
of hypothermia. 3hrs of hypothermia led to a strong increase in [Ca2+]m, which was 
significantly inhibited by dopamine pre-treatment (Fig. 4). Like dopamine, BAPTA-AM 
prevented mitochondrial Ca2+ accumulation. The effect of dopamine on the mitochondrial 
Ca2+ influx could be overcome by ionomycin. 
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Figure 4  A 
 






























Figure 4 Ca2+ is accumulated in mitochondria during hypothermia. A: HUVEC were 
incubated 2hrs prior to cold storage with 25µM DA or not. The cells were washed and 
labelled with Rhod-2 and Mitotracker-green directly before hypothermic preservation. 3hrs 
after initiation of hypothermia, the cells were analysed by confocal microscopy using the 
corresponding excitation and emission wave lengths. Specificity of Rhod-2 staining for 
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absence of Rhod-2 staining when the cells were treated with CCCP to dissipate the 
mitochondrial membrane potential. B: HUVEC were pre-treated with 25µM of DA for 2hrs and 
subsequently subjected to hypothermia in the absence or presence of ionomycin (10µM). 
Untreated HUVEC stored at 4ºC in the presence or absence of BAPTA (10µM) were also 
included in these experiments. HUVEC were labelled prior to cold storage as in A. Rhod-2 
fluorescence was measured 3hrs after initiation of hypothermia. The results are expressed as 
mean Rhod-2 fluorescence intensity ± SD (*: p<0.01, unpaired t-test). A total of 4 experiments 
were performed, comprising at least 30 cells for each condition.  
 
Respiratory chain inhibitors 
A consequence of mitochondrial Ca2+ accumulation is MPT and loss of mitochondrial 
membrane potential (∆Ψ). During hypothermia, dopamine prevents the loss of ∆Ψ [22]. We 
tested if respiratory chain inhibitors (myxothiazol, Na-azide), an inhibitor of ATP synthase 
(oligomycin) and an uncoupler (CCCP), all of which are known to generate mitochondrial 
ROS, were able to overcome the protective effect of dopamine or EDTA. Myxothiazol (data 
not shown) and Na-azide both abrogated the protective effect of dopamine completely (Fig 5). 
Oligomycin and CCCP were less effective in this regard. It must be stressed that none of these 
compounds influenced cell viability when tested in similar concentrations on HUVEC that 
were kept at 37ºC (data not shown). In the presence of EDTA, HUVEC were still protected 
from hypothermia mediated cell death, even when Na-azide, CCCP or oligomycin were added 
to the cells (Fig 5).  




Figure 5 Influence of respiratory chain inhibitors and ionomycin on dopamine’s protective 
effect. Prior to cold storage, HUVEC were pre-treated with 25µM of DA for 2hrs or left 
LDH release (490nm) 
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untreated. Hereafter the cells were subjected to hypothermia for 24hrs in the absence or 
presence of ionomycin (10µM), oligomycin (10µM), Na-azide (10µM) or CCCP (10µM). In 
untreated cells hypothermia was performed in the presence or absence of 10mM of EDTA. 
Supernatants were collected and assessed for LDH release. The results are expressed as 




In the present paper we studied the importance of  redox imbalance, changes in calcium 
homeostasis and depletion of ATP in hypothermia mediated cell death and evaluated the 
mechanisms by which dopamine protects against these deleterious effects. The main findings 
of this study are: first, hypothermia leads to a redox imbalance. This is not the result of an 
increased ROS production but rather due to depletion of SH-reduction equivalents. Second, 
hypothermia leads to a calcium influx, which in turn results in an increased mitochondrial 
Ca2+ concentration ([Ca2+]m). Third, hypothermia leads to ATP depletion. Fourth, dopamine 
pre-treatment of HUVEC renders the cells transiently resistant to hypothermia induced cell 
death. The loss of SH-reduction equivalents is significantly less, ATP depletion is retarded 
and mitochondrial calcium accumulation is significantly inhibited under these conditions.  
Recently, the role of Ca2+ in cold preservation damage of liver endothelial cells and 
hepatocytes has been questioned (27). It was suggested that cold induced injury occurred 
predominantly via an iron dependent pathway. Because EDTA, BAPTA-AM and even 
dopamine, also have the propensity to chelate iron, our results do not unequivocally point out 
towards a critical role for Ca2+ in this process. Yet, if iron chelation is the major mechanism 
by which dopamine exerts its protective effect, a number of issues have to be addressed. 
Importantly, it does not explain why dopamine prevents intracellular Ca2+ accumulation. 
Furthermore, it does not explain why Ca2+ release from the intracellular stores can overcome 
the protective effect of dopamine. The protective effect of dopamine is strictly redox 
dependent (22), however, we can not exclude that oxidation of dopamine impairs the ability to 
chelate iron. Unpublished findings also have shown that protection mediated by dihydroxy 
phenolic compounds, was only observed when the hydroxyl groups were in ortho- or para- 
but not in meta-position. While any of these compounds are able to chelate iron, the meta-
dihydroxy phenolic compounds cannot be oxidized, and hence cannot donate reduction 
equivalent. This also emphasizes that iron chelation is unlikely underlying the protective 
effect of dopamine.  
There is convincing evidence that redox potential can influence Ca2+ release from the 
endoplasmatic reticulum (ER) (28). Koshita et al (29) found that Ca2+ release from the 
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sarcoplamatic reticulum could be induced by oxidizing compounds and that this was blocked 
in the presence of GSH. In untreated HUVEC depletion of SH-reduction equivalents occurred 
already within 4 hrs of hypothermic preservation. Although the mechanism by which this 
occurred, i.e. oxidation or release from the cell, has not been addressed in this study, it is an 
eligible condition that could lead to Ca2+ release from the ER. Subsequently, Ca2+ might enter 
the cells via store-operated channel, leading to a critical Ca2+ concentration in the cytosol (30-
32). A number of observations are in line with this sequel of events. Firstly, at early time-
point dopamine completely prevented the depletion of SH-reduction equivalents. Although at 
24 hrs also in dopamine treated cells SH-reduction equivalents were partially depleted, this 
was significant less compared to untreated cells. Secondly the protective effect of dopamine 
could be abrogated by thapsigargin, a compound that prevents the re-uptake of Ca2+ in the ER 
and hence results in partial depletion of Ca2+ from the ER through leakage into the cytosol. 
Because thapsigargin could not abrogate cell protection when cold preservation was 
performed in the presence of EDTA, this indicates that the amount of Ca2+ released from the 
ER is not sufficient for cell death and that cell death dependents on additional Ca2+ influx.  
This study does not argue against an important role for iron in cold preservation injury. In fact, 
a number of studies already have shown the importance of iron in this respect. Kerkweg et al. 
(23) have demonstrated that the chelatable iron-pool is increased during hypothermia. 
Moreover, studies using deferoxamine have clearly demonstrated the beneficial effect of iron 
chelating on hypothermia mediated cell death (23, 24). Over-expression of HO-1 has also 
been shown to be beneficial with respect to hypothermic preservation injury (33). This is 
partly mediated via the generation of CO as reviewed by Nakao et al. (34). CO can bind iron 
directly and hence might prevent the formation of hydroxyl radicals by Fenton chemistry. 
Formation of radicals in conjunction with depletion of SH-reduction equivalents will result in 
a redox imbalance, thereby linking the iron dependent pathway with Ca2+ overload.  
Since ATP is required to maintain Ca2+ homeostasis, it can be argued that suppression of 
mitochondrial activity under hypothermic conditions might be the initial event leading to Ca2+ 
overload. Based on time course experiments however, an increased [Ca2+]m was evident 
within 3hrs of hypothermia, while ATP depletion was marginally influenced at this time-point. 
Although in dopamine treated cells ATP depletion was also observed after 24 hrs of 
hypothermic preservation, we have previously demonstrated that at this time-point the 
mitochondrial membrane potential (∆Ψ) was still intact (22). Inasmuch as respiratory chain 
inhibitors or uncouplers could overcome the protective effect of dopamine, this was unlikely 
due to an impaired ATP generation as hypothermia per se is associated with a decreased 

















mitochondrial activity. Nevertheless, these compounds are able to generate mitochondrial 
ROS production (33), which subsequently might leak to the cytosol, oxidize dopamine and 
thus abolish its protective effect. 
Based on our results and data from the literature we propose the following model of 
hypothermic preservation injury as depicted in Figure 6. We are aware that this model should 
not be generalized for all cells or tissues. Nevertheless, it explains why the protective effect of 
dopamine is redox dependent and why dopamine prevents Ca2+ overload during hypothermic 
preservation.   
 














Figure 6 Proposed model for hypothermia mediated damage and mechanism by which 
protection can be achieved. 
 
 
What are the possible implications from this study for organ preservation? One important 
implication is that during organ preservation cellular calcium entry must be prevented. To 
avoid the deleterious effects of Ca2+ accumulation in the cells, Ca2+ has been omitted from 
most preservation solutions (35). However, these solutions are not completely devoid of Ca2+ 
since a small amount of this cation is likely to be present in the solvent. Moreover, complete 
omission of Ca2+ can lead to opening of unselective cation channels and hence to membrane 
depolarization. In fact, addition of small amounts of calcium to preservation solutions has 
proven to be more protective in experimental liver transplantation (36, 37). Based on the 
deferoxamine
Calcium influx (outside-inside)
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proposed model, prevention of cellular calcium entry can be achieved either by reducing iron 
mediated oxidative stress or by preventing the occurrence of a redox imbalance. In the present 
study we have demonstrated that dopamine is capable to prevent redox imbalance. Because 
this phenomenon is not exclusive for dopamine, but holds true for other hydrophobic 
dihydroxyphenolic compounds (22), the use of such compounds devoid of hemodynamic 
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Previous studies have demonstrated that catecholamines protect endothelial cells against cold 
preservation-induced damage. Based on the differences in potency of protection amongst 
catecholamines and related substances, we hypothesized that variation of the molecular 
structure may yield more efficacious compounds.  
Modification of dopamine by an alkanoyl group greatly improved efficacy of protection. This 
was associated with increased cellular uptake and loss of hemodynamic action. Further 
variation revealed that only compounds bearing two hydroxyl groups in ortho- or para-
position at the benzene nucleus, i.e. strong reductants, were protective and the protective 
efficiency were correlated with logP value. Although a strong reducing capacity was required 
for protection, general antioxidants, e.g. N-acetyl cysteine and ascorbate, did not prevent cold 
preservation-induced cell damage. Similarly, inhibition of NADPH oxidase had no effect on 
cell viability during hypothermia. Although dopamine increases heme oxygenase 1 (HO-1) 
expression, its protective effect is not mediated by this enzyme as shown by knockout 
experiments. In conclusion, our data demonstrate that protection against cold preservation 
injury by catecholamines is exclusively mediated by two structural entities, i.e. strong 














Hypothermic preservation of allografts is common practice in transplantation medicine. 
However, organ quality deteriorates with increasing cold ischemia time. Thus, hypothermic 
preservation is also a major cause of pre-transplantation injury (1, 2). The mechanism behind 
prolonged hypothermic preservation damage has been the subject of many studies over the 
past decades. Ultimately, these studies have resulted in major improvements of preservation 
techniques and cold storage solutions. Already in the early days of organ preservation, it 
became evident that hypothermic preservation leads to ATP depletion, dysregulation in 
calcium homeostasis and eventually cell swelling (3). The use of hyperosmolaric solutions 
has been shown to limit the problem of cell swelling, however, the problems that are 
associated with ATP depletion during hypothermic preservation of solid organs are not solved 
yet.  
The ATP-dependent endothelial barrier function, which prevents paracellular transport of 
proteins and solutes, is severely compromised during hypothermic preservation. This is due to 
the rearrangement of endothelial adherence and tight junction proteins as well as to changes in 
F-actin, vimentin and α-tubulin expression (4). The loss of endothelial barrier function might 
explain the formation of tissue oedema in allografts that have been subjected to long periods 
of hypothermic preservation.  
In hibernating mammals body temperature can decrease as low as 4°C without causing any 
apparent harm to these animals. Even when body temperature is increasing during short 
periods of arousal, no tissue damage occurs. This tolerance against hypothermia is an adaptive 
response, which, from an evolutionary point of view, has been lost in men. Catecholamines 
play a pivotal role in the hibernation response as they inhibit apoptosis of brown adipose 
tissue in a beta-receptor dependent fashion (5). Interestingly, we have demonstrated that 
catecholamines have the propensity to protect human endothelial cells against cold 
preserevation-induced damage (6, 7). This protection is not receptor mediated, does not 
require de novo protein synthesis and is completely abolished by prior oxidation of 
catecholamines (8). It is also clear from other studies that several catechol-containing 
compounds, e.g. bioflavonoids or other structures that are readily oxidized to form (homo-) 
quinones (9), behave similar to catecholamines with regard to their cryoprotective effect. 
Therefore, we believe that structural entities within these compounds might be collectively 
responsible for protection. Amongst these entities, the catechol moiety is of particular interest. 
Catechols, i.e. ortho-dihydroxyphenols, can be readily oxidized and therefore can act as 
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scavenger for reactive oxygen species (ROS) (10). Moreover, catechols are of critical 
importance for iron acquisition in prokaryotes, by virtue of their ability to bind iron (10, 11). 
As has been shown for deferoxamin, iron chelation protects cells against hypothermia-
induced injury (12). 
As implicated by their nomenclature, all catecholamines contain the catechol structure. Yet, 
they differ extremely in their efficacy to protect endothelial cells against hypothermic 
preservation injury (8).  This suggests that apart from the catechol moiety, also the amine side 
chain must play an important role in protection.  
We hypothesized that modification of the catecholamine structure will yield more efficacious 
compound. In the present study we investigated the molecular entities within catecholamines 
that convey protection, by systematic variation of their molecular structure. This included 
alterations in their lipophilicity, by attachment of various alkyl- or aryl-derived residues in the 
amine side chain and alterations in their reducing capacity by modifications of the 
substituents at the benzene nucleus. As a consequence, these newly synthesized molecules 
strongly differ in logP values and reducing capacities, thus enabling to dissect the structural 
requirements for catecholamines that convey protection.  
 
Materials and Methods  
Cell isolation and culture 
Human umbilical vein endothelial cells (HUVEC) were isolated from fresh umbilical cords as 
described previously (25). The cells were cultured in endothelial cell growth medium (EGM) 
(Promocell, Heidelberg, Germany) in T25 or T75 flasks (Greiner, Frickenhausen, Germany) 
coated with gelatine (1%). Confluent monolayers were passaged by Trypsin/EDTA (Sigma-
Aldrich, St. Louis, MO). Characterization of endothelial cells was performed on the basis of a 
positive uptake of acetylated LDL, Factor VIII related antigen and PECAM (CD31) 
expression, and negative staining for smooth muscle alpha actin. 
 
Hypothermic preservation injury 
Hypothermic preservation injury of HUVEC was assessed by lactate dehydrogenase (LDH) 
release. LDH assays were performed as recommended by the manufacturer (Roche 
Diagnostics, Mannheim, Germany). Briefly, HUVEC were plated in 24-well plates, grown 
until confluence and pre-incubated with test substances for 2 hrs. The plates were washed 
three times with 1ml of PBS and stored for 24 hrs at 4°C in phenol red free medium. A 100µl 
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aliquot of each supernatant was used to determine LDH release. In each experiment 100µl of 
phenol red free medium was used as blank. The results are expressed as OD490nm corrected 
for the blank. 
 
Synthesis of compounds 
Test compounds were synthesized from commercially available precursors (Fluka, Neu-Ulm, 
Germany, unless stated otherwise). Solvents were from Merck (Darmstadt, Germany). All 
compounds were purified to homogeneity by recrystallization from aqueous methanol as 
demonstrated by thin layer chromatography (TLC) (Si 60, detection by fluorescence 
quenching and by charring with 5% sulfuric acid). Samples investigated by NMR (Bruker 
AC250) yielded spectra in accordance with the expected structures. LogP values were 
calculated using the engine at www.daylight.com/daycgi/clogp. All compounds synthesized in 
this study are shown in Table 1. 
 
General procedure for acylated dopamine derivatives 
Carboxylic acids were converted to their mixed anhydride derivatives by reacting with ethyl 
chloroformate, which was reacted with the appropriate amines. Briefly, 2 mmole carboxylic 
acid was dissolved in 10 mL acetonitrile. To this solution 2.1 mmole N-ethyldiisopropylamine 
was added under stirring, followed by addition of 2.1 mmole of ethyl chloroformate. Two 
hours later, the mixture was diluted with 15 mL ethyl acetate and washed twice with 5 mL 
brine. The organic layer was dried over MgSO4 and the solution was used for further 
experiments. Dopamine hydrochloride was dissolved in DMF at 50 mg/mL, stoichometric 
amounts of N-ethyldiisopropylamine and ethoxycarbonylcarboxylate were added and the 
mixture incubated overnight protected from light. The mixture was partitioned in 1 ml 0.1 M 
NaHCO3 and 2 mL ethyl acetate, the organic layer washed with 0.1 M H2SO4 and brine, and 
finally dried over MgSO4. Evaporation of the solvent yielded the acylated product which was 
homogenous in TLC. Aminophenols required a five-fold excess of phenol over fatty acid as 
higher acylation products are easily formed (26). 
 
General procedure for dihydroxybenzoyl amides 
2.5 mmole (377 mg) of the acid was dissolved in 4 ml THF. Subsequently, 2.5 mmole amine 
and 2.5 mmole (515 mg) DCC, dissolved in 2 ml THF, were added to the solution and mixed. 
The solution was kept over night at room temperature and filtrated hereafter to remove 
precipitates. The filtrate was concentrated in vacuo and re-dissolved in 10 ml ethyl acetate. 
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The organic phase was washed in three sequential steps with 10 ml 0.5 M H2SO4, brine and 
5% NaHCO3. Finally the organic phase was washed with brine and dried over MgSO4. The 
solvent was removed in vacuo.  
 
[3H]N-Octanoyl dopamine (5) 
To 1.85 MBq 7,8-3H dopamine (Amersham) dissolved in 50 µL of 0.01M acetic acid 
containing 50% ethanol was added, under nitrogen atmosphere, 20 µL of a 1 M solution of 
octanoyl-ethoxycarbonyl anhydride in ethylacetate, 10 µL pyridine and 20 µL DMF. After 
one hour, the reaction was mixed with 1 ml 0.1 M phosphate pH 7.5 and 0.5 mL ethyl acetate. 
The aqueous phase was re-extracted and the combined extracts were washed with 1 mL 0.1 M 
phosphate pH 3.7. About 65% of radioactivity was recovered. TLC (Si60, ethyl acetate / 
acetic acid 10:1), spraying with En3hance (NEN) and 7 d exposure on X-ray film revealed 
>90% purity as judged by comigration of nonradioactive N-octanoyl-dopamine. 
 
Tracer studies and subcellular fractionation 
HUVEC cultured to confluence in T175 flasks were incubated with 925 kBq (10 µCi) of 3H-
N-octanoyl-dopamine or 3H-dopamine for 2 hrs. Hereafter the cells were washed and 
processed further for subcellular fractionation. Subcellular fractionation was performed using 
a commercially available kit from Geno Technology Inc. (St. Louis, MO). All steps were 
performed at 4°C. Briefly, cell lysates were prepared and homogenized by douncing. The cell 
homogenate was centrifuged for 2 min at 2,000 x g. Thereafter, the supernatant containing 
cytosolic proteins as well as cellular organelles was further centrifuged for 2 min at 4,000 x g. 
Cytosolic proteins and cellular organelles were present in the supernatant (S1). The pellet (P1) 
contained cell membranes and the nuclear fraction. S1 was further centrifuged for 20 min at 
10,000 x g to separate the cellular organelles (pellet P2) from cytosolic proteins (supernatant 
S2). P2 was subjected to a hypotonic shock (27) for 10 min followed by centrifugation (20min 
10,000 x g) to separate mitochondria (pellet P3) from lysosomes (supernatant S3). 
Supernatant S2 was further centrifuged for 1h at 100,000 x g. Purity of the subcellular 
fractions was tested by Western blot analysis using antibodies against mitochondrial COX IV 
(New England Biolabs, Frankfurt, Germany) and cytosolic GAPDH (Abcam plc, Cambridge, 
UK). Radioactivity was measured in small aliquots collected directly after douncing and in 
aliquots of P1, P3 and S2. Aliquots of the purified fractions were mixed with 3 mL 
scintillation cocktail and counted in a Beckman LS6000. 
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Measurement of hemodynamic parameters 
Male Fisher rats (250 g) were anaesthetised with ketamine and xylazine. Dopamine or N-
octanoyl-dopamine (0.05 µmoles/kg body weight for both) was infused into the femoral vein. 
Systemic blood pressure (mean arterial pressure, mmHg) was continuously measured by a 
femoral arterial catheter (Portex Fine Bore Polythene Tubing 0,4mm ID, SIMS Portex, 
England). 
 
Silencing of heme oxygenase 1 (HO-1)  
HUVEC were seeded in 6-well plates (2 x 105 cells per well) and transfected with HO-1 
siRNA (Santa Cruz, Heidelberg, Germany) according to the manufacturer’s recommendation. 
After 24hrs the transfection medium was replaced with fresh normal growth medium for 
48hrs. Thereafter, the expression of HO-1 protein was determined by Western blot analysis as 
described (18). Nonspecific siRNA (Santa Cruz, Heidelberg, Germany) was used as a 
negative control.  
 
Results 
New compounds were synthesized as described in methods and tested along with other 
substances for their protective effect against hypothermic damage. From the dose-response 
curves, EC50 values were calculated for each of the synthesized substance summarized in 
Table 1. Modification of dopamine by a middle- or long-chain alkanoyl group (compound 5-8) 
greatly improved efficacy (about 40 times compared to dopamine). The two aromatic residues 
employed, tosyl (compound 9) and phenylpropionyl (compound 10), also significantly 
improved efficacy. Although the latter two compounds were structurally related to 
dobutamine, they were slightly less effective than dobutamine (compound 4). Removal of the 
3-hydroxyl group from the highly active lipophilic compound 5 resulted in the generation of 
the closely related tyramine derivative (compound 11). The efficacy of compound 11 was 
strongly decreased compared to compound 5. This could indicate either the requirement for a 
strongly reducing catechol function, or suggest a receptor mediated phenomenon requiring the 
intact dopamine fragment. 
 
 




   Compound #         Fig     EC50 [µM]      strong reducing agent ?    logP (calc.) 
                 1 1A ~ 75 + 0.169* 
2 1A >100 + -0.989* 
3 1A >100 + -0.685* 
4 1A 5 + 2.433* 
5 1B 2.1 ± 0.2 + 2.929 
6 1B 0.9 ± 0.2 + 3.987 
7 1B 1.2 ± 0.2 + 5.045 
8 1B 1.3 ± 0.2 + 6.103 
9 1B 12 ± 1 + 2.253 
10 1B 9 ± 1 + 1.852 
11 1B >100 - 3.526 
12 2 >100 + 1.622 
13 2 >100 + 1.062 
14 2 >100 + 1.622 
15 2 >100 - 1.622 
16 2 >100 - 0.992 
17 2 >100 - 2.252 
18 2 1.2 ± 0.1 + 4.621 
19 2 2.4 ± 0.2 + 3.741 
20 2 6 ± 1 + 4.6 
21 2 > 100 - 4.621 
22 2 > 100 - 3.671 
23 2 ~ 90 - 3.741 
 
The protective effect of various compounds against cold preservation-induced endothelial cell 
damage, expressed as the concentration required to inhibit 50% of LDH release, vs. 
lipophilicity, expressed as logP (calculated, * denotes experimental values taken from public 
sources). 
To test this hypothesis, we synthesized the octylamide derivatives (compound 18-23) of all 
possible dihydroxybenzoic acids (compound 12-17), comprising three reducing and three 
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non-reducing (or weakly-reducing) structures. While the free acids (compound 12-17) were 
all ineffective, the reducing octylamides (compound 18 – 20) exhibited EC50 values between 
1.2 and 6 µM. In addition, the non-reducing octylamides (compound 21 – 23) that cover the 
same range of lipophilicity were all ineffective. In addition, we tested the hemodynamic 
action of dopamine against that of compound 5. As expected from the loss of charge on 
nitrogen in the octanoyl derivative 5, it did not influence mean arterial pressure in vivo, 
compatible with the hypothesis that n-acylation of dopamine impairs receptor binding.  








A: Catecholamines previously reported to exert protective effect on endothelial cells against 
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B: Structurally related derivatives of dopamine and a derivative lacking one of the two 




  R1   R2 
  H   H    1 Dopamine 
OH   H    2 Noradrenaline 
OH  CH3    3 Epinephrine 
(Adrenaline) 
  H 4-(4-hydroxyphenyl)butyl(2)  4 Dobutamine 
     R  
n-octanoyl    5 
n-decanoyl    6 
n-dodecanoyl    7 
n-tetradecanoyl    8 
p-tosyl     9 
phenylpropionyl  10 
R = n-octanoyl   11  











C: Chemically possible isomers of the dihydroxybenzoyl fragment used as free acids (R = OH) 
or as much more lipophilic n-octyl amides (R = C8H17). While the compounds with hydroxyl 
groups in ortho- or par-position (2,3; 3,4 or 2,5) are strong reducing agents, the other 
















                                      Apocynin 24       Tempol 25 
 
D: Structure of the chemically unrelated substances apocynin (a NADPH oxidase inhibitor) 
and tempol (2,2,6,6-tetramethylpiperidine-1-oxyl), a stable radical often employed as a low 
molecular weight superoxide dismutase mimetic. 
 
All compounds identified as protective cover diverse structures with only one common 
property, i.e. the reducing capacity. Therefore, it is unlikely that a specific receptor interaction 
is involved in the protective properties of these compounds. In order to investigate whether 
the protection reflects a general antioxidant effect, we also employed other biologically 
relevant reducing compounds and specific inhibitors of certain oxidative pathways. Both 
ascorbate and N-acetyl cysteine were not protective when used up to 300 µM. Similarly, 
apocynin (24), an inhibitor of NADPH oxidase, did not protect HUVEC from cold 
preservation induced damage at concentrations up to 3 mM. The stable radical tempol 
position of  R=OH    R=NH-C8H17 
OH moieties 
      2,3    12  18 
      3,4    13  19 
      2,5    14  20 
      2,4    15  21 
      3,5    16  22 
      2,6    17  23 
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(2,2,6,6-tetramethylpiperidin-n-oxyl) (25), a scavenger of reactive oxgen species, was also not 
protective at concentrations up to 300 µM . 
Collectively our experimental data thus suggest that a highly protective agent requires a 
suitably substituted dihydroxybenzene moiety and a certain degree of lipophilicity. The 
relationship between relative hydrophobicity (logP) and protection (EC50) is given in figure 2. 











Figure 2 EC50 values expressed as mean plotted against calculated logP values for the 
reducing compounds shown in table 1. A sigmoid (Boltzmann) line was found to fit the data 
set with A1= 1.22, A2=1000, x0=-0.67, dx = -0.58  
 
To investigate how the change in lipophilicity affects the cellular uptake of the compounds 
and their distribution in different subcellullar compartments, [3H] labeled compound 5 was 
synthesized from 7,8-[3H] dopamine. Based on the amount of radioactive [3H] label, total 
uptake of compound 5 was approximately 4 times higher than the unmodified dopamine in 
HUVEC.  Subcellular distribution of these compounds remained almost unaffected, with the 
exception of mitochondria. The relative concentration of compound 5 was about twice as 
much compared to dopamine, corresponding to approximately 8 times more radioactivity in 
the mitochondria when compound 5 was tested against dopamine.  
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Since HO-1 over-expression has been shown to be beneficial with respect to hypothermia-
mediated cell damage (13), we investigated the influence of hypothermia on HO-1 expression 
and how this was modulated in dopamine pre-treated HUVEC. Dopamine did not 
significantly change the expression of HO-1 directly before cold storage. However, when 
HUVEC were stored at 4°C HO-1 expression was significantly diminished in untreated 
HUVEC. In contrast, in dopamine pre-treated cells HO-1 expression was maintained during 
hypothermia (Figure 3A). This could indicate that the protective effect of dopamine is 
mediated by stabilization of HO-1.  To test this hypothesis, knockdown experiments using 
HO-1 siRNA were performed.  HO-1 expression was almost completely lost 3 days after 
siRNA transfection. Even 5 days after transfection HO-1 expression did not reappear in 
transfected cells, and this was not influenced by addition of dopamine on day 4 (Figure 3B). 
HO-1 siRNA transfection could not overcome the protective effect of dopamine (Figure 3C). 
Hence, protection against hypothermia-mediated cell death by catechol compounds does not 










Figure 3 A:  Influence of hypothermia on HO-1 expression. HUVEC were pre-incubated for 2 
hous with dopamine (25 µM) or were untreated. Hereafter the cells were stored for 24 hours 
at 4°C. Proteins were isolated directly before and after cold storage, or 2 hours after 
rewarming. HO-1 was detected by Western blot analysis. For equal loading control, the 













B:   HO-1 expression in HUVECs transfected with HO-1 siRNA. The expression of HO-1 was 
assayed 72 hours (3 days) or 120 hours (5 days) after transfection. Dopamine was either or 
not added at day 4 after transfection. Expression of HO-1 and GAPDH was assessed as 




C:   Effect of dopamine on cold preservation injury in siRNA-transfected HUVEC. The cells 
were treated with HO-1 (+) or control (-) siRNA. Three days after transfection the cells were 
pre-incubated for 2 hrs with 25 µM of dopamine (hatched bars) or left untreated (open bars). 
LDH release was assessed after 24 hrs of cold storage. The results of a representative 




























Elucidation of structural requirements for substances to achieve protective activity against 
cold preservation damage of endothelial cells may both promote our understanding of the 
mechanisms involved in preservation injury of organ allografts and might eventually lead to 
the use of more effective and specific compounds for organ preservation. In this study, we 
analysed the protective potency of a series of substances that represent structural variations of 
the dopamine / dobutamine scaffold, compounds that have been shown earlier to protect 
against cold preservation injury both in vitro and in vivo (4-7, 14).  
The variety of structures that are protective strongly disfavors the involvement of a receptor 
mediated process that would respond much more selective to the significant molecular 
modifications that were made. Moreover, the in vivo experiments where we could show that 
n-acetylation of dopamine completely abrogates its hemodynamic action are not in favor of 
receptor involvement. The only common feature that all protective compounds tested possess 
is the requirement for the presence of two hydroxyl groups at the benzene nucleus, located 
either in ortho or in para position. These isomers are known to be strong reducing agents due 
to the ease of quinone formation, which can not occur for the meta isomers. An additional 
requirement for protection is sufficient lipophilicity. As expected, the acylated dopamine 
derivatives enter cells more efficiently than the parent compound, but also seem to 
accumulate to a greater extent in mitochondria. Damage of mitochondria in endothelial cells 
is prevented by catecholamines as shown earlier (8). Therefore mitochondria might be 
considered as relevant targets for protection by catecholamines, although the functional 
relevance of an increased mitochondrial catecholamine uptake needs to be further defined. 
The increase in lipophilicity is evident upon acylation, because a nonpolar acyl chain is added 
and catecholamines lose their ability to form a cation. We are aware that the calculated logP 
value may differ from experimentally determined value, however, the calculated values for 
the catecholamines show significant agreement with published experimental data.  
As logP refers to the uncharged compounds, the assumption that the importance of logP is 
embedded in a better cellular uptake may not be entirely true.  Dihydroxybenzoic acids are 
present in their ionized forms at physiological pH, e.g. in the culture medium, which also 
might influence their cellular uptake. Within the series of uncharged amide compounds, the 
assumption is expected to be valid. The aryl derivatives 9 and 10 exhibit a slightly lower 
efficacy as expected from their logP value. However, they do not possess an alkyl chain that 
would allow them to insert into lipid membranes more efficiently.  
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Based on the structural requirement we postulate that insertion of the compounds into lipid 
compartments, which is underlined by the need for lipophilicity, might prevent oxidative 
damage at or near the membrane. Regardless of the detailed mechanism, an efficient 
protective substance requires an ortho- or para-dihydroxybenzene partial structure, is 
preferably uncharged with an alkyl chain and exhibits an overall lipophilicity exceeding a 
logP value of 3. 
During hypothermic preservation an increase in the chelatable transition iron pool has been 
described to occur in a variety of cells (15-17). Catechols are able to form complexes with 
iron, which could further explain their protective effect. However, on the basis of our findings, 
this mechanism does not significantly contribute to protection. In most studies on mixed 
ligand complexes of iron, catechol yields the most stable complexes. Although meta- and 
para-compounds, i.e. resorcinol and hydroquinone (or their functional derivatives) usually 
result in approximately equally stable iron complexes, they yield much less stable iron 
complexes than the catechol compounds. In our study, the ortho- and para-compounds were 
both equally protective against cold perservation damage, while the meta-derivatives were not 
protective. Thus, the protective behavior does not match with the expected behaviour for 
formation of iron complexes.  
Also the expression of HO-1, which has been shown to be beneficial with respect to cold 
preservation (13), seems not to be involved in the protective properties of lipophilic catechol 
containing compounds. In earlier studies, dopamine has been shown to induce HO-1 
expression (18), but these concentrations were approximately 10 times higher compared to the 
concentrations required for protection against cold preservation injury. Nevertheless, 
lipophilic catechol containing compounds do preserve HO-1 expression during cold storage. 
This is an interesting aspect in the context of organ transplantation since HO-1 inhibits 
ischemia reperfusion injury (19, 20) and mediates anti-inflammatory effects (21, 22). 
In conclusion, we have demonstrated that the protective effect of catecholamines on cold 
preservation injury is mediated exclusively by two structural entities, i.e. a strong reducing 
capacity and a minimal lipophilicity. These requirements can also be fulfilled in other 
dihydroxyphenolic compounds that lack hemodynamic action. Since acylated dopamine 
derivatives (23) and alkyl dihydroxybenzamides (24) have been described as anti-
inflammatory agents, clinical use of such compounds in organ transplantaion seems to be a 
promising strategy not only to limit pre-transplantation injury in donor organs but also to limit 
the inflammatory response after transplantation. 
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Prolonged hypothermia, as occurs during solid organ transplantation, negatively influences 
transplantation outcome. Proteolysis is one of the deleterious events implicated in 
preservation injury of organ allografts. This strongly affects graft quality and hence 
immediate organ function. Since donor catecholamine treatment improves transplantation 
outcome after renal transplantation, the present study was conducted to examine the influence 
of dopamine (DA) pre-treatment on hypothermia induced proteolysis in endothelial cells 
subjected to prolonged cold storage. 
HUVECs were highly susceptible to cold storage, which was reflected by morphological 
changes, loss of viability and by significant changes in cellular proteome. DA pre-treatment 
prevented cell death during cold storage. Western blot analysis demonstrated a time 
dependent up-regulation of calpain 1 and 2 during cold storage, which could be prevented by 
addition of EDTA. DA pre-treatment abolished auto-proteolysis of calpain 1. Analysis of 
ubiquitination revealed a significant increase in ubiquitinated conjugates after cold storage. 
This was not prevented by DA pre-treatment. Neither proteasome nor calpain inhibitors 
prevented cell death during cold storage. 
In endothelial cells subjected to cold preservation, activation of the calpain pathway and the 
ubiquitin proteasome system occurs. Although DA pre-treatment inhibits the former, calpain 
inhibition did not protect endothelial cells during cold storage. DA pre-treatment might 
influence proteolysis, but proteolysis is not the major cause of endothelial cell death.  













Static cold storage is commonly used for organ preservation of allografts to bridge the time 
between organ explantation and implantation. Extended preservation times have allowed 
overcoming important logistical hurdles such as HLA-based organ sharing across 
geographical boundaries (1, 2). Being inexpensive, easy to apply and independent of technical 
devices, cold static storage is still the most practical way of organ preservation amongst the 
different preservation methods. However, prolonged cold ischemia time is associated with an 
increased rate of organ failure. Organ failure might occur as a consequence of endothelial 
barrier dysfunction (3-5), leading to parenchymal oedema, infiltration by polymorphonuclear 
leukocytes (PMNs) and ultimately to delayed graft function (6).  
The use of organs from so called “marginal” donors has increased dramatically to meet the 
growing demand of organ allografts. Yet, organs obtained from these donors might be more 
susceptible to cold preservation injury, resulting in a higher rate of delayed graft function (7, 
8) and possibly in a decreased allograft survival (9). Understanding the mechanisms that lead 
to tissue injury during hypothermic preservation is therefore of utmost importance to prevent 
organ damage and hence to improve graft quality.  
Prolonged hypothermia is associated with cell and tissue damage as a consequence of necrosis 
or apoptosis (10). Apoptosis involves a complex network of enzymes that is tightly regulated 
by pro- and anti-apoptotic proteins, in which execution of cell death is mostly performed by 
caspases, calpains and cathepsins (11, 12). Although it is still a matter of debate whether 
apoptosis or necrosis are the major process leading to deterioration of graft quality during 
organ preservation, the use of anti-apoptotic drugs has shown encouraging results in pre-
clinical and experimental studies (13). 
Proteolyses is generally mediated by activation of a variety of enzymes. This might occur as a 
consequence of ATP depletion and an increase in cytosolic calcium. In particular, activation 
of the Ca2+-dependent proteases, i.e. calpains, seems to be corollary to the imbalance in 
intracellular calcium homeostasis during cold storage (14, 15). Apart from elevated 
intracellular calcium concentrations, other mechanisms could also contribute to increase 
calpain activity, such as cleavage of calpastatin by caspases (16) or increased phospholipase 
activity (17).  
The ubiquitin proteasome system (UPS) might be equally involved in proteolysis during cold 
preservation (18). It has been generally accepted that the most prominent function of the UPS 
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is to label cytosolic and nuclear proteins for proteosomal degradation. In addition, the UPS is 
involved in cell-cycle regulation, signal transduction and antigen processing (19-21).  
Since we have previously reported that dopamine (DA) treatment of endothelial cells result in 
protection against cold preservation injury, in the present study we assessed to what extent 
hypothermia changes the cellular proteome and if DA treatment affects the major proteolytic 
pathways.   
 
Material and methods 
 
Cell isolation and culture 
Human umbilical vein endothelial cells (HUVEC) were isolated from fresh umbilical cords as 
previously described (22). The cells were cultured in endothelial cell growth medium (EGM) 
(Promocell, Heidelberg, Germany) in T25 flasks (Greiner, Frickenhausen, Germany) coated 
with gelatin (1%). Confluent monolayers were passaged by Trypsin/EDTA (Sigma-Aldrich, 
St. Louis, MO). Characterization of endothelial cells was performed on the basis of a positive 
uptake of acetylated LDL, a positive expression of Factor VIII related antigen and PECAM 
(CD31) (Dako, Glostrup, Denmark), and a negative staining for alpha smooth muscle actin. 
All experiments were performed with cell lines at passage three to seven. 
 
Two-dimensional electrophoresis  
Iso-electric focusing (IEF) was performed on precast 18 cm IPG strips with linear pH ranges 
using an IPGphor unit (Amersham Pharmacia, Frieburg, Germany). The strips were placed in 
ceramic strip holders and rehydrated in 350 µl rehydration buffer (8 M urea, 2% CHAPS, 
0.5% IPG buffer pH 3-10) containing 50 µg of protein extracts and protease inhibitors and a 
few grains of bromophenol blue. The strips were covered with 2 ml dry strip cover fluid 
(Amersham Pharmacia, Frieburg, Germany) and rehydrated over night by applying 30 V by 
constant temperature (20˚C) on the IPGphor unit. The following IEF protocol was used: 30 
min gradient up to 500 V, 30 min 500 V, 30 min gradient up to 2000 V, 30 min 2000 V, 1 hr 
gradient up to 8000 V, 4 hrs 8000 V. After focusing the strips were washed with water and 
immediately used for the second dimension. Before loading on SDS-polyacrylamide gels 
(PAGE), the strips were equilibrated for 20 min in equilibration buffer containing 
iodoacetamide. Hereafter the strips were carefully washed with water and transferred to the 
SDS-PAGE. The gels were sealed on top with agarose sealing solution (0.5% low melting 
agarose in 25 mM Tris, 192 mM glycine and 0.1% SDS). Electrophoresis was carried out over 
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Protein spots were excised from the gel and washed twice with deionized water, acetonytril 
(ACN)/water (1:1, v/v) and ACN. Proteins were digested overnight at 37˚C with 165 to 330 
ng sequencing grade trypsin (Promega, Mannheim, Germany) in 40 mM ammonium 
bicarbonate. The reaction was stopped by freezing. 
 
MALDI-TOF MS 
MALDI-TOF mass spectra were recorded in the positive ion reflector mode with delayed 
extraction on a Reflex II TOF instrument (Bruker Daltonics, Bremen, Germany) equipped 
with a SCOUT 26-inlet and a 337 nm nitrogen laser. Ion acceleration voltage was set to 26.5 
kV, the reflector voltage was set to 30 kV and the first extraction plate was set to 20.6 kV. 
Mass spectra were obtained by averaging 200 to 300 individual laser shots. Calibration of the 
spectra was performed internally by two-point linear fit using autolysis products of trypsin. 
Sample preparation for MALDI mass fingerprints was achieved by co-crystallization of the 
matrix with ZipTip (Millipore, Schwalbach/Ts, Germany) concentrated samples. Database 
search was done against the NCBInr database using the MASCOT algorithm 
(www.matrixscience.com). 
  
Measurement of ubiquitin-conjugates and free ubiquitin 
HUVEC were incubated for 2hrs with 25µM of dopamine (DA, Fresenius Kabi Deutschland 
GmbH, Bad Homburg, Germany). The culture flasks were washed 3 times with PBS 
(Invitrogen, Karlsruhe, Germany) and stored for different time period at 4°C in UW-solution. 
Hereafter the cells were collected using Trypsin/EDTA and centrifugation. The pellet was 
resuspended in 50 µl of distilled water to which a proteinase inhibitor cocktail (Roche, 
Mannheim, Germany) was added and immediately shock frozen in liquid nitrogen. The cells 
were subsequently lysed by 5 cycles of freezing in liquid nitrogen and quickly rewarming at 
37˚C.  After the final rewarming, the samples were centrifuged and the supernatants were 
frozen at -20˚C until use. Ubiquitin-conjugates and free ubiquitin were assessed by 
immunoblotting using rabit anti-ubiquitin antibody (Sigma, St. Louis, MO) and densitometric 
quantification of the chemo luminescence signal as described previously (23). 




HUVEC were harvested with trypsin/EDTA (Sigma-Aldrich, St. Louis, MO) and 
subsequently washed twice with cold PBS. The cells were lysed in lysis buffer (10 mM Tris, 
2% SDS, 0.5% beta-mercaptoethanol) (all from Sigma-Aldrich, St. Louis, MO). Protein 
concentrations were measured using Coomassie-Reagent (Pierce, Rockford, USA). Samples   
(20 µg protein extract) were heated to 95°C for 5 min, loaded and separated on 10-20% SDS-
polyacryamide gels followed by semi-dry blotted onto PVDF membranes (Roche, Mannheim, 
Germany). The membrane was blocked with blocking buffer (5% w/v nonfat dry milk 
in PBS-T) for 1h at room temperature. Thereafter, the blot was incubated with a polyclonal 
anti-calpain 1 or anti-alpain 2 (Cell Signaling Technology, Danvers, MA) or anti-ubiquitin 
antibody (Sigma, St. Louis, MO) overnight at 4°C. Subsequently the membrane was 
thoroughly washed with TBS-T and incubated with the appropriate horseradish peroxidase 
conjugated secondary antibody (Jackson ImmunoResearch, Baltimore, MD) for 1 h at room 
temperature. Proteins were visualized using enhanced chemo luminescence technology 
according to the manufacturer’s instructions (Pierce, Rockford, IL). To confirm equal protein 
loading, membranes were re-probed with a polyclonal anti-p42/p44 antibody (Cell Signaling 
Technology, INC., Rockland, Beverly, MA) or monoclonal anti-GAPDH antibody (Abcam, 
Cambridge, UK). 
 
Measurements of intracellular Ca2+ concentrations 
Measurements of intracellular Ca2+ concentrations were performed according to Koppel et al 
(24). HUVEC were incubated with phenol-red free medium (PRF) containing 4µm Fura-2 
AM (Invitrogen, Karlsruhe, Germany) at 37°C for 1hr. The cells were washed with PBS twice 
and treated with dopamine for 2hrs. After washing the cells with PBS twice, PRF medium 
was added and the cells were subjected to 4°C for 3hrs. Coverslips were then mounted into a 
thermostatically regulated microscope chamber. A Zeiss Axiovert 35 (Zeiss, Hanau, Germany) 
inverted fluorescence microscope, equipped with a fluor 40/1.30 oil immersion objective and 
a charge-coupled device imaging camera (General Scanning, Planegg, Germany), was 
employed to detect fluorescence changes. Dual wavelength excitation at 340 and 380 nm was 
performed by an imaging system (Till Photonics, Planegg, Germany).  After calibration, the 
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Lactate dehydrogenase assays were performed as recommended by the manufacturer (Roche 
Diagnostics, Mannheim, Germany). Briefly, HUVEC were plated in 24-well plates, grown 
until confluence and stimulated with 25µM dopamine (DA) for 2hrs. The plates were washed 
3 times with 1ml of PBS and stored for 24hrs at 4°C in PRF medium. A 100µl aliquot of each 
supernatant was used to determine LDH release. In each experiment 100µl of PRF medium 
was used as blank. The results are expressed as OD490nm, corrected for the blank value. 
 
Statistical analysis 
Data are presented as mean ± SD for the indicated number of separate experiments. All 
analyses were based on more than three separate experiments. Differences between groups 





We previously have demonstrated that hypothermic storage of endothelial cells severely 
affects cell viability, accompanied by profound changes in the expression of cytoskeleton 
proteins (5). To investigate to what extent hypothermia changes the cellular proteome, 2D-gel 
electrophoresis was performed (Fig 1). In general, we observed that there was a quantitative 
difference in the expression of a number of proteins when the cells were subjected to 
hypothermia for 24 hrs. A total of 50 spots were selected for further analysis. We were able to 
get protein sequence information in 47 of these spots. Quantitative analysis revealed that 16 
different proteins were reduced in their expression (table1).  
 
Because the reduction in protein expression during hypothermia might have been caused by 
proteolysis, we next investigated if the major proteolytic pathways, i.e. the caspase, calpain 
and proteosomal pathway, were activated during hypothermia. We did not observe activation 
of the caspase pathway as neither cleavage of the procaspases 8 and 9 nor that of caspase 3 
occurred during hypothermia (data not shown). In contrast, activation of the calpain pathway 
was evident.  This was reflected by an increase in the auto-proteolytic cleavage of calpain 1 
(µ-calpain) during cold storage. 
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Figure 1 Proteome analysis of HUVEC. Endothelial cells were either kept at 37˚C (A) or 
stored for 24 hrs at 4˚C in UW solution (B). Proteins were isolated and processed as 
described in materials and methods. Proteome analysis was performed for both conditions 
with three different HUVEC cultures. 2-D gel electrophoresis was performed for each 
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individual sample. The result of a representative gels is shown. Numbers indicate the spots 
that were used for protein identification. 
 
Dopamine pre-treatment completely prevented the cleavage of calpain 1 (Fig 2A). Calpain 2 
(m-calpain) was upregulated already 6 hrs after the onset of cold storage. In endothelial cells 
that were treated with dopamine prior to hypothermia this was not observed (Fig 2B). 
Similarly, addition of EDTA prevented upregulation of m-calpain. Since the latter findings 
suggest that during cold storage an influx of extracellular calcium might occur which 
subsequently activates the calpain pathway, we assessed intracellular calcium concentration 
three hrs after the onset of cold storage in untreated and DA treated endothelial cells.  Indeed, 
intracellular calcium concentrations were significantly increased after cold storage. This did 
not occur when the cells were pre-treated with DA or when EDTA was added to the 
preservation solution during cold storage (table 2).  




















In addition, to activation of the calpain pathway, protein degradation could occur via the UPS. 
Since protein ubiquitination is required for proteosomal degradation we determined if 
Table 1: identification of proteins that were decreased in expression during cold storage 
Cathepsin D, preprotein45 





Cathepsin D, Chain B31 
Elongation factor 1 delta30 
Elongation factor 1 delta29 




Ubiquitin carboxy-terminal hydrolase L111 
GST, Chain A10 
Thioredoxin B, Chain A9 
Eukaryotic translation initiation factor 58 
Fatty acid binding protein 52 
                   proteinSpot number
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hypothermia increased the amount of ubiquitin conjugates and free ubiquitin. The amount of 
free ubiquitin did not significantly change during hypothermia. However, the amount of 
ubiquitin conjugates was significantly increased. This was not influenced by dopamine pre-





Figure 2 Influence of hypothermia on calpain expression. (A) HUVEC were either 
treated for two hrs with dopamine (D, 25 µM) or left untreated (M). Hereafter the cells were 
stored for different time-period at 4˚C in University Wisconsin (UW) solution, or kept at 37˚C. 
Protein extracts were assessed for µ-calpain by means of Western blotting. P42/44 was used 
to demonstrate equal loading. Note that the 75 kDa auto-proteolytic fragment only occurs in 
untreated cells (M) stored at 4˚C. In addition, the expression of µ-calpain reduces with 
increasing cold storage time in untreated cells. (B) HUVECs were treated as in A. Apart from 
untreated (M) and dopamine treated (D) cells, EDTA (E) was added to the preservation 
solution during cold storage. Protein extracts were assessed for m-calpain by means of 
Western blotting. P42/44 was used to demonstrate equal loading. Note that the expression of 
m-calpain is increased in untread HUVEC. The results of a representative experiment is 
shown, a total of 4 different experiments were performed and yielded similar results. 
 
To test if activation of the calpain pathway and UPS were required for cell death during cold 
storage, endothelial cells were pre-treated with calpain inhibitor I, or the proteasome inhibitor 
lactacystine and stored at 4˚ C. The inhibitors were also present during cold preservation. Cell 
death was not prevented by these inhibitors as assessed by LDH release. The caspase 3 
inhibitor ZVAD also did not prevent cell death. In contrast, LDH release was significantly 
inhibited by DA pre-treatment of the endothelial cells (Fig 4).  
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Figure 3 Influence of hypothermia on free ubiquitin and ubiquitinated protein conjugates. 
HUVEC were treated for two hrs with 25 µM of dopamine (+) or left untreated (-). The cells 
were then stored at 4˚C in UW solution or kept at 37˚C in HUVEC medium. The result of a 
representative experiment is depicted (n=3). 
 
                   Table 2: Intracellular Ca2+ concentrations after 3 hrs of hypothermia 
38 ± 12 39 ± 15 Dopamine treated 
40 ± 10 120 ± 42* Not treated 
 
   + EDTA 
 
     - EDTA 
 
*: Results are expressed as mean intracellular Ca2+ concentration (nM),  
P<0.01 not treated vs. Dopamine treated. P<0.01 –EDTA vs. +EDTA 






Figure 4 Modulation of hypothermia mediated cell death. HUVEC were treated for 2 hrs with 
25 µM of dopamine (DA), 40 µM of the calpain inhibitor I, 20 µM of the proteasome inhibitor 
lactacysteine or 50 µM of the caspase inhibitor ZVAD. Hereafter the cells were stored for 24 
hrs at 4˚C in UW solution. With exception of dopamine, all inhibitors were present during 
cold storage. Untreated endothelial cells (Medium) were included in each experiment. A total 
of 5 different experiments were performed, the results are expressed as mean LDH release ± 




Although static cold storage is the most commonly used method for organ preservation, 
prolonged cold storage of allografts is associated with poor graft function (25, 26). Amongst 
the different mechanisms that might affect cell viability during cold storage, several studies 
have indicated that proteolysis might play an important role (5, 28). In previous in vitro and in 
vivo studies (25-27), we have shown that DA treatment significantly protects endothelial cells 
against hypothermia mediated cell damage. In the present study we assessed to what extent 
hypothermia influences the cellular proteome and if activation of proteolytic pathways during 
hypothermia was affected by DA treatment. The main findings of this study were as follows. 
Firstly, hypothermia leads to a reduction in the expression of a number of cellular proteins. 
Secondly, both the calpain and UPS pathway are activated during cold storage in HUVEC. No 
evidence for the activation of the caspase pathway was found. Thirdly, DA treatment affected 
activation of the calpain pathway, most likely by preventing influx of extracellular calcium. 
Increased ubiquitination was not prevented by DA treatment. Fourthly, inhibition of caspase-3, 
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Preservation injury is multifactorial and its mechanism is still incompletely defined. The 
complexity of preservation injury is further illustrated by the fact that different organs differ 
in tolerance against cold ischemia. Over the past decade however, a number of studies have 
shown that hypothermia-mediated cell damage can be overcome by appropriate treatment (29, 
30). In particular the use of iron chelators or hydrophobic anti-oxidants has yielded 
encouraging results, showing their protective effect on different cell types (29-31). Yet, the 
mechanism by which cell damage occurs during cold storage might differ in detail between 
the cells that have been studied. Even when comparing the different studies using the same 
cell type, there are conflicting data in this regard. Although both Natori et al (32) and Sindram 
et al (33) have suggested that apoptosis is the major cause of sinusoidal endothelial cell death 
in liver allografts that are stored in UW solution, in the former study this was mediated by 
caspase activation while in the latter calpain activation was clearly involved. In our study 
using human umbilical vein endothelial cells we did not find activation of caspase during cold 
storage, in stead auto-proteolysis of µ-calpain and upregulation of m-calpain occurred. 
Activation of calpain might be a consequence of increased intracellular Ca2+ concentrations. 
During cold storage Ca2+ homeostasis is significantly affected because hypothermia most 
likely prolongs Ca2+ channel influx and alters ion exchangers that trigger enhanced 
sarcoplasmic reticulum (SR) Ca2+-induced Ca2+ release. Depressed Ca2+- and Na+-pump 
activities may lead to Ca2+ and Na+ overload via Na+-H+ exchange and reversed Na+-Ca2+ 
exchange (34, 35).  
The relevance of cellular Ca2+ influx for cell death during hypothermia has also been 
questioned. Recently Knoop et al (36) showed that cold storage of hepatocytes and 
endothelial cells in calcium-free media led to an increased cell injury whereas a physiological 
calcium concentration (2.5mM) was protective. These data do not corroborate with our own 
findings in that we clearly demonstrate that addition of EDTA not only prevented Ca2+ influx 
but also prevented cell death (our unpublished data). Similar findings were observed for DA 
treatment. It most be noted that both DA and EDTA have the propensity to chelate iron and 
thus we can not exclude that iron chelation is partly underlying this protection.  
The UPS has also been implicated in cold preservation cell damage as has been reported by 
Majetschak M et al (18). In line with our data on endothelial cells, they found an increase in 
ubiquitin-protein conjugates in heart allografts subjected to cold storage. However, we could 
demonstrate that DA treatment did not prevent the increase in ubiquitin conjugates despite the 
fact that it protected endothelial cells during cold storage. It thus seems that proteosomal 
degradation of cellular proteins is not instrumental for cell death under these conditions. This 
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is further supported by the finding that lactacysteine could not prevent cell damage. It must 
also be stressed that cell death not necessarily depends on proteolysis, even as this might 
occur during prolonged hypothermia. As previously demonstrated, prolonged hypothermia 
results in severe structural changes (30) and functional deterioration of mitochondria (5), 
which will likely affects cell viability.  
It remains to be assessed if differences in the cellular proteome that occur during cold storage 
are completely attributable to proteolysis. We have shown in previous studies that proteolysis 
at least occurs for some proteins, i.e. paxillin and vimentin (5), but loss in protein expression 
might equally be caused by cell death and subsequent release in the preservation solution.  
In conclusion, our study demonstrates that hypothermia results in profound changes in the 
cellular proteome. Activation of the calpain pathway and UPS might occur during 
hypothermia, but inhibition of calpain or the proteosome could not prevent cell death. 
Although our data should not be generalized, as the mechanisms that lead to hypothermic cell 
death may differ for each cell type and model being studied, they clearly indicate that the 
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HMGB1 and adenosine are both released by 
endothelial cells during hypothermic preservation 
 



































Hypothermic preservation of solid allografts causes profound damage of vascular endothelial 
cells. This in turn might activate innate immunity. In the present study we employed an in 
vitro model to study to what extent supernatants of damaged endothelial cells are able to 
activate innate immunity and to study the nature of these signals. The expression of HMGB1 
and adhesion molecules on HUVEC was studied by immunofluorescence, FACS and 
Westernblotting. Cytokine production was performed by ELISA. HMGB1 expression was 
completely lost in endothelial cells after hypothermic preservation. This was associated with 
cell damage as it only occurred in untreated endothelial cell but not in cells rendered resistant 
to hypothermia-mediated damage, by dopamine treatment. Only supernatants from 
hypothermia susceptible cells up-regulated the expression of IL-8 and adhesion molecules in 
cultured endothelial cells in an HMGB1-dependent manner. In whole blood assays, both 
supernatants of hypothermia susceptible and resistant cells inhibited TNFα production, 
concomitantly with an increased IL-10 secretion. The activity of the supernatants was found 
already after 6 hrs of hypothermic preservation, and paralleled the decrease in intra-cellular 
ATP levels. Modulation of TNFα and IL-10 production by these supernatants was completely 
abrogated by prior treatment with adenosine deaminase and was similar to the response of an 
A2R agonist. Our study demonstrates that both HMGB1 and adenosine are released during 
hypothermic preservation. While release of HMGB1 is caused by cell damage, release of 





















Allocation of organ allografts has become possible by adequate improvements in organ 
preservation. In transplantation of solid organs, static cold storage is the most widely used 
modality for organ preservation. Yet, acute shortage of donor organs and the inevitable 
pressure to use sub-optimal donors, has made this method questionable to prevent 
deterioration of organ quality (1, 2). Prolonged hypothermic preservation remains a 
significant cause of pre-tranplantation injury of allografts. Because pre-tranplantation injury 
significantly affects short and long term organ function (3-5), cold ischemia time is a 
critically important factor for transplantation outcome (3, 4). Tissue injury caused by 
hypothermia is largely mediated by oxidative stress (6-8). Injury to endothelial cells may lead 
to impaired control of vascular permeability (9), thrombosis (10) and inflammation (10, 11).  
According to the danger hypothesis (12), tissue damage might evoke immune activation and 
therefore tissue damage seems to increase tissue immunogenicity of the allograft. Although 
this theory has now widely been accepted, the signals that initiate immune activation and 
modulate innate immunity are not clearly defined in organ transplantation. 
High mobility group box chromosomal protein 1 (HMGB1) is a highly conserved chromatin 
binding protein which is abundantly expressed in mammalian tissues (13). In addition to its 
crucial roles in stabilizing nucleosome formation, facilitating gene transcription and 
modulating steroid hormone receptors, its role in innate immunity has been widely 
appreciated (13-15). HMGB1 can be passively released by necrotic cells (16) or actively 
secreted by monocytes, macrophages and dendritic cells via a non-classical vesicle-mediated 
secretory pathway (17-19). The presence of extracellular HMGB1 is not only a telltale that a 
cell or tissue has suffered from damage, but also provides “danger” signals to a variety of 
cells that constitute the innate immune system (14, 20, 21). Binding of HMGB1 to the 
receptor for advanced glycation end products (RAGE) on endothelial cells and monocytes 
increases the expression of adhesion molecules and stimulates the production of an array of 
pro-inflammatory cytokines (22, 23). The involvement of Toll like receptor (TLR) 2 and 4 in 
cell activation by HMGB1 has also been demonstrated (24). 
We and others have previously shown that cold preservation of endothelial cells results in a 
rapid loss of endothelial barrier function (9) and induces necrosis of these cells (25-27). 
Therefore, cold preservation of allografts might be accompanied by the release of HMGB1 
from endothelial cells and hence might contribute to activation of the innate immune system 
and subsequently to inflammation (13-15, 22, 23).  
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Apart from signals that activate innate immunity, other factors might be present that 
downregulate inflammation. In particular adenosine, a purine nucleoside that is released 
extracellularly, has a potent endogenous anti-inflammatory potential (28). Under 
circumstances, such as ischemia, a rapid and massive degradation of intracellular ATP 
eventually leads to accumulation of AMP, which in turn, is converted to adenosine (29, 30). 
Also during cold preservation of organ allografts, intracellular ATP is depleted within hours, 
an eligible condition for extracellular release of adenosine. It is therefore plausible that 
adenosine release during hypothermic preservation of allografts is another pivotal modulator 
of the immune response in the recipient. 
In the present study, we used an in vitro model to investigate if hypothermic preservation of 
endothelial cells is associated with the release of HMGB1 and adenosine. In addition, the 
functional relevance of these factors, in terms of immune activation was studied.  
 
Materials and methods 
Reagents 
Endothelial cell growth MedKIT, Phenol-red free medium (Promocell, Heidelberg, Germany), 
PBS, RPMI1640 (GIBCO, invitrogen, NY), Fetal bovine serum (FBS) Gold (PAA 
laboratories GmbH, Pasching, Austria), Tripsin/EDTA solution, LPS from E.coli, CGS 21680, 
DMSO, TritonX-100 (Sigma, St. Louis, MO), Bovine Serum Albumin (SERVA, Heidelberg, 
Germany), 37% formaldehyde (Mallinckrodt Baker, Deventer, Holland), Ficoll-paqueTM 
plus (Amersham Biosciences AB, Uppsala, Sweden), PGN-BS (B. subtilis), Pam3CSK4, Poly 
(I:C), Flagellin (B. subtilis), CL087, ssRNA40/LyoVec, ODN2006 (Invitrogen, San Diego, 
CA). ZM241385 (Tocris Cookson Inc., Ellisville, MO), HMG1 (Proteinone, Bethesda, MD). 
 
Cell culture  
Human umbilical vein endothelial cells (HUVECs) were isolated from fresh umbilical cords 
as described previously (26). The cells were grown in basal endothelial medium 
supplemented with 10% FBS and essential growth factors until they formed a confluent 
monolayer. Cold preservation was performed essentially the same as described (26). In brief, 
2 hrs before cold preservation was started HUVECs were either treated with Dopamine (DA, 
30 µM) or left untreated. The cells were stored at 4˚C in Phenol-red free (PRF) cell-culture 
medium or preservation solution (university of Wisconsin, UW) depending on the specific 
experiment.   
Immunohistochemical staining 
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HMGB1 staining was performed on HUVECs and peripheral blood mononuclear cells 
(PBMC).  HUVECs were cultured on glass coverslips until confluence. The cells were treated 
for 2 hrs with DA (30µM) or left untreated and stored for 24 hrs at 4˚C in UW solution. Cells 
that were cultured for the same period of time at 37˚C were included in each experiment.  
PBMCs were isolated by Ficoll-Paque plus density-gradient centrifugation and mounted on 
glass by cytospin centrifugation. All cells were fixed in 4% freshly-made formaldehyde for 
1hr at room temperature followed by permeabilization with ice-cold 0.5% Triton X-100 for 5 
min. The cells were then incubated for 30 min. at room temperature with PBS containing 2% 
BSA to block unspecific background staining. A polyclonal rabbit anti-HMGB1 antibody 
(Biomol., Lakeplacid, NY,) was added overnight to the samples at 4˚C. After extensively 
washing with PBS/BSA the samples were incubated for 1hr at room temperature with a 
Texas-red-conjugated goat anti-rabbit IgG (Molecular Probes, Leiden, The Netherlands) or 
FITC conjugated swine anti-rabbit IgG (Dako, Hamburg, Germany). Cells were incubated 
with DAPI or TOTO3 (Molecular Probes, Leiden, The Netherlands) for 15 min at room 
temperature to visualize nuclei. Fluorescence signals were analyzed by fluorescence and 
confocal microscopy.   
 
Assessment of intracellular ATP 
Confluent HUVEC monolayers were treated for 2hrs with 30 µM dopamine or left untreated. 
Subsequently the cells were washed and stored at 4°C. Intracellular ATP was extracted at 
serial time points and measured by luciferase driven bioluminescence using the ATP 
Bioluminescence Assay Kit CLS II (Roche Diagnostics, Mannheim, Germany). 
 
Activation of endothelial cells by supernatants 
To test if the supernatants of endothelial cells that were stored for 24 hrs at 4ºC contain 
biological activity, normal cultured HUVEC were incubated for 24 hrs at 37ºC with the 
supernatants in a 1:1 dilution. Hereafter IL-8 production was measured by enzyme-linked 
immunosorbent assay (ELISA) as recommended by the manufacturer (Beckman Coulter, 
Marseille Cedex, France). HMGB1 specificity in the supernatants was tested by immune-
absorption. To this end, HMGB1 by adding a polyclonal rabbit anti-HMGB1 antibody 
(Biomol., Lakeplacid, NY) or normal rabbit IgG was added for 1 hr followed by the addition 
of protein A/G (1 hr) (Santa Cruz, Heidelberg, Germany). The supernatants were centrifuged 
and used for further experiments. Absorption of HMGB1 was demonstrated by Westernblot 
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(data not shown). Apart from IL-8 production activation of HUVEC by the supernatants was 
also tested by FACS analysis as described below. 
 
FACS analysis 
HUVECs were cultured in medium supplemented with supernatants (dilution 1:1) from 
endothelial cells that were subjected to cold preservation. FACS analysis was performed with 
2×106 cells using the following FITC conjugated monoclonal antibodies; anti-human ICAM-1, 
anti-human VCAM-1 and anti-human E-selectin (all from Becton Dickinson, Heidelberg, 
Germany). Antibodies were added for 30 min at 4ºC followed by extensively washing with 
PBS. FACS analysis was performed on a FACScalibur equipped with the CELLQuest 
software (Becton Dickinson, Heidelberg, Germany). The data were analysed by Windows 
Multiple Document Interface (WinMDI) software (Version 2.8). 
 
Whole blood assay 
Blood was obtained from healthy adult donors with informed consent and diluted 1:1 with 
PRF medium or with supernatants obtained from HUVECs that were stored for 24 hrs at 4˚C 
in PRF medium. HUVECs were either left untreated or treated with DA (30 µM) 2 hours prior 
to cold storage as described above. The diluted blood was subsequently plated in 24 well 
plates containing either culture medium or one of the following stimuli: 20µg/ml PGN-BS (B. 
subtilis), 10µg/ml Pam3CSK4, 50µg/ml Poly (I:C), 0.5µg/ml LPS, 1µg/ml Flagellin (B. 
subtilis), 1µg/ml CL087, 1µg/ml ssRNA40/LyoVec, 1µM ODN2006 (Invivogen, San Diego, 
CA). In some experiments, recombinant HMGB1 (0.1µg/ml) (Proteinone, Bethesda, MD) or 
the adenosine receptor A2A agonist CGS 21680 (5µM) (Sigma, St. Louis, MO) was added. 
The concentrations of different TLR ligands were based on a previous publication (31) and 
product data sheet. The plates were incubated for 24hrs at 37˚C (5% CO2/ 95% humidity) 
after which supernatants were harvested and assessed for TNFα and IL-10 production. TNFα 
and IL-10 concentrations the supernatant after whole blood stimulation were measured by 




Supernatants from HUVECs that were subjected to cold preservation for 24hrs were analysed 
for the presence HMGB1 by western blot. The supernatant were 50x concentrated by means 
of centricon columns (Millipore, Billerica, MA). The presence of HMGB1 in cell nuclei 
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isolated from the same HUVEC was also analysed. SDS-PAGE and Westernblotting was 
performed essentially similar as described (26). Briefly, samples were resolved on 10 % SDS-
PAGE and electrotransferred onto PVDF filters. Hereafter the filters were incubated overnight 
with 5% non-fat dry milk powder in PBS to block unspecific background staining. A 
polyclonal rabbit anti-HMGB1 antibody (Biomol., Lakeplacid, NY) followed by a 
horseradish peroxidise-conjugated goat anti-rabbit IgG (Santa Cruz Biotechnology, 
Heidelberg, Germany) (both dissolved in PBS/0.2 % Tween-20/5 % non-fat dry milk powder) 
were subsequently added for 60 minutes. Visualization of immunoreactive bands was 
performed by chemiluminescence reagent (PerkinElmer LAS Inc., Boston, MA) according to 
the manufacture’s instructions.  
 
Statistical analysis 
Data were presented as mean ± SD for the indicated number of separate experiments. All 
analyses were based on more than three separate experiments. Differences between groups 





Release of HMGB1 during cold preservation 
The expression of HMGB1 was investigated by means of immunefluorescence. In cultured 
HUVEC, HMGB1 expression was found both in the nuclei and in an extra-nuclear 
compartment in close vicinity to the nucleus (Fig. 1, upper panel to the left). By using 
confocal immunefluorescence microscopy extra-nuclear HMGB1 expression could be 
confirmed (Fig. 1A, upper panel, in the middle). Extra-nuclear HMGB1 expression was only 
found in HUVEC and not in PBMC (Fig. 1A, upper panel to the right). In untreated HUVEC 
that were subjected to 24 hrs of cold preservation, the extra-nuclear compartment was 
completely lost, while nuclear staining of HMGB1 was strongly diminished (Fig. 1A, lower 
panel to the left). Cold-preservation of untreated HUVEC was characterized by release of 
LDH, which was completely abrogated by 2 hours of dopamine treatment prior to cold 
preservation (data not show). Under the latter condition, loss of HMGB1 expression was not 
observed (Fig. 1A, lower panel to the right). Westernblot analysis of isolated nuclei and 
supernatants confirmed the loss of HMGB1 in nuclei of untreated cells concomitantly with 
the appearance of the protein in the supernatant (Fig. 1B). 
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Figure 1 A: HMGB1 expression in endothelial cells. Cultured HUVEC (upper two panels to 
the left) and freshly isolated PBMC (upper panel to the right) were stained for HMGB1 as 
described in the materials and methods section. Analysis of HMGB1 was performed by means 
of immune-fluorescence (upper panels to the left and to the right) and by confocal microscopy. 
Original magnification: 200x and 400x respectively. The lower panels show HMGB1 
expression in untreated HUVEC (to the right) and dopamine treated HUVEC (to the left after 
24 hrs of cold storage. Original magnification: 400x. B: Westernblot analysis of HMGB1 in 
cell nuclei from HUVEC before (37˚C) and after cold storage (4˚C). Note the disappearance 
of HMGB1 from the nuclei after cold storage of untreated HUVEC (-) and its appearance the 
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Figure 2 Upregulation of adhesion molecules and IL-8 production by supernatants. A: 
Normal cultured endothelial cell were incubated for 24 hrs with supernatants obtained from 
untreated (bold line) and dopamine treated (thin line) HUVEC that were subjected to 24 hrs 
of cold storage.  Note that supernatants from untreated HUVEC up-regulates the expression 
of ICAM-1, E-selectin and VCAM-1 compared to supernatants from dopamine treated 
HUVEC. Filled histogram represents the negative control. The results from a representative 
experiment (n=5) is depicted. B: Normal cultured endothelial cell were incubated for 24 hrs 
with supernatants obtained from untreated (Sup-untreated) and dopamine treated (Sup-Da-
treated) HUVEC that were subjected to 24 hrs of cold storage. The supernatants were 
immune-absorbed with anti-HMGB1 (filled bars) or normal rabbit IgG as described in the 
materials and methods section. IL-8 production was measured by ELISA using triplicates for 
each condition. The results are expressed as mean IL-8 production (ng/ml) ± SD from 4 
different experiments.  
 
 
Modulation of adhesion molecules and IL-8 expression in cultured endothelial cells 
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To test if the release of HMGB1 from unprotected HUVEC has functional significance, 
cultured endothelial cells were stimulated with supernatants of untreated or dopamine treated 
HUVEC for 24 hrs, after which the expression of ICAM-1, E-selectin and VCAM-1 was 
determined. The expression of all three adhesion molecules was upregulated by supernatants 
obtained from untreated HUVEC (Fig. 2A). Similarly, IL-8 production was two times higher 
in endothelial cell cultures stimulated with supernatants of untreated HUVEC. This was due 
to the release of HMGB1 since depletion of HMGB1 from these supernatants by means of 
immune-absorption completely normalized IL-8 production (Fig. 2B). 
 
Modulation of TNFα and IL-10 production 
We next investigated if supernatants obtained from HUVEC after cold storage are able to 
modulate LPS mediated TNFα and IL-10 production in whole blood assays. Both 
supernatants from untreated and dopamine treated HUVEC (n=6) consistently suppressed 
TNFα production, while the production of IL-10 was increased. This was unlikely mediated 
by HMGB1 since addition of recombinant HMGB1 augmented both TNFα and IL-10 
production (Fig. 3).  
Figure 3 
Figure 3 LPS mediated TNFα and IL-10 production in whole blood assays. Whole blood was 
diluted 1:1 in normal PRF medium to which either nothing (open bars) or 0.1 µg/ml 
recombinant HMGB1 (filled bars) was added. In addition, whole blood was diluted 1:1 with 
supernatants obtained after cold storage of untreated HUVEC (Sup-untreated; dotted bars) 
or dopamine treated (Sup-Da-treated; hatched bars). To each condition 0.5 µg/ml of LPS was 
added. TNFα and IL-10 production was assessed after 24 hrs by ELISA, using triplicates for 
each condition. A total of 6 experiments were performed with different blood donors and 
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Although upregulation in TNFα and IL-10 production was also observed when other TLR 
ligands were added to the whole blood assay, inhibition of TNFα production by supernatants 
obtained from HUVEC after cold storage only occurred in a TLR4 dependent fashion (Fig. 4). 
This was also found for the upregulation in IL-10 productiom. Supernatants from dopamine 
treated and untreated HUVEC behaved similar in this regard (data not shown).  
 
Figure 4 
Figure 4 Modulation of TLR-mediated TNFα and IL-10 production. Whole blood was diluted 
1:1 in normal PRF medium (open bars) or in supernatants of untreated HUVEC (Sup-
untreated), obtained directly after 24 hrs of cold storage. To the wells either nothing (no) or 
different TLR ligands (TLR 1-9) was added. The different ligands that were used were as 
follows:  PGN-BS (20µg/ml) (TLR1), Pam3CSK4 (10µg/ml) (TLR2), Poly (I:C) (50µg/ml) 
(TLR3), LPS 500 ng/ml (TLR4), Flagellin (1µg/ml) (TLR5), CL087 (1µg/ml) (TLR6), ssRNA 
(1µg/ml) (TLR8) and ODN2006 (1µM) (TLR9). TNFα and IL-10 production was assessed as 
described in figure 3. A total of 4 different experiments were performed. The result of a 
representative experiment is expressed as mean cytokine production (pg/ml) ± SD.  
 
 
The modulatory activity found in the supernatants was present already 6 hrs after cold storage 
and coincided with loss of intra-cellular ATP levels (Fig. 5). Although intracellular ATP 
levels further decreased in time during cold preservation, modulation of TNFα and IL-10 
production was maximal after 6 hrs. In subsequent experiments the involvement of adenosine, 
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blood assays were performed in normal phenol red free (PRF) medium, addition of the non-
specific adenosine A2A and A2B receptor agonist NECA significantly inhibited TNFα 
production, while IL-10 production was significantly up-regulated to a similar extent as 
supernatants from HUVEC after cold storage (Fig. 6A). The specific adenosine A2A receptor 
agonist CGS 21680 did not differ from NECA in this regard (data not shown). Addition of 
NECA HUVEC supernatants did not influence TNFα or IL-10 production (Fig. 6A). In 
contrast, addition of adenosine deaminase (ADA) completely abrogated the modulatory effect 
of the supernatants, while addition of ADA to normal PRF medium did not influence the 




A.                                                                              B. 
 
 
Figure 5 Acquirement of TNFα suppressing activity in supernatants and intracellular ATP 
depletion in time. A: Whole blood was diluted 1:1 in normal PRF medium (filled bars) and in 
supernatants of untreated HUVEC (Sup-untreated) or in supernatants of dopamine treated 
HUVEC (Sup-Da-treated), obtained directly after 6 hrs (open bars) or 12 hrs (hatched bars) 
of cold storage. To each condition 0.5 µg/ml of LPS was added. TNFα production was 
assessed as described in figure 3. A total of 3 different experiments were performed. The 
result of a representative experiment is expressed as mean TNFα production (pg/ml) ± SD. B: 
Untreated (open bars) and dopamine treated (filled bars) HUVEC were stored at 4˚C for 
different periods of time. Hereafter, intra-cellular ATP was measured as described in 
materials and methods. The total amount of ATP before cold storage was taken as 100% for 
each condition. The result of a representative experiment is depicted and expressed as mean 
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 Figure 6 




Figure 6 Modulation of LPS induced cytokine production is mediated by adenosine. A: Whole 
blood was diluted 1:1 in normal PRF medium (open bars) and in supernatants of untreated 
HUVEC (filled bars; Sup-untreated) or in supernatants of dopamine treated HUVEC 
(hatched bars; Sup-Da-treated), obtained directly after 24 hrs of cold storage. To each 
condition 0.5 µg/ml of LPS was added. The whole blood assay was performed in the absence 
(medium) or presence of NECA (10µM) B: Similar as in A, but the supernatants were not 
treated (medium) or treated with adenosine deaminase (7U/ml) before initiation of the 
experiments. In A and B, TNFα and IL-10 production were assessed as described in figure 3. 
A total of 4 different experiments were performed. The result of a representative experiment is 





Long-term graft survival of renal allografts obtained from living donors is generally better 
than that obtained from post-mortem donors, despite better HLA-matching of the latter (32). 
According to the danger hypothesis (12), this might be explained by the fact that, immune 
activation following transplantation will be much stronger in allografts that have suffered 
from severe damage during the transplantation process. Compared to allografts from living 
donors, pre-transplantation injury in allografts from post-mortem donors is expected to be 
larger as a consequence of brain dead (33, 34) and prolonged hypothermic preservation (3). 
While brain death influences micro-circulation and organ perfusion (35) and is associated 
with inflammation in end-organs (33, 34), hypothermic preservation causes cell necrosis in a 
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activation is however not clear yet. In the present study we therefore investigated if 
hypothermic preservation of endothelial cells is associated with the release of HMGB1 and 
adenosine, two important molecules known to modulate innate immunity. The major findings 
of this study are first, HMGB1 expression is completely lost in endothelial cell that underwent 
necrosis during hypothermic preservation. This is not observed in endothelial cells rendered 
resistant to cold preservation damage by dopamine pre-treatment. Second, HMGB1 released 
in the supernatant of damage cells is biologically active as it upregulates adhesion molecules 
and IL-8 production in viable endothelial cells. Third, during hypothermic preservation 
adenosine is released independent of cell damage. Adenosine modulates TNFα and IL10 
production in monocytes in an TLR4-dependent fashion.  
 
To our knowledge, extra-nuclear HMGB1 expression in viable endothelial cells has thus far 
not been reported. Although Mullins et al (36) have reported that in LPS or TNFα stimulated 
HUVEC relocation of HMGB1 to the cytoplasm can occur, they did not mention relocation of 
HMGB1 to a specific intracellular compartment. Our findings on the extra-nuclear 
compartment of HMGB1 in HUVEC was unlikely due to a fixation or staining artefact, since 
HMGB1 expression in PBMC that were processed similarly as HUVEC, did not reveal an 
extra-nuclear HMGB1 compartment. Based on the HMGB1 staining pattern we speculate that 
this compartment might be related to the endoplasmic reticulum (ER), however this must be 
confirmed in future studies. In support of ER localization is a recent report from Ivanov et al 
(37) who showed co-localization of HMGB1 with markers of the ER, the ER Golgi 
intermediate compartment (ERGIC) and the Golgi in bone marrow derived dendritic cells and 
macrophages.  
 
Since prolonged hypothermic preservation leads to tissue necrosis, the finding that HMGB1 
was lost during cold preservation was not surprising. Cold preservation injury can be 
prevented by appropriate pre-treatment of cells with a number of compounds, e.g. 
catecholamines (8, 9) and iron scavengers (26, 38). Prevention of the loss of HMGB1 
expression in dopamine treated HUVEC demonstrates that hypothermia per se does not cause 
the release of HMGB1 but that this reflects cell necrosis. Although, we did not address if 
HMGB1 expression was also reduced in organ allografts after hypothermic preservation, a 
number of studies have unambiguously demonstrated the occurrence of tissue necrosis under 
this condition (39, 25). Therefore it is likely that HMGB1 is indeed released during cold 
preservation of whole organs. The presence of HMGB1 in organ allografts might influence 
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neutrophil infiltration (40), endothelial production of pro-inflammatory cytokines (41), 
recruitment and proliferation of smooth muscle cells (42) and homing of endothelial 
progenitor cells (43). 
 
Apart from HMGB1, adenosine could also be demonstrated in supernatants of HUVEC after 
cold storage. This might explain why supernatants of damaged cells downregulated TNFα 
production in whole blood assay, despite the presence of HMGB1. Adenosine release was 
associated with ATP hydrolysis and occurred independent of cell necrosis. Extra-cellular ATP 
can be converted to adenosine by a cascade of ectonucleotidases including CD39 and CD73, 
both of which are expressed on endothelial cells (44, 45). Because ATP hydrolysis also occurs 
intracellularly, adenosine can alternatively be released through nucleoside transporters (45). 
 
We have previously in vitro demonstrated, that endothelial barrier dysfunction is restored 
after cold preservation by dopamine pre-treatment (9). Since adenosine enhances barrier 
function (44-47), this might underlie the beneficial effect of dopamine on barrier function. 
Although adenosine was also released during cold storage in untreated cells, it can not restore 
barrier dysfunction in these cells as they become necrotic with increasing cold preservation 
time (26). The involvement of adenosine on barrier function however, has not been directly 
addressed in the present study. 
 
Because in vitro HMGB1 and adenosine are released in the supernatants and organ allografts 
are flushed before implantation, it can be argued that release of these factors do not have any 
significance in organ transplantation. Endothelial cells express the receptor for advanced 
glycation end products RAGE (48), a putative receptor for HMGB1, which might already 
bind its ligand during cold preservation. Subsequent warm reperfusion then can cause 
receptor activation leading to phenotypic and functional changes in endothelial cells. The 
relevance of endogenous release of adenosine during hypothermia is indeed questionable as 
adenosine is added to some preservation solution, e.g. UW. 
 
In conclusion, our study identified two mediators, i.e. HMGB1 and adenosine, that are 
released during cold preservation and that are able to influence innate immunity. While the 
release of HMGB1 is associated with tissue necrosis and activation of innate immunity, 
adenosine release is independent of cell damage and suppresses activation of the innate 
immune system in an TLR4-dependent fashion. Prevention of cold preservation injury by 
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adequate donor treatment might thus prevent release of HMGB1 and preserve the action of 
adenosine on endothelial barrier function, thereby improving immediate graft function and 
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Heme oxygenase-1 (HO-1) exerts anti-inflammatory effects via heme degradation, resulting 
in the generation of biliverdin, Fe2+ and carbon monoxide (CO). Since CO itself up-regulates 
HO-1 expression, perpetuation of the anti-inflammatory effect is expected. We investigated 
how CO releasing molecules (CORM), i.e. CORM-3, modulate the expression of adhesion 
molecules on endothelial cells and if HO-1 mediated perpetuation was involved. 
CORM-3 consistently inhibited the expression of VCAM-1 and E-selectin on TNF-α 
stimulated human umbilical vein endothelial cells (HUVEC), while ICAM-1 expression was 
marginally affected and only in 3 out of 8 lines tested. Although CORM-3 did not influence 
initial NFκB-activation, this was significantly reduced at later time-points. Down-regulation 
of VCAM-1 and E-selectin expression by CORM-3 also occurred when CORM-3 was added 
24 hrs after TNF-α stimulation or when TNF-α was removed. This was paralleled by 
deactivation of NFκB, concomitantly with a reduction in VCAM-1 mRNA. Although TNF-α 
removal was more effective in this regard, VCAM protein was down-regulated more rapidly 
when CORM-3 was added compared to TNF-α removal. Induction of HO-1 occurred in a 
dose- and time-dependent manner and was mediated by Nrf2. Neither in HO-1 nor in Nrf2 
siRNA-transfected HUVEC the efficacy of CORM-3 to down-regulate VCAM-1 expression 
was lost. In Nrf2 siRNA-transfected HUVEC CORM-3 no longer induced HO-1. 
In conclusion, our study demonstrates that CORM-3-mediated anti-inflammatory effects are 
independent of HO-1 up-regulation. Although CORM-3 most likely exerts its effect by 
inhibition of sustained NFκB activation, down-regulation of VCAM expression also seems to 
















Leukocyte extravasation occurring at the onset of inflammation is a highly regulated process 
characterized by bidirectional communication between endothelial cells and leukocytes. Upon 
exposure of endothelial cells to inflammatory mediators, adhesion molecules and chemokines 
are rapidly upregulated, which in turn facilitate leukocyte migration (1-4). In addition, ligand 
binding to CXC chemokine receptor 1 (CXCR1) and CXCR2 stimulates neutrophils to release 
a number of factors including proteases, cytokines, chemokines, and other chemoattractants 
that amplify inflammation and extend duration of the latter (5). Hence, understanding the 
mechanisms controlling down-regulation of pro-inflammatory cytokines and adhesion 
molecules is now being widely recognized as a prerequisite for the identification of novel 
drug targets for inflammatory disease (2, 6, 7). 
In addition to its unambiguous role in oxidant-induced injury (8-10), unequivocal evidence 
demonstrates that the heme oxygenase system (HO) is involved in the control of 
inflammatory processes (11-13, 16). The HO system comprises several isoenzymes (14, 15), 
of which the inducible HO-1 isoenzyme appears to be particularly important as anti-
inflammatory mediator (11-13, 17). HOs are the rate-limiting enzymes in degradation of heme 
into carbon monoxide (CO), Fe2+ and biliverdin, the latter being subsequently converted to 
bilirubin (18, 19). 
Although a number of studies have postulated putative mechanisms by which HO-1 exerts its 
anti-inflammatory effect, some of the published data are controversial. While Soares et al 
have shown that HO-1down-regulates VCAM and E-selectin expression via bilirubin and iron 
chelation with no apparent involvement of CO (12, 13), Otterbein et al and Sethi et al clearly 
demonstrate the anti-inflammatory potential of CO in macrophages and monocytes (11) as 
well as in endothelial cells (20, 21). The salutary effect of CO has also been shown for organ 
transplantation and ischemia reperfusion injury (22, 23). 
Recently, a new class of molecules, termed CO-releasing molecules (CORM), has been 
described (24) that are composed of transition metal carbonyls. They are capable of liberating 
CO under appropriate conditions. In particular, CORM-3 
(tricarbonylchloro(glyconato)ruthenium(II)) and CORM-A1 (sodium boranocarbonate), 
which both are fully water-soluble, rapidly liberate CO when dissolved in physiological 
solutions. These molecules might therefore be of therapeutically interest to modulate ongoing 
inflammatory reactions by delivering CO in a controllable fashion (25). In addition, these 
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molecules have been widely used to increase our understanding of the biological function of 
CO (26-27).  
Interestingly, CO itself can induce the expression of HO-1 in an Nrf2-dependent fashion as 
was demonstrated in hepatoma cells (29). In addition, CO stabilizes HIF-1α, a putative 
transcription factor for HO-1 expression, in macrophages (30). Since induction of HO-1 by 
CO might perpetuate the anti-inflammatory effect of CO we now investigated whether (A) 
HO-1 is induced by CORM-3 in endothelial cells, (B) its expression is regulated by the 
transcription factors Nrf2 or HIF-1α, and (C) if the anti-inflammatory effect of CORM was 
perpetuated by HO-1.  
 
Materials and methods 
 
Reagents 
Reagents were obtained from the sources as indicated: endothelial cell culture medium 
(Promocell, Heidelberg, Germany), PBS (GIBCO, invitrogen, NY), fetal bovine serum (FBS) 
Gold (PAA laboratories GmbH, Pasching, Austria), trypsin/EDTA solution, DMSO, Tween 
20, DEAE-Dextran, chloroquine, Hepes, Triton X-100, DTT, sodium deoxycholate, Tris-base, 
EDTA, APS, SDS, TEMED, tricarbonyldichlororuthenium(II) dimer, glycine, sodium 
ethoxide, human recombinant TNF-α (Sigma, St. Louis, MO), bovine serum albumin 
(SERVA, Heidelberg, Germany), protease inhibitor cocktail, 1st strand cDNA synthesis Kit 
(Roche Diagnostic, Mannheim, Germany), NF-κB consensus oligonucleotides, Dual-Glo 
Luciferase Assay System (Promega, Mannheim, Germany), Coomassie protein assay reagent 
(Pierce, Rockford, IL), Trizol (Invitrogen, Carlsbad, CA), chloroform, isopropanol, 
tetrahydrofuran, β-mercaptoethanol (Merck, Darmstadt, Germany). Primers and all reagents 
were purchased for TaqMan PCR (ABI, Darmstadt, Germany). All antibodies for flow 
cytometric analysis were purchased from R&D System (Minneapolis, MN) and all FACS 
reagents from Becton Dickinson (Heidelberg, Germany). All antibodies used for Western 
blotting, including horseradish peroxidase (HRP) conjugates, antibodies for supershifts as 
well as siRNAs were purchased from Santa Cruz Biotechnology (Heidelberg, Germany) with 
exception of the anti-HO-1 (Stressgen, Victoria, Canada) and the anti-GAPDH antibodies 
(Abcam Cambridge, UK). chemiluminescence reagent was purchased from PerkinElmer LAS 
Inc. (Boston, MA). 
 
Cell culture  
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Human umbilical vein endothelial cells (HUVECs) were isolated from fresh umbilical cords 
as described previously (31). The cells were grown in basal endothelial medium 
supplemented with 10% FBS and essential growth factors until they formed a confluent 
monolayer. Cells were stimulated with 50ng/ml of TNF-α in the presence or absence of 
different concentrations of CORM-3. Unstimulated cells served as control. 
 
Synthesis of tricarbonylchloro(glycinato)ruthenium(II) 
Tricarbonylchloro(glycinato)ruthenium(II) ([Ru(CO)3Cl(glycinate)]) was synthesized starting 
from a commercially available compound, tricarbonyldichlororuthenium(II) dimer 
([Ru(CO)3Cl2]2). Briefly, [Ru(CO)3Cl2]2 (0.5 g) and glycine (0.151 g) were placed under 
nitrogen in a round-bottomed flask. Methanol (291 ml) and sodium ethoxide (0.132 g) were 
added and the reaction was allowed to continue under stirring for 18 hrs at room temperature. 
The solvent was then removed under pressure and the yellow residue redissolved in 
tetrahydrofuran (THF). The yellow solution was evaporated down to give a pale yellow solid 
(yield 92-96%) and was stored in closed vials at -20ºC. For each experiment CORM-3 was 
dissolved freshly in PBS. 
 
FACS analysis 
HUVECs were cultured in medium supplemented with 50ng/ml TNF-α in the presence or 
absence of 1mM CORM-3. HUVECs cultured in endothelial medium were used as control. 
FACS analysis was performed with 2×106 cells using the following FITC-conjugated 
monoclonal antibodies: anti-human ICAM-1 (BBIG-I1), anti-human VCAM-1 (BBIG-V3) 
and anti-human E-selectin (BBIG-E5). Antibodies were added for 40 min at 4ºC followed by 
extensive washing with PBS. FACS analysis was performed on a FACScalibur equipped with 
the CELLQuest software. The data were analysed by Windows Multiple Document Interface 
(WinMDI) software (Version 2.8). 
 
Westernblot analysis 
HUVECs were stimulated for different time periods with 50ng/ml TNF-α in the presence or 
absence of 1mM CORM. Hereafter, the cells were harvested and lysed in 50 µl lysis buffer 
containing 10mM Tris-base, 150mM NaCl, 5mM EDTA, 1% Triton X-100, 0.5% sodium 
deoxycholate, 1µM DTT and proteinase inhibitor cocktail. In some experiments, nuclear 
proteins were isolated as previously described (32, 33). Protein concentrations were assessed 
using Coommassie reagents. SDS-PAGE and Western blotting were performed essentially 
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similar as described (31). Briefly, samples were resolved on 10 % SDS-PAGE and transferred 
onto PVDF filters by semi-dry blotting. The filters were incubated with 5% non-fat dry milk 
powder in PBS for 1 hour at room temperature to block unspecific background staining and 
hereafter incubated overnight at 4oC with specific polyclonal antibodies, depending on the 
experiment that was performed. The following antibodies were used: polyclonal rabbit anti-
HO-1 antibody, polyclonal rabbit anti-Nrf2 antibody, polyclonal rabbit anti-IκB alpha 
antibody, polyclonal goat anti-VCAM-1 antibody, polyclonal rabbit anti-NF-κB p50 antibody, 
polyclonal rabbit anti- NF-κB p65 antibody. After extensive washing in PBS/Tween/5 % non 
fat dry milk powder, the filters were incubated 60 minutes with appropriate horseradish 
peroxidase-conjugated polyclonal IgG, followed by 3 times washing in PBS/Tween. 
Visualization of immunoreactive bands was performed by chemiluminescence reagent 
according to the manufacturer’s instructions. The filters were re-probed with monoclonal anti-
Histone H1 antibody or monoclonal anti-GAPDH antibody to demonstrate equal loading. 
 
Electrophoretic mobility shift assay (EMSA) 
Nuclear extracts were obtained from HUVECs as described above. Protein concentrations 
were determined by Bradford assay. EMSA was performed essentially as previously 
described (32, 33). Briefly, NF-κB consensus oligonucleotides were labelled to a specific 
activity >5x107cpm/µg DNA. 10 μg of nuclear extracts were added to 1 ng of labelled 
oligonucleotide in a total volume of 20 µl containing 10 mM HEPES (pH=7,5), 0.5 mM EDTA, 
70 mM KCl, 2 mM DTT, 2% glycerol, 0.025% NP-40, 4% Ficoll, 0.1 M PMSF, 1 mg/ml BSA 
and 0.1 µg/µl poly di/dc. In each experiment specificity of binding was demonstrated by adding 
cold consensus or mutated NF-κB oligonucluotides to the nuclear extracts. In addition, 
supershifts were performed by adding anti-p65 and p55 antibodies to the samples. DNA-protein 
complexes were separated on 5% non-denaturating polyacrylamide gels electrophoresed in low 
ionic strength buffer and visualized by autoradiography.  
 
RNA isolation, reverse transcriptase PCR, quantitative TaqMan PCR  
Total RNA was isolated from confluent endothelial cell monolayers using Trizol®-Reagent. 
Thereafter, DNase treatment was carried out, using RNase free DNase I (Ambion, Darmstadt, 
Germany). RNA concentration and quality were assessed by RNA 6000 Nano assays on a 
Bioanalyzer 2100 system (Agilent, Boeblingen, Germany). 500 ng of total RNA was reverse-
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transcribed into cDNA using the 1st Strand cDNA Synthesis Kit. cDNA was diluted in 20 µl 
DEPC-treated water and stored at –20°C until use.  
For reverse transcriptase PCR 1µl of cDNA was amplified in a 50µl reaction mix containing 
10mM dNTPs, 50pM of each primer, 2.5 units Taq polymerase and 1.5mM MgCl2. The 
primers used were as follows: HO-1 forward: 5’- GCT CAA CAT CCA GCT CTT TGA GG-
3’ and reverse: 5’- GAC AAA GTT CAT GGC CCT GGG A-3’; VCAM forward: 5’- CGA 
TCA CAG TCA AGT GTT CAG TTG-3’ and reserve: 5’- GCA ATT CTT TTA CAG CCT 
GCC T-3’; GAPDH forward: 5’- GTC TTC ACC ACC ATG GAG AA-3’ and reserve: 5’- 
ATC CAC AGT CTT CTG GGT GG-3’. The cycling conditions used for various primers 
were as follows: 4 min of denaturation at 94oC, followed by 28 (VCAM-1) or 25 (HO-1 and 
GAPDH) cycles of amplification, each consisting of denaturation for 30s at 94oC, annealing 
for 30s at 59oC (VCAM-1), 62 oC (HO-1) or 55oC (GAPDH) and extension for 45s at 72oC. 
After the last amplification a final extension for 10 min at 72oC was performed for each 
reaction. PCR products were analysed on a 1 % agarose gel containing ethidium bromide. 
Quantitative real-time RT-PCR was performed on the ABI-Prism 7700 sequence detection 
system with the TaqMan universal PCR master mix No AmpErase UNG (part no. 4324018). 
Taqman probes for VCAM-1 (part No. HS00174239_m1) and β-actin (part No. 
HS99999903_m1). Samples were run under the following conditions: initial denaturation for 
10 minutes at 95o C followed by 40 cycles of 15 s at 95o C and 1 minute at 60o C. The levels 
of gene expression in each sample were determined with the comparative cycle threshold 
method. PCR efficiency was assessed from the slopes of the standard curves and was found to 
be between 90% and 100%. Linearity of the assay could be demonstrated by serial dilution of 
all standards and cDNA. All samples were normalized for an equal expression of β-actin. 
Each experiment was repeated 3 times with similar results. 
 
Reporter assays 
HUVECs were transfected with a reporter construct containing 3 hypoxia response elements 
(3HRE.luc) (34) or a construct containing an anti-oxidant response element from the HO-1 
promoter (HO-ARE.luc) (35). All transfections were performed using DEAE-dextran as 
described previously (36) and in each case the ubiquitin-dependent Renilla luciferase reporter 
was co-transfected. Two days after transfection, cells were stimulated for 24 hrs with CORM-
3. Luciferase activity was measured using the Dual-Glo Luciferase Assay System. All 
experiments were performed in triplicate and ARE- or HRE-dependent luciferase activities 
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were normalized for luciferase acivity generated by the Renilla luciferase control reporter. 
The results are expressed as fold increase compared to unstimulated controls. 
 
Cell transfection with siRNA 
HUVECs were seeded in 12-well plate at a density of 0.5-2×105 one day before transfection 
with HO-1 siRNA, Nrf2 siRNA or control siRNA. Transfection was performed according to 
the manufacturer’s instructions. Briefly, cells were incubated for 6 hrs in transfection medium 
supplemented with siRNA and transfection reagent. Hereafter, endothelial cell culture 
medium containing 20% FBS was added without removing the transfection solution and the 
cells were allowed to grow for an additional 24hrs. For each experiment the efficacy of 
siRNA was demonstrated by disappearance of the specific band in Western blot analysis. 
 
Statistical analysis 
Data are presented as mean ± SD for the indicated number of separate experiments. All 
analyses were based on more than three separate experiments. Differences between groups 





Inhibition of adhesion molecules by CORM  
CORM-3 inhibited TNF-α-mediated induction of VCAM-1 and E-selectin in all cell lines 
tested (n=8), while inhibition of ICAM-1 only occurred in 3 of these (figure 1A). Inhibition of 
adhesion molecule expression was mediated by the release of CO since a degassed solution of 
CORM-3 was ineffective (figure 1A, lower panel). To exclude that loss of adhesion molecule 
expression was due to proteolytic cleavage from the cell membrane, Western blot analysis 
with whole cell lysates was performed. As demonstrated for VCAM-1, induction by TNF-α 
was significantly attenuated by CORM-3 and was completely absent when endothelial cells 






















Figure 1 Modulation of TNF-α induced expression of adhesion molecules by CORM-3. (A): 
Eight different HUVEC lines were stimulated for 24 hrs with 50 ng/ml of TNF-α in the 
absence (normal line) or presence of 1 mM of CORM-3 (bold line) and surface expression of 
ICAM-1, VCAM-1 and E-selectin determined by flow cytometry. Basal expression of adhesion 
molecules is also depicted (dotted line). While limited TNF-a-induced expression of ICAM-1 
occurred only in 3 out of 8 cell lines exposed to CORM-3 (upper panel), a weaker induction 
of VCAM-1 and E-selectin by TNF-a was consistently observed. Degassed CORM-3 solution 
revealed no effect (lower right panel). (B): Time-dependent modulation of VCAM-1 
expression by CORM-3. HUVEC were stimulated for different time periods with 50 ng/ml of 
TNF-α in the absence (-) or presence of 1 mM of CORM-3 (+). Hereafter, cell lysates were 
n=3, CORM-3 
responsive 
CORM-3 Degassed CORM-3 





time of TNF-α stimulation (hrs)
   M  -             + -            +   -               + 
       4        8        24 
CORM-3 (1 mM) 
Chapter 7: The anti-inflammatory effect of CO releasing molecules 
 
 122
prepared and subjected to Western blotting. Membranes were incubated with anti-VCAM-1 
antibody and hereafter reprobed with anti-GAPDH antibody to control for equal loading. A 
total of 3 independent experiments were performed, the result of a representative experiment 
is shown. 
 
CORM-3 acts through the NF-κB pathway 
Since up-regulation of the adhesion molecules studied depends on activation of NF-κB, we 
next assessed if CORM-3 interferes with this process. Within one hour of TNF-α stimulation 
NF-κB-binding activity was detected in nuclear extracts of endothelial cells. However, neither 
at this time point nor after 2 hrs of TNF-α stimulation CORM-3 significantly influenced NF-
κB binding activity (figure 2A upper panel). In line with this, no influence of CORM-3 on the 
degradation of IκBα was observed (figure 2A, lower panel). In contrast to these early time 
points, NF-κB binding activity was significantly reduced after 4 hrs of TNF-α stimulation in 
CORM-3-treated cells and gradually declined (figure 2B). This was reflected by a decrease in 
the nuclear expression of NF-κB p65. Nuclear expression of NF-κB p50, however, was not 
changed by CORM-3 (figure 2C). 
Figure 2   A 
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Figure 2 Influence of CORM-3 on TNF-α-mediated NF-κB activation. (A): Endothelial cells 
were stimulated for 1 or 2 hrs with 50 ng/ml of TNF-α in the absence (-) or presence of 1 mM 
of CORM-3 (+). Endothelial cells exposed to culture medium (M) only served as control. 
Nuclear extracts were prepared and used for EMSA as described in Materials and Methods 
(upper panel). To assess the influence of CORM-3 on IκBα degradation, cells were 
stimulated for different time periods using the same concentrations of TNF-α and CORM-3. 
Cell lysates were analysed by Western blot for IκBα and GAPDH to demonstrate equal 
sample loading (lower panel). (B): Influence of CORM-3 on NF-κB activation was also 
analysed at later time points. HUVEC were stimulated as in (A) and nuclear extracts were 
prepared at 0, 4, 12 and 24 hrs after TNF-α stimulation. Specificity of the shifted bands was 
demonstrated by addition of an excess of cold consensus (CC) or cold mutant (CM) 
oligonucleotides to the samples. (C): Nuclear expression of NF-κB p65 and NF-κB p50 in 
TNF-α-stimulated HUVEC. Cells were exposed to TNF-α as above in the presence (+) or 
absence (-) of 1 mM of CORM-3. At the time intervals indicated nuclear extracts were 
obtained and studied for expression of p65 and p50. To confirm equal loading of lanes, 
membranes were stained with anti-histone antibodies. In A, B and C, the results of 1 out of 4 
individual experiments are shown. 
 
 
The presence of TNF-α was required to maintain VCAM-1 and E-selectin expression on 
endothelial cells, since an almost complete down-regulation of these adhesion molecules 
occurred within 24 hrs after TNF-α removal. Although the expression of ICAM was also 
down-regulated when TNF-α was removed from the culture medium, it was still increased 
when compared to basal expression levels. Interestingly, when CORM-3 was added after 24 
hrs to the TNF-α-containing culture medium, this also resulted in a complete loss of VCAM-1 
and E-selectin expression (figure 3A). In contrast, the expression of ICAM-1 was not 
influenced. Hence, CORM-3 is able to down-regulate VCAM-1and E-selectin even in the 
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While TNF-α removal resulted in a rapid decrease in nuclear NF-κB binding activity evident 
already 3 hrs after removal, NF-κB binding activity was attenuated at early time-points after 
CORM-3 addition. Twelve hrs after addition of CORM-3, however, NF-κB binding activity 
was also decreased in these cells (figure 3B). In line with these observations, steady-state 
VCAM-1 mRNA expression decreased much faster when TNF-α was removed compared to 
addition of CORM-3 (figure 3C). Nevertheless, in time response experiments we repeatedly 
observed that disappearance of VCAM-1 protein occurred much faster upon addition of 
CORM-3 than after TNF-α removal (figure 3D). CORM-3 did not influence stabilization of 
VCAM-1 mRNA since steady-state VCAM-1 mRNA decreased to a similar extent in 
actinomycin D-treated HUVEC both in the absence or presence of CORM-3 (data not shown).  
 
Figure 3  
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Figure 3 Influence of CORM-3 or TNF-α removal on (A) surface expression of adhesion 
molecules, (B) NF-κB activation, (C) expression of VCAM-1 mRNA and (D) expression of 
VCAM-1 protein. HUVEC were stimulated for 24 hrs with 50 ng/ml of TNF-α. Hereafter, the 
cells were washed to remove TNF-α or CORM-3 was added in the continued presence of 
TNF-α. Cells that were kept in the presence of TNF-α alone for similar time periods served 
as control. (A): Surface expression of ICAM-1, VCAM-1 and E-selectin after TNF-α 
stimulation (normal line), after addition of CORM-3 or removal of TNF-α (bold line). Basal 
expression of these adhesion molecules is also depicted (dotted line). (B): Nuclear extracts 
were prepared for electrophoretic mobility shift assays at 3, 6 and 12 hrs after TNF-α 
removal or after addition of CORM-3. Nuclear extracts were also prepared directly after 24 
hrs of TNF-α stimulation (TNF-α) or from cells that were kept in the presence of TNF-α but 
not exposed to CORM-3 (no TNF-α removal). Cells that were kept in culture medium (M) 
NF-κB 
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were included to demonstrate TNF-α-mediated NF-κB activation. (C): Steady-state VCAM-1 
mRNA expression. HUVEC were stimulated with TNF-α for 24 hrs. Hereafter, cells were kept 
in the presence of TNF-α (open bars) or washed (filled bars) or CORM-3 was added to the 
cells (hatched bars). Subsequently, the cells were cultured for various time periods and total 
RNA was isolated. Results are expressed as fold increase compared to basal VCAM-1 mRNA 
expression. Significant differences were found between TNF-α removal and CORM-3 
addition at T=3 hrs, T=6 hrs (p<0.01 for both time points) and T=12 hrs (p<0.05). (D): 
HUVEC were treated as in C. At various time periods after TNF-α removal or CORM-3 
addition, cell extracts were prepared. VCAM-1 protein was analysed by Western blotting. In 
A, B, C and D the results of representative experiments are shown. At least 3 different 
experiments were performed. 
 
HO-1 is induced by CORM-3 in an Nrf2-dependent fashion 
CORM-3 induced the expression of HO-1 in a time- and dose-dependent manner (figure 4A). 
While HO-1 was already slightly upregulated at a concentration of 100 µM, this was much 
more pronounced when 1 mM was used (figure 4A, upper panel). At the latter concentration 
upregulation of HO-1 protein was apparent already 3 hrs after addition of CORM-3 (figure 
4A, middle panel). Degassing of the CORM containing solution did not completely abrogate 
upregulation of HO-1, suggesting that this was partly mediated by the 
tricarbonylchlororuthenium(II) derivative itself (figure 4A, upper panel). PCR analysis 
revealed that upregulation of HO-1 mRNA occurred at similar concentrations as was observed 
for HO-1 protein (figure 4A, right panel).  
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Figure 4 Induction of HO-1 by CORM-3. (A): HUVEC were incubated for 24 hrs with 
different concentrations of CORM-3 or degassed CORM-3. Hereafter, cell lysates were 
studied by Western blot analysis for HO-1 and GAPDH expression (upper panel). In a second 
set of experiments, HUVEC were incubated for different time periods with 1 mM of CORM-3. 
The expression of HO-1 was assessed by Western blotting (middle panel). To demonstrate 
that HO-1 expression was regulated at the transcriptional level, total RNA was isolated from 
HUVEC that were incubated with different concentrations of CORM-3. RT-PCR for HO-1 
and GAPDH was subsequently performed (right panel). (B): Nuclear translocation of Nrf2 
was assessed by Western blot analysis of nuclear protein isolated from HUVEC that were 
stimulated for different time periods with 1 mM of CORM-3. (C): HUVEC were transfected 
with reporter constructs containing either the ARE consensus sequence of the HO-1 promoter 
(HO-ARE) or with a reporter construct containing 3 hypoxia responsive elements (3HRE). In 
each case co-transfection was performed with the ubiquitin-dependent Renilla luciferase 
reporter. Luciferase activities were normalized for luciferase acivity generated by the Renilla 
luciferase control reporter. The results are expressed as fold increase compared to 
unstimulated controls. Significance was only found for the HO-ARE reporter, p<0.01 
untreated vs. CORM-3 treated. In A, B and C the results of representative experiments are 
shown. At least 4 different experiments were performed. 
 
Since these data suggested that CORM-3-mediated HO-1 expression was transcriptionally 
regulated, we next investigated the involvement of three transcription factors that have been 
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occurred after CORM treatment (data not shown). In contrast, nuclear translocation of Nrf2 
was clearly evident 3 hrs after CORM-3 treatment (figure 4B). CORM-3 did not induce 
expression of a hypoxia-responsive element-dependent luciferase reporter construct, while 
this was the case in cells transfected with an Nrf2 reporter (figure 4C).  
 
CORM-3 induced HO-1 expression does not contribute to inhibition of VCAM-1 expression  
Since CORM-3 induces HO-1 expression, this might further increase intracellular CO 
concentrations and hence may perpetuate down-regulation of adhesion molecules in the 
presence of TNF-α. To address this issue, we first stimulated endothelial cells with 1 mM of 
CORM-3 to induce HO-1 followed by a challenge with TNF-α. Despite an increase in HO-1 
expression, induction of VCAM-1 by TNF-α was not influenced in these cells (figure 5A). To 
formally exclude a role for HO-1 in down regulation of VCAM-1 expression we also used a 
siRNA approach to deplete HO-1 or Nrf2. The expression of both HO-1 and Nrf2 was almost 
completely blocked by this approach (figure 5B). Nevertheless, neither TNF-α-induced 
VCAM-1 expression, nor inhibition hereof by CORM-3 was significantly changed in HO-1- 
and Nrf2-depleted endothelial cells, respectively (figure 5C upper panel). Compatible with the 
pivotal role of Nrf2 in HO-1 induction, Nrf2 siRNA treatment abolished the upregulation of 
HO-1 by CORM-3 (figure 5C, lower panel).  
 
 Figure 5     
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Figure 5 Induction of HO-1 is not involved in CORM-3 mediated downregulation of VCAM-1 
expression. (A): HUVEC were incubated for 24 hrs with CORM-3 (bold line) or left untreated 
(normal line). Hereafter, the cells were washed and stimulated for 24 hrs with 50 ng/ml of 
TNF-α. Basal expression of VCAM-1 is depicted as dotted histogram. (B): HUVEC were 
transfected with Nrf2, HO-1 or control siRNA. Two days after transfection the expression of 
HO-1 and Nrf2 was assessed by Western blot analysis. (C): Transfected cells were 
subsequently stimulated for 24 hrs with TNF-α (50ng/ml) or TNF-α plus CORM-3 (1 mM). 
The expression of VCAM-1 (upper panel) and HO-1 (lower panel) was assessed by Western 





Based on current evidence, the HO-1 pathway is of undisputable importance for the control of 
inflammation. Overexpression of HO-1 modulates pro-inflammatory processes in a number of 
cells including macrophages and endothelial cells (11, 12, 37, 38), yet, the mechanisms by 
which HO-1 exerts its salutary effects are not completely delineated. In the present study we 
investigated the role of HO-1 in perpetuation of the anti-inflammatory effect of CORM-3. The 
main findings of this study were the following. First, CORM-3 consistently inhibited the 
upregulation of VCAM-1 and E-selectin after TNF-α stimulation, but the influence on ICAM-
1 was only marginal. Second, initial activation of the NF-κB pathway by TNF-α is not 
influenced by CORM-3. Instead, CORM-3 deactivates sustained activation of this pathway. 
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Third, HO-1 is induced by CORM-3 in an Nrf2 dependent fashion. Fourth, induction of HO-1 
does not contribute to down-regulation of VCAM-1 and E-selectin expression by CORM-3. 
 
There is some controversy on the main mediators through which HO-1 acts as a modulator of 
inflammation. Clearly, this might be related to the different cell types, i.e. macrophages (11, 
37) or endothelial cells (12, 38), that were used in different studies. While in vitro (11, 39) 
and vivo studies (40, 41) have demonstrated that CO acts as an anti-inflammatory mediator, 
more recent studies have questioned this paradigm by showing that bilirubin and/or Fe2+ 
chelation, both of which are increased as a consequence of HO-1 activity, play a more 
important role in down-regulation of adhesion molecules under inflammatory conditions (12, 
13). Our own findings do not corroborate with the latter studies, as we demonstrate that 
CORM-3 has the propensity to inhibit VCAM-1 and E-selectin expression through the release 
of CO. Still, it can be argued that while CORM-3 strongly upregulates HO-1, downregulation 
of these adhesion molecules could occur though generation of bilirubin and ferritin-mediated 
Fe2+ chelation. Two lines of evidence are, however, against this assumption. First, pre-
treatment of endothelial cells with CORM-3 did not largely influence VCAM-1 and E-selectin 
expression upon a subsequent challenge with TNF-α in the absence of CORM-3. Second, 
when induction of HO-1 was prevented by means of siRNA CORM-3 was still effective.  
 
It must be emphasized that this study does not argue against the important role of the HO-1 
system in control of inflammation, as it inherently demonstrates its anti-inflammatory 
potential through generation of CO, but our data do suggest that upregulation of HO-1 per se 
not necessarily exerts anti-inflammatory properties. This notion is compatible with in vitro 
studies of Foresti et al using cardiomyocytes (42). They showed that although hypoxia 
increased the expression of HO-1, cardiomyocytes were still vulnerable to damage during 
reoxygenation unless, hemin was added during the hypoxic phase. Therefore, substrate 
availability seems to be an important factor that influences the anti-inflammatory effect of 
HO-1. Production of cellular heme is a multistep process that includes mitochondrial and 
cytoplasmic elements. The rate-limiting step is the production of δ-aminolevulinic acid from 
succinyl CoA and glycine which is catalyzed by δ-aminolevulinic synthase (ALAS) (43, 44). 
ALAS is tightly regulated, in a negative feedback manner by heme, and positively by an 
increase in intracellular Ca2+ or proten kinase C activation (45). 
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Taking into account that CO has a high affinity for Fe2+ and acts as ligand to complete the co-
ordination shell of this atom, it is likely that CO-Fe complexes will form (46, 47). Moreover, 
CORM-3 behaved similar as cells stably transfected with HO-1 in regard to Fe homeostasis, 
as demonstrated by Watts et al (48). Hence, if Fe2+ chelation can inhibit TNF-α mediated 
expression of adhesion molecules, not surprisingly, similar effects can be expected by the 
addition of CORM-3. 
 
There is consistency amongst the in vitro studies that the major adhesion molecules that are 
affected by HO-1 are VCAM-1 and E-selectin (12). Nevertheless, in vivo studies also 
demonstrate down-regulation of ICAM-1, as a consequence of HO-1 expression (49, 50, 51). 
In addition, both basal and TNF-α induced expression of ICAM-1 are increased in Hmox1-/- 
compared to Hmox1+/+ endothelial cells (13). Our findings are in agreement with these studies 
in that VCAM-1 and E-selectin were consistently downregulated by CORM-3, while ICAM-1 
was marginally influenced and only in three out of eight HUVEC lines tested. In comparison, 
to VCAM-1 and E-selectin, ICAM-1 also behaved differently with respect to TNF-α removal. 
The expression of the former two adhesion molecules was completely lost 24 hrs after TNF-α 
removal but ICAM-1 expression was still increased at this time point. 
 
The involvement of the NF-κB pathway as a target by which HO-1 modulates the expression 
of adhesion molecules seems consistent throughout the different studies (52). If the NF-κB 
pathway plays a pivotal role in HO-1-mediated modulation of adhesion molecules, then the 
question that arises is why CORM-3 not consistently affects ICAM-1 expression, although the 
role of NF-κB activation in the regulation of ICAM-1 has been clearly demonstrated (53, 54). 
Our finding that TNF-α removal results in deactivation of the NF-κB pathway indicates the 
importance of sustained NF-κB activation for maintaining high levels of all three adhesion 
molecules. Yet, deactivation of NF-κB through the addition of CORM-3 to TNF-α-stimulated 
endothelial cells occurred much slower and did not affect ICAM-1 expression. It thus seems 
that, although deactivation of NF-κB, and hence reduction in mRNA transcription, have a 
major effect on the expression of VCAM-1 and E-selectin, post-translational mechanisms 
might contribute to down-regulation of these molecules by CORM-3. In line with this, it was 
found that downregulation in VCAM-1 protein by TNF-α removal was much slower 
compared to addition of CORM-3, although NF-κB deactivation occurred much faster under 
the former condition.  
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Induction of HO-1 by CORM-3 occurred in an Nrf2-dependent manner. This is compatible 
with previous findings in hepatoma cells (29). Although HIF1α stabilization by CO has been 
described in macrophages (30), it was not involved in the induction of HO-1 in our study 
using endothelial cells. A number of molecules, mostly anti-oxidants, have the propensity to 
downregulate adhesion molecules. HO-1 might be a common denominator for the anti-
inflammatory effects mediated by these anti-oxidants as most of these affect the keap1/Nrf2 
pathway and result in an increased HO-1 expression (35, 55). Our study however showed that 
neither Nrf2 nor HO-1 was involved in downregulation of VCAM-1 expression by CORM-3. 
 
In conclusion, our study demonstrates that CORM-3 can downregulate VCAM-1 and E-
selectin even in the continued presence of TNF-α. Although HO-1 was induced by CORM-3, 
it did not influence the expression of adhesion molecules. We speculate that the 
downregulation of adhesion molecules is mediated by deactivation of the NF-κB pathway, 
concomitantly with an increased turn-over of these proteins. How CORM-3 influences protein 
turn-over is at present unclear. Our data also suggest that CORM-3 is of potential therapeutic 
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CORM-3 protects endothelial cells during cold 
preservation, resulting in improved vascular function and 
inhibition of intimal hyperplasia after aorta 
transplantation in rats 
 

















Carbon monoxide releasing molecules (CORMs) are a novel class of compounds that can 
deliver CO to tissues in a controllable fashion. Here, we investigated the beneficial effect of 
CORM-3 on cold preservation-induced injury in vitro and its influence on vascular function 
and on neo-intima formation after aorta transplantation. 
Abdominal aortas from Lewis rats were cold preserved in UW with or without CORM-3. 
Hereafter, whole mount staining for CD31, acetylcholine mediated vasorelaxation and 
transplantation in syngenic rats were performed.   
During cold preservation CORM-3 protected human umbilical vein endothelial cells (HUVEC) 
against necrosis and prevented denudation and intercellular gap formation in isolated rat 
abdominal aortas. Cold-preservation resulted in a profound loss of acetylcholine-mediated 
vasorelaxation of aorta segments, which was restored when CORM-3 was added during 
preservation. Vasorelaxation in response to the NO-donor SNP was not changed by cold 
preservation and not influenced by CORM-3. Cold preservation of aortic isografts in UW for 
24 hrs resulted in a significant increase in fibrotic adventitial remodeling and neo-intima 
formation two months after transplantation compared with isografts that were not subjected to 
cold preservation. Presence of CORM-3 during cold preservation significantly reduced 
fibrotic adventitial remodeling and neo-intima formation.  
Our study demonstrates that addition of CORM-3 to the UW preservation solution prevents 
endothelial damage, thereby limiting vascular loss of function directly after cold preservation. 
Because CORM-3 also prevents intimal hyperplasia, our findings might offer better 
approaches for organ preservation in order to limit transplant loss resulting from chronic 















Allocation of organ allografts has become possible by adequate improvements in organ 
preservation. In solid organ transplantation, static cold storage is the most widely used 
modality for preserving cadaveric organs prior to transplantation. However, with increasing 
cold ischemia time, organ quality and function are deteriorating as a consequence of a series of 
events such as oxidative stress, intracellular iron release and calcium overload (1-3). Cold 
preservation injury is a major cause of pre-tranplantation injury of allografts and is 
significantly associated with initial organ non-function and late transplant loss (4-7). 
Chronic transplant vasculopathy remains a leading cause for chronic organ loss after 
transplantation (8, 9) and is characterized by a prominent vascular remodeling in which the 
luminal areas of arteries become obliterated due to occlusive intimal hyperplasia. Although 
the etiology of intimal hyperplasia is not well delineated, pre-transplantation injury is 
recognised as an important cause for this complication. In addition, as donor allogeneic 
endothelial cells of the graft’s vasculature are under continuous attack of the recipient’s 
immune system, an imbalance between damage and repair might contribute to intimal 
hyperplasie (10). Participation of migrating smooth muscle cells and proliferation of recruited 
progenitor cells in neo-intima formation have been well documented in primarily 
experimental models of transplant vasculopathy (11, 12).  
Carbon monoxide (CO), an endogenous by-product of heme catalysis by heme oxygenase 
(HO), has a diversity of cell biological functions, including cGMP-mediated vasorelaxation 
(13, 14), inhibition of cell proliferation (15, 16), inhibition of apoptosis (17) and suppression 
of inflammation (18). Based on these effects it is not surprising that CO has the propensity to 
protect different organs against ischemia and reperfusion injury (19, 20-23). It has been 
postulated that the mechanism by which CO mediates organ protection is, amongst others, via 
the induction of HO-1 and activation of the p38 MAPK signalling pathway (13, 17, 18). In 
most organ transplantation studies involving CO, delivery of CO was performed by 
ventilation (19, 21, 22). As a novel approach to deliver CO, Motterlini et al has reported on a 
new class of compounds, termed CO-releasing molecules (CORMs), which are able to release 
CO in a controllable manner under physiological conditions (24). In particular, the fully 
water-soluble CORM-3 (tricarbonylchloro(glyconato)ruthenium(II)) and CORM-A1 (sodium 
boranocarbonate), can be potentially used as additives in preservation solutions (23, 25). 
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Because endothelial cell injury is a prominent feature of cold ischemia (26), strategies to 
mitigate cold preservation injury might be a beneficial approach to limit intimal hyperplasia. 
In the present study we employed in vitro and in vivo models to test the hypothesis that addition 
of CORM-3 to the preservation solution protects vascular endothelial cells from damage, and 
hence better preserves vascular function during cold storage. In addition, we hypothesize that a 
reduction in endothelial cell damage will significantly decrease neo-intima formation. To study 
the effect of CORM-3 on neo-intima formation developing as a result of solely cold 
preservation-induced endothelial damage and not alloantigen-driven immunity, a syngeneic 
Lewis-to-Lewis aortic transplant model was used.  
 
 Materials and methods 
 
Reagents 
Endothelial cell growth medium MedKIT, Phenol-red free medium (Promocell, Heidelberg, 
Germany), PBS (Invitrogen, Karlsruhe, Germany), Fetal bovine serum (FBS) Gold (PAA 
laboratories GmbH, Pasching, Austria), Tripsin/EDTA solution, DMSO, TritonX-100, 
tricarbonyldichlororuthenium(II) dimer ([Ru(CO)3Cl2]2), glycine, sodium ethoxide,  
tetrahydrofuran, acetylcholine (Ach), sodium nitroprusside (SNP), 1H-[1, 2, 4]oxadiazolo[4, 
3-alpha]quinoxalin-1-one (ODQ)  (Sigma, St. Louis, MO), Bovine Serum Albumin (SERVA, 
Heidelberg, Germany), 37% formaldehyde (Mallinckrodt Baker, Deventer, Holland). 
 
Synthesis of tricarbonylchloro(glycinato)ruthenium(II) 
Tricarbonylchloro(glycinato)ruthenium(II) ([Ru(CO)3Cl(glycinate)]) was synthesized from a 
commercially available compound, tricarbonyldichlororuthenium(II) dimer ([Ru(CO)3Cl2]2). 
Briefly, [Ru(CO)3Cl2]2 (0.5 g) and glycine (0.151 g) were placed under nitrogen in a round-
bottomed flask. Methanol (291 ml) and sodium ethoxide (0.132 g) were added and the 
reaction was allowed to continue under stirring for 18 hrs at room temperature. The solvent 
was then removed under pressure and the yellow residue re-dissolved in tetrahydrofuran 
(THF). The yellow solution was evaporated down to give a pale yellow solid (yield 92-96%) 
and was aliquoted and stored in closed vials at room temperature. For each experiment 
CORM-3 was dissolved freshly in PBS. 
 
Cell culture and CORM-3 treatment  
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Human umbilical vein endothelial cells (HUVECs) were isolated from fresh umbilical cords 
and cultured as described previously (2). The cells were seeded in 24-well plates in basal 
endothelial medium supplemented with 10% FBS and essential growth factors until they 
formed a confluent monolayer. Cells were then stored for 24 hrs at 4oC in UW solution in the 
presence or absence of different concentrations CORM-3. In some experiments cells were 
pre-treated with different concentrations CORM-3 for 6 hrs prior to cold preservation. 
Thereafter the cells were washed two times with PBS and stored for 24 hrs at 4°C in UW 
solution. Directly after cold preservation cell damage was assessed by measuring lactate 
dehydrogenase (LDH) (Roche Diagnostics, Mannheim, Germany) activity in the supernatants 




Inbred male Lewis rats weighing 250 to 300g were obtained from Charles River (Sulzfeld, 
Germany). Animals were kept under standard conditions and fed standard rodent chow and 
water ad libitum. All procedures were performed according to the Guide for the Care and Use 
of Laboratory Animals published by the National Academy of Sciences and were approved by 
the local authorities (RP Karlsruhe, AZ 35–9185.81/91/07).  
 
Vascular function 
Abdominal aortas were explanted from Lewis rat, and either directly used for subsequent 
experiments or stored for 24hrs at 4oC in UW solution in the presence or absence of 50µM 
CORM-3. Vascular function measurement was performed according to previous description 
by Witte et al (27). Briefly, the aortas were prepared and cleaned from peri-adventitial fat and 
surrounding connective tissues, cut transversely into 2-mm width rings and mounted on 
stainless steel hooks in individual organ baths containing Krebs-Henseleit solution (NaCl 
119mM, KCl 3mM, MgCl2 1.2mM, CaCl2 1.5mM, NaH2PO4 1.2mM, NaHCO3 20mM, 
Glucose 10mM) at 37 ºC and aerated with 75% N2, 20% O2 and 5% CO2. The aortic rings 
were placed under a resting tension of 15mN and equilibrated for 60 minutes. During this 
period, tension was periodically adjusted to the desired level and the Krebs-Henseleit solution 
was changed regularly. The aortic rings were challenged by increasing concentration of KCl 
(20mM, 30mM, 40mM, 50mM, 80mM and 124mM) in Krebs solution in which NaCl was 
substituted by KCl to keep osmolarity constant. The maximal contraction forces to potassium 
chloride were determined according to the responsive curves. Aortic rings were washed until 
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resting tension was obtained again. KCl 50mM was used to pre-contract the aortic rings until 
a stable plateau was reached. Concentration response curves were constructed by 
cumulatively adding acetylcholine (Ach, 10-9-10-4 M) or sodium nitroprusside (SNP, 10-9-10-5 
M) to elicit the endothelium-dependent (Ach) or endothelium-independent (SNP) relaxations. 
The data were monitored and analysed using the LabView-based software previously 
developed in our lab. 
 
Whole mount aorta staining 
To study the effect of cold preservation with or without CORM-3 on endothelial integrity, 
freshly isolated or cold preserved aortas were transversely cut into 3-4 mm segments and 
fixed at room temperature for 2hrs in freshly prepared 4% formaldehyde. After fixation, the 
segments were washed three times with PBS for 1hr. Subsequently, the segments were 
incubated for 20 min in PBS containing 1% BSA, 0.5% Triton and 5% rabbit serum, followed 
by extensively washing with PBS. The segments were incubated overnight at 4oC with a 
purified mouse anti-rat CD31 antibody (BD Pharmingen, Heidelberg, Germany) diluted in 
PBS. After washing, rabbit anti-mouse Texas-red conjugated IgG was added for 2hrs. Nuclei 
were visualized by addition of TOTO3 10 min before mounting. Finally, the aorta segments 
were longitudinally cut into halves and mounted onto glass slides in 50% glycerol/PBS, with 
the luminal side up. Fluorescence was analysed by confocal microscopy using the 




Aorta transplantation was performed in the syngeneic Lewis-to-Lewis strain combination. All 
animals received ketamine and xylazine (100 and 6 mg/kg i.p., respectively) as an anesthetic 
agent. A 1.5 cm long segment of the descending abdominal aorta was removed, thoroughly 
flushed with UW-solution, and either directly transplanted or subjected to 24 hrs of cold 
preservation in UW solution. Aortas were preserved in UW solution at 4°C either in the 
presence or absence of 50µM of CORM-3. Aortas were orthotopically transplanted in 
between the renal arteries and bifurcation. The cranial anastomosis was made as close to the 
renal arteries as technically possible to minimize diameter difference. End-to-end 
anastomoses were performed using 9-0 nylon suture. Total warm ischemic time in the 
recipient was consistently ~30 minutes. Grafts were harvested 2 months after transplantation 
and then processed for histological analysis as described below.  
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Quantification of intimal hyperplasia 
Two months after transplantation, aorta grafts from each groups (n=5) were harvested, fixed 
in 4% formaldehyde and mounted in paraffin. Sections were cut (5 µm) from at least 4 
different segments of the graft, deparaffinized according to standard methods and stained with 
hematoxylin/eosin.  
The degree of intimal hyperplasia was assessed by morphometric analysis and expressed as 
mean ratio of the intima surface (µm2) / intima + media surface (µm2) in different sections 
and segments of the transplanted aorta.  
 
Statistical analysis 
Data are presented as mean ± SD or mean ± SEM for the indicated number of separate 
experiments. All analyses were based on more than three independent experiments. 
Differences between groups were determined by Student’s t test. A p-value of less than 0.05 




CORM-3 protects endothelial cells against cold preservation damage 
Addition of CORM-3 to the preservation solution protected endothelial cells against cold 
preservation damage in all HUVEC cell lines tested (n=5). The protective effect of CORM-3 
was detected over a wide concentration range of CORM-3, with maximal inhibition already 
occurring at 16 µM (Figure 1A, black circles). To test if the protective effect of CORM-3 was 
dependent on the release of CO, similar concentrations of degassed CORM-3 were tested in 
parallel experiments. In contrast to CORM-3, degassed CORM-3 did not inhibit LDH release 
during cold preservation (CORM-3 vs. degassed CORM3, p<0.01) (Figure 1A, filled squares). 
We also investigated if CORM-3 pre-treatment of HUVEC, followed by cold preservation in 
the absence of CORM-3, was equally effective as addition of CORM-3 only during cold 
preservation. Pre-treatment was less effective compared to treatment during cold preservation, 
as significant higher concentrations of CORM-3 were required for protection (Figure 1A, 
open triangles). The protective effect of CORM-3 was largely independent of cGMP, since 
inhibition of guanylate cyclase (GC) by ODQ only marginally, though significantly, inhibited 
the protective effect of CORM-3 on cold preservation-induced endothelial damage (Figure 
1B). Similar results were observed with higher concentrations of ODQ (data not shown). 
    Figure 1  
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Figure 1 CORM-3 treatment renders vascular endothelial cells resistance to hypothermia-
induced cell damage. (A) Different concentrations of CORM-3 were either added to HUVECs 
during cold preservation (filled circles) or HUVECs were pre-treated for 6 hrs with similar 
concentrations of CORM-3 before cold preservation was started (open triangles). A degassed 
solution of CORM-3 (filled squares) tested in the same concentration range was used to 
demonstrate that the effect was mediated by CO release. (B)  HUVECs were pre-treated for 1 
hr with 50µM of ODQ or left untreated. Hereafter the cells were subjected to 24 hrs of cold 
preservation in the presence or absence of 50µM of CORM-3. ODQ was also present during 
cold preservation in the pre-treated group. Directly after cold storage cell damage was 
assessed by LDH-release in the supernatants. All experimental conditions were performed in 
triplicate. The results of a representative experiment are expressed as mean ± SD. A total of 5 
experiments were performed. (* p<0.01)  
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We next assessed if also the endothelium in aorta segments were damaged during cold 
preservation and to what extent this was prevented by the addition of CORM-3 to the 
preservation solution. The endothelium in aorta segments that were stored for 24 hrs at 4oC 
was dramatically changed compared with freshly isolated, no cold preserved aorta’s. After 
cold preservation, endothelial cells displayed an irregular morphology with large intercellular 
gaps between the cells and in the majority of cells nuclear condensation and fragmentation 
occurred (Figure 2, left panel). In contrast, when CORM-3 was added during cold 
preservation cell morphology, CD31 expression and nuclear appearance (Figure 2, middle 
panel) was similar to that observed in freshly isolated aorta’s that were not subjected to cold 
preservation (Figure 2, right panel). 
Figure 2 
Figure 2 Influence of CORM-3 on endothelial integrity in aorta segments subjected to cold 
preservation. Whole mount staining for CD31 (red) was performed as described in the 
Material and Method section. Nuclear staining is depicted in blue. Note that in the aorta 
segments subjected to cold preservation in the absence of CORM-3, endothelial cell 
morphology was irregular with intercellular gaps (bold arrows) appearing between adjacent 
endothelial cells. Also in the majority cells nuclear condensation and fragmentation (arrow) 
was observed (left panel). In contrast, aorta segments to which 50 µM of CORM-3 was added 
during cold preservation (middle panel) appeared to be similar to freshly isolated aorta 
segments not subjected to cold preservation (right panel). Original magnification: 200x                    
Since endothelial NO production plays a critical role in vasorelaxation (27, 28), we 
subsequently tested if this response was impaired by cold preservation. Endothelial 
naiveCP CP-CORM-3
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dysfunction was defined as a reduction in maximal relaxation in response to acetylcholine. 
After 24hrs of cold preservation, vascular function was markedly impaired, as indicated by a 
significant reduction in maximal relaxation compared to freshly isolated aortas (aortas with 
cold preservation vs freshly isolated aortas: 24.6± 10.7% vs 54.1± 2.6%, p<0.01).  When 
CORM-3 (50µM) was added during cold preservation, endothelial function was significantly 
improved, reaching a maximal relaxation of 43.4±7.6% (cold preservation-CORM-3 vs cold 
preservation, p<0.05) (Figure 3A). In contrast to the endothelium-dependent vasorelaxation 
response, the endothelium-independent response was not affected by cold preservation. 
Addition of the NO donor sodium nitroprusside (SNP) to the organ bath resulted in a dose-
dependent vasorelaxation. No significant differences between the two treatment groups and 
freshly isolated aorta’s were observed (Figure 3B), indicating that, unlike endothelial cell 
function, medial smooth muscle cell function is not impaired due to 24 hrs cold preservation. 
Figure 3 
   A                                                                                B 
Figure 3 Administration of CORM-3 during cold preservation improves vascular function. 
Isolated abdominal rat aortas were subjected to cold preservation (CP) for 24 hrs in the 
presence (CP-CORM-3, black circles) or absence (CP, open circles) of 50µM of CORM-3. 
Naïve aortas without cold preservation (black diamonds) were included as control. (A) 
Endothelial function was analysed by endothelium-dependent relaxation in response to 
cumulative acetylcholine concentrations (10-9-10-4 M). (B) Smooth muscle cell function was 
demonstrated by endothelium-independent relaxation in response to cumulative sodium 
nitroprusside concentrations (10-9-10-5 M). Five animals were included in each group and 16-
18 aortic segments of each group were analysed. The results were expressed as mean 
maximal relaxation ± SEM at indicated concentration Ach or SNP. (*p<0.05, CP-CORM-3 vs 
CP)   
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To demonstrate the influence of cold preservation on vascular remodelling, we performed 
abdominal aorta transplantations in the syngeneic Lewis-to-Lewis rat strain combination. 
Before transplantation, donor aorta grafts were stored for 24 hrs at 4˚C in UW solution with 
or without 50µM CORM-3. When the aortas were harvested two months after transplantation, 
macroscopic inspection consistently revealed massive amounts of fibrous tissue surrounding 
transplants that were preserved at 4oC in the absence of CORM-3 (Figure 4A, middle panel). 
In contrast, grafts that were preserved in the presence of CORM-3 did not display any signs of 
adventitial fibrous remodeling, (Figure 4A, right panel), resembling the naïve aorta of non-
transplanted animals (Figure 4A, left panel).  
                                      B 
       
 




No CP, transplanted Two months after transplantation
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Figure 4 Addition of CORM-3 during cold preservation inhibits vascular remodeling.  (A) 
Syngeneic aorta transplantations were performed as described in the Material and Method 
section. The aortas were subjected to 24 hrs of cold preservation in the absence (CP) or 
presence (CP-CORM-3) of 50µM CORM-3. Two months after transplantation the grafts were 
harvested and macroscopically examined. Note the presence of fibrous tissue surrounding the 
graft (arrow) in the aortas subjected to cold preservation in the absence of CORM-3 (middle 
panel). This was not observed when 50 µM of CORM-3 was added during cold preservation 
(right panel). For comparison an aorta from a naïve non-transplanted rat is also depicted 
(left panel). (B) After macroscopic examination, the grafts were harvested and tissue sections 
were analysed by light microscopy using H&E staining. Representative photographs of 
transplanted grafts not subjected to cold preservation (No CP), subjected to cold preservation 
in the absence (CP) or presence of 50 µM of CORM-3 (CP-CORM-3) are depicted. Intimal 
hyperplasia is shown as the tissue in between the black arrows. Original magnification: 200x. 
(C) Quantitative analysis of intimal hyperplasia. Grafts from group CP and CP-CORM-3 
were analysed by means of quantitative computerized morphometry. Grafts from the No-CP 
group were not analysed because intima thickening was only marginally present and only at 
the site of anastomosis. The degree of hyperplasia was assessed as described in the Materials 
and Method section. The results are expressed as mean ratio [intima surface (µm2) / intima + 
media surface (µm2)] ± SEM of 5 different sections for each group and with n=6 animals in 
each group. (*p<0.01).  
 
Histological analysis revealed that two months after transplantation neo-intima formation was 
marginal in the Lewis-to-Lewis model when no cold preservation was performed (Fig. 4B, 
picture to the left). Cold preservation significantly aggravated neo-intima formation when the 
aortas were preserved at 4°C in the absence of CORM-3 (Figure 4B, middle panel), while 
addition of CORM-3 to the preservation solution obviously attenuated neo-intima formation 
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Quantitative analyses using computerized  morphometry (i.e. determination of the ratio of 
intima surface / media + intimal surface) in different sections and segments of the graft 
revealed that the degree of intimal hyperplasia was significantly reduced in CORM-3- treated 
aorta grafts (cold preservation-CORM-3 vs cold preservation, 0.12±0.01 vs 0.45±0.04, p<0.01) 




Chronic allograft vasculopathy (CAV) is a leading cause for late allograft loss after organ 
transplantation (5, 6, 10, 12). Both prolonged cold ischemia time and immune-mediated 
mechanisms are believed to contribute to CAV. A characteristic finding in CAV is intimal 
hyperplasia, arising from the migration and proliferation of smooth muscle cells (SMC) 
culminating in the formation of an occlusive neo-intima. In the present study we hypothesized 
that prevention of endothelial damage during cold preservation can significantly ameliorate 
intimal hyperplasia. We therefore first analysed if addition of CORM-3 to UW preservation 
solution can protect in vitro cultured HUVECs and aorta endothelium from cold preservation 
injury. Secondly, we assessed to what extent cold preservation affects endothelial function, 
defined as vasorelaxation in response to acetylcholine. Finally we addressed if prevention of 
vascular injury by addition of CORM-3 during cold preservation reduces intimal hyperplasia 
after transplantation. To exclude alloimmune-mediated mechanisms in the development of 
intimal hyperplasia, these latter in vivo studies were performed in the syngeneic Lewis-to-
Lewis aorta transplant model. The main findings of our study are the following: CORM-3 
protects in vitro cultured HUVECs as well as aorta endothelium against cold preservation-
induced damage. Cold preservation causes impaired endothelial function reflected by a 
diminished endothelium-dependent but not -independent vasorelaxation response. Addition of 
CORM-3 during cold preservation improves vascular function and limits intimal hyperplasia 
after transplantation. 
 
The finding that CO beneficially affects intimal hyperplasia in an aorta transplantation model 
is in itself not novel as this has already been demonstrated by Otterbein et al (29). However, 
in their model the recipients were treated, as opposed to our study in which only the graft was 
treated during cold preservation. Moreover recipient treatment was performed by means of 
CO inhalation over the whole observation period, starting directly after transplantation. In 
addition they did not perform cold preservation of the allograft. This is not trivial because our 
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data indicate that cold preservation severely damages endothelium in vitro as well as in aorta 
grafts before transplantation. Based on their data it is therefore unclear if CO treatment of the 
recipient is able to prevent intimal hyperplasia in the face of pre-existing vascular injury. Our 
study clearly shows that prevention of endothelial injury during cold preservation is very 
efficacious in limiting intimal hyperplasia in a syngeneic aortic transplant model. We are 
however aware that a syngeneic donor – recipient combination is not reflecting the clinical 
practice of organ transplantation and that ongoing alloimmune-mediated vascular damage is 
of importance for the development of intimal hyperplasia. Nevertheless, this study 
emphasizes the pivotal role of cold preservation damage on vascular remodeling, and suggests 
that if CO treatment would be implemented in transplantation medicine, it should be 
preferably already start during cold preservation. 
 
Indeed, several studies have shown that application of donor CO treatment can ameliorate 
chronic allograft nephropathy (30) and improve islet allograft survival (31). In all of these 
studies, however, cold preservation was not performed. Although our data indicate that pre-
treatment with CORM-3 followed by cold preservation in the absence of CORM-3 was to 
some extent protective, much higher concentrations of CORM-3 were required to achieve 
protection. Hence, the beneficial effect of donor CO conditioning might be partly lost upon 
prolonged cold preservation. Addition of CORM-3 to the preservation solution has also been 
studied in heart grafts, but they were not transplanted (25). After ex vivo reperfusion of these 
grafts, a significant improvement in systolic and diastolic function as well as coronary flow 
was found. Our own data with aorta grafts also show functional improvement after cold 
preservation when CORM-3 was added to the preservation solution. The role of cGMP in 
functional improvement by CORM-3 was not assessed in our study, although in vitro 
experiments revealed that the protective effect of CORM-3 on LDH-release by HUVECs was 
only marginally influenced in the presence of a guanylate cyclase inhibitor.  
 
Vascular remodeling following cold preservation and transplantation was not only restricted 
to intimal hyperplasia, but also the amount of fibrous tissue surrounding the graft was clearly 
increased. Intimal hyperplasia and expansion of the fibrous tissue were both attenuated when 
cold preservation was performed in the presence of CORM-3. This might be related to the 
inhibitory effect of CO on the proliferation of smooth muscle cell (32) and fibroblasts (33). 
However, as ongoing inflammation might amplify smooth muscle cell proliferation and since 
CO has anti-inflammatory properties, inhibition of inflammation can not be completely 
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excluded. Specific immunohistochemisty for various leukocyte subsets was not performed 
since microscopical analysis of H&E stained sections did not reveal a significant amount of 
inflammatory cells in both the CORM-3 treated and non-treated grafts.    
 
In conclusion, our study demonstrates that endothelial damage during cold preservation is an 
eligible condition for intimal hyperplasia after transplantation and that it can occur 
independently of an anti-donor immune response.  Since chronic allograft vasculopathy 
remains a major cause for transplant loss, prevention of vascular injury before organ 
implantation is of utmost importance. This objective can simply be achieved by addition of 
CORM-3 to the preservation solution. Further studies are nevertheless warranted to assess the 
efficacy of this approach for transplantation outcome in vascularized allogeneic solid organs.    
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Solid organ transplantation, as a treatment modality for patients with end-stage organ disease, 
has become possible by adequate improvements in surgical techniques, organ preservation and 
immunosuppression. Organs procured from deceased donors have already suffered from 
damage as a consequence of brain death. Some of these donors are hemodynamic instable, 
which might lead to disturbances in organ perfusion (1, 2). Optimal donor management is 
therefore of critical importance to the success of transplantation. Apart from the deleterious 
event of brain death, organ allografts are further injured when in transit to the recipient. Static 
cold storage is the most widely used approach for organ preservation, yet allograft quality and 
function deteriorate with the increasing cold preservation time (3-5). The studies presented in 
this thesis were aimed to understand why prolonged cold preservation leads to endothelial cell 
injury, how this injury subsequently influences vascular function and might provoke 
inflammation, and finally to find strategies to prevent endothelial damage during static cold 
storage. With respect to the latter, we focussed on two different compounds, i.e. dopamine 
and related compounds and on carbon monoxide releasing molecules (CORMs).  
Donor preconditioning might be a meaningful strategy to maintain organ allograft quality (7, 
8). Most of the published experimental studies on donor preconditioning were aimed at 
reducing ischemia/reperfusion (IR) injury, a complex interrelated sequence of events that 
classically involves the vascular endothelium and activated leukocytes (6-9). Interestingly, 
donor dopamine usage is significantly associated with a reduced risk for delayed graft 
function, a reduced incidence of acute rejection episodes and an improvement of long-term 
graft survival (10-13). Usually, dopamine is given to the donor because of hemodynamic 
instability, but the beneficial effect of dopamine on transplantation outcome is independent of 
blood pressure stabilization. Recent studies from our group have demonstrated that dopamine 
can protect cells and tissues against cold preservation injury, which might explain, at least 
partially, the salutary effect of donor dopamine usage (14, 15).  
Although different organs can withstand different time periods of cold ischemia before 
significant damage occurs, in general tissue damage increases, and hence organ quality 
deteriorates, with increasing cold ischemia time (3, 4, 14). As an example, cold ischemia time 
longer than 8-10 hrs for heart and lung allografts is considered to be undesirable while for 
renal allografts cold ischemia time is usually longer (3, 4, 16). One of the clinical 
complications of organ allografts that have been subjected to prolonged cold ischemia time is 
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the loss of the endothelial barrier function (17-20). In vitro dopamine can not completely 
prevent endothelial barrier dysfunction during cold preservation. Nevertheless, this treatment 
restores barrier function rapidly upon rewarming (15). 
In Chapter 2, we employed a rat model to test the hypothesis that dopamine treatment 
ameliorates tissue damage associated with hypothermic preservation and reperfusion of lung 
allografts. As tissue oedema is a consequence of barrier dysfunction, resulting in an increase 
in lung weight and an increase in pulmonary arterial and inspiratory pressure (21), we used 
these parameters as read out for barrier dysfunction and assessed the effect of different time 
periods of cold storage followed by reperfusion in an isolated ventilated and perfused lung 
model. In line with our previous in vitro findings (15), this study showed that a cold 
preservation time longer than 6 hrs resulted in profound oedema formation. Dopamine pre-
treatment significantly inhibited oedema formation as was reflected by a decrease in peak 
inspiratory pressure (PIP), pulmonary arterial pressure (PAP) and lung weight compared to 
lungs obtained from untreated rats. These findings have also been reported for human lung 
allografts that were not suitable for transplantation (22). In addition, dopamine pre-treatment 
significantly abrogated CINC-1 production, the upregulation of adhesion molecules during 
reperfusion was likewise inhibited. Since pulmonary oedema largely contributes to poor lung 
function after transplantation (23), implementation of donor dopamine in donor management 
might be considered even in hemodynamic stable donors. Our group finished recently a 
prospective randomized multi-centre study on the beneficial effect of donor dopamine usage in 
hemodynamic stable donors on delayed graft function after renal transplantation. Analysis of the 
data revealed that dopamine treatment significantly reduced the risk for delayed graft function, 
this effect was more pronounced when cold ischemia time was long. Whether other organ 
allografts also have been benefited from dopamine is currently being investigated in this study. 
It also remains to be addressed if the effect of dopamine in the isolated and ventilated lung model 
was receptor mediated or not. Several studies have indicated that the Na/K ATPase plays an 
important role in fluid handling in lungs. Stimulation of β-adrenergic receptors activates the 
Na/K ATPase (24). Therefore, unlike in the in vitro studies, the effect of dopamine might be 
receptor-mediated. Further studies are required to elucidate this issue.  
In order to understand the beneficial effect of dopamine on cold preservation injury, in 
Chapter 3, we employed an in vitro model and investigated the changes in intracellular ATP 
concentration, redox balance and Ca2+ homeostasis during hypothermic preservation and how 
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this was influenced by dopamine pre-treatment. Our study demonstrated that increased 
oxidative stress, reflected by the occurrence of a redox imbalance, changes in Ca2+ 
homeostasis and depletion of intracellular ATP are major cellular events that are associated 
with hypothermic preservation. As demonstrated previously, dopamine pre-treatment renders 
endothelial cells transient resistance to hypothermia-induced damage. Dopamine pre-
treatment furthermore prevents the occurrence of a redox imbalance and mitochondrial [Ca2+] 
overload. Also ATP depletion is retarded during cold preservation in dopamine treated 
endothelial cells. Based on the results, we postulate that mitochondrial [Ca2+] overload is a 
key event in cold preservation injury and that perhaps prevention of this by dopamine might 
explain the protective effect of dopamine. As the protective effect of dopamine is strictly 
redox-dependent, we must assume that the increase in intracellular [Ca2+] during hypothermic 
preservation is initiated by a redox imbalance. It has been demonstrated in other studies that 
depletion of glutathione (GSH) activates ryanodin receptors in the endoplasmic reticulum and 
consequently Ca2+ is released from intracellular stores (25, 26). Subsequently activation of 
store-operated calcium channels will result in an influx of Ca2+ from the extracellular milieu 
(27-29). This sequel of evens is compatible with two important observations described in 
Chapter 3: firstly dopamine prevents depletion of SH reduction equivalents, and secondly 
depletion of Ca2+ from the intracellular stores by thapsigargin treatment can overcome the 
protective effect of dopamine. However, the release of Ca2+ from the intracellular stores is not 
sufficient to drive cell death, because thapsigargin treatment can not overcome the protective 
effect of EDTA. The reason why ATP is depleted much faster in untreated endothelial cells 
might be the consequence of ATP exhaustion to maintain Ca2+ homeostasis or might be the 
result of cell leakage.  
This study did not address why depletion of SH reduction equivalents occurred during cold 
preservation. However, as deferoxamine (30, 31) or HO-1 over-expression (32) have shown 
to be also protective during cold preservation, we postulate that an increase in the chelatable 
intracellular iron pool (30) might give rise to hydroxyl radicals by Fenton chemistry. These 
radicals, in turn might convert GSH to GSSG. In the presence of intracellular dopamine, the 
hydroxyl groups of the catechol moiety of dopamine can scavenge hydroxyl radicals and thus 
prevent oxidation of GSH.   
 Inasmuch as our study indicates that prevention of a Ca2+ influx during cold preservation 
might be beneficial, it does not imply that Ca2+ should be completely omitted from 
Chapter 9: General discussion 
 
 159
preservation solutions. Omission of Ca2+ from the extracellular milieu can lead to opening of 
unselective cation channels and hence to membrane depolarization (33, 34). In fact, addition 
of small amounts of Ca2+ to preservation solutions has proven to be more protective in 
experimental liver transplantation (33, 34).  
If we appreciate that dopamine can prevent intracellular Ca2+ accumulation in a redox-
dependent manner, the next question to be addressed is then what are the structural 
requirements for dopamine to be protective. Since we already have demonstrated that the 
protective effect of dopamine is not receptor-mediated, occurs relatively fast, is not specific 
for dopamine but also holds true for other dihydroxyphenolic compounds and does not require 
de novo protein synthesis (14, 15), we postulated that structural entities within these 
compounds mediate protection. Further studies to elucidate the structure-function relationship 
with respect to protection against cold preservation damage are described in Chapter 4. In 
this study we analysed the protective potency of a series of related compounds that either 
differ in their relative hydrophobicity or in the position of the dihydroxyl groups. We could 
demonstrate that the relative hydrophobicity, expressed as LogP value, tightly correlates with 
the efficacy of protection. The importance of the relative hydrophobicity is that it facilitates 
cellular uptake. However, hydrophobicity alone is not sufficient to mediate protection, 
because protection also requires reducing substituents on the benzene ring. This is 
emphasized by the fact that only ortho- or para- positioned hydroxyl groups on the bezene 
ring will yield protective compounds. Meta-dihyroxybenzene or benzoic acids do not convey 
protection even when the hydrophobicity was increased by covalent coupling of a fatty acid. 
Ortho- and para-dihydroxybenzenes are known to be strong reducing agents due to the ease of 
quinone formation, while the meta-dihydroxyl derivatives have no radical scavenging 
potential since oxidation of the hydroxyl groups does not occur under normal conditions.  
 
These two structural entities found in our study together with the data presented in Chapter 3 
may promote the understanding of the mechanisms involved in preservation injury of organ 
allografts and might eventually lead to the use of more effective compounds for organ 
preservation that are devoid of hemodynamic action. Since acylated dopamine derivatives and 
alkyl dihydroxybenzamides have been demonstrated to be anti-inflammatory agents (35, 36), 
clinical application of these compounds seems to be a promising strategy not only for 
prevention of pre-transplantation injury in donor organs but also to ameliorate inflammation 
after transplantation. 
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During cold preservation degradation of cytosolic proteins has been reported (15, 37). 
Proteolysis is generally mediated by activation of a variety of enzymes. This might occur as a 
consequence of ATP depletion and an increase in cytosolic calcium. In particular, activation 
of the Ca2+-dependent proteases, i.e. calpains, seems to be corollary to the imbalance in 
intracellular calcium homeostasis during cold storage (38, 39). The ubiquitin proteasome 
system (UPS) (40) and caspases (41) might be equally involved in proteolysis during cold 
preservation. In Chapter 5, we investigated to what extent cold storage changes the cellular 
proteome and if activation of these proteolytic pathways occurred in HUVEC during cold 
storage. Our findings demonstrated that indeed activation of the calpain pathway and the 
ubiquitin proteasome system occurs under cold preservation conditions. In dopamine pre-
treated cells activation of the calpain pathway did not occur, however, ubiquintination was not 
influenced by dopamine. Neither proteasome inhibitors nor an inhibitor of calpain 1 were able 
to prevent cell death during hypothermic preservation. These data thus suggest that although 
proteolysis might occur during cold preservation, inhibition of single proteolytic pathways is 
not effective to prevent cell death during cold storage. It must be noted, that inhibition of 
multiple proteolytic pathways was not tested in this study.   
 
According to danger hypothesis, tissue injury of allografts is not only recognized in the 
recipient by the immune system, but also evokes immune activation (42). Hypothermic 
preservation induces cell necrosis and tissue damage in a time-dependent fashion (14, 43). 
Nevertheless it is not yet clear how hypothermic preservation might cause immune activation. 
In Chapter 6, we therefore investigated if soluble factors were released upon hypothermic 
preservation that might signal to the innate immune system. We focussed on HMGB1 and 
adenosine, two important molecules known to modulate innate immunity (44-47). We showed 
that expression of HMGB1 is completely lost in endothelial cells subjected to cold 
preservation, but not when the cells were rendered resistant by dopamine pre-treatment. 
HMGB1 was bioactive, indicated by the findings that supernatants of damage cells were able 
to upregulate the expression of adhesion molecules and the production of IL-8 in an HMGB1-
dependent fashion. However, the unexpected finding that the same supernatants were also 
able to downregulate TNF-α production in LPS stimulated whole blood assays suggested that 
other factors were likely present. Subsequent experiments revealed that adenosine is also 
released during hypothermic preservation and that adenosine was responsible for the 
inhibitory effect on TNF-α production. While the release of HMGB1 only occurred in 
damaged cells, the release of adenosine was independent of cell damage. Because adenosine 
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not only modulates innate immunity but also improves endothelial barrier function (48, 49), 
adequate donor treatment might thus prevent the release of HMGB1 but might preserve the 
action of adenosine on the endothelium.  
 
Because HMGB1 and adenosine are released during cold preservation and organ allografts are 
flushed before implantation, it can be argued that these in vitro findings have no relevance for 
organ transplantation. Endothelial cells express the receptor for advanced glycation end-
products RAGE (50), a putative receptor for HMGB1, which might already bind its ligand 
during cold preservation. Subsequent warm reperfusion then can cause receptor activation 
leading to phenotypic and functional changes in endothelial cells. The relevance of adenosine 
release during hypotherimia is indeed questionable as adenosine is added to some 
preservation solutions, e.g. UW.  
 
Leukocyte extravasation, as occurring during inflammation, is a highly regulated process in 
which adhesion molecules expressed on the endothelial cell-surface interact with their ligands 
on leukocytes (51). In addition, leukocytes are recruited to the sites of inflammation via 
endothelial production of chemokines. Up-regulation of these inflammatory mediators 
facilitates leukocyte migration and subsquently amplifies inflammation (52). Understanding 
of the mechanisms that control inflammation are of utmost importance to identify putative 
targets for the development of anti-inflammatory drugs. In recent years, a new class of 
molecules, termed carbon monoxide releasing molecules (CORM), has been described that 
are capable of liberating CO under appropriate conditions. In particular, CORM-3 
[tricarbonylchloro(glyconato)ruthenium(II)] and CORM-A1 (sodium boranocarbonate), 
which both are fully water-soluble, rapidly liberate CO when dissolved in physiological 
solutions (53). In Chapter 7, we studied how CORM-3 modulates the expression of adhesion 
molecules on endothelial cells and if HO-1 mediated-perpetuation was involved. Our results 
showed that CORM-3 consistently inhibited the upregulation of VCAM-1 and E-selectin on 
TNF-α stimulated HUVEC, partly due to the deactivation of NFκB. Interestingly, down-
regulation of VCAM-1 and E-selectin expression by CORM-3 even occurred when CORM-3 
was added 24 hrs after TNF-α stimulation. Sustained expression of VCAM-1 required the 
continuous presence of TNF-α. TNF-α removal was more effective in the reduction of 
VCAM-1 mRNA level, but VCAM-1 protein was down-regulated more rapidly when CORM-
3 was added compared to TNF-α removal. This suggests that the modulation of VCAM-1 by 
CORM-3 most likely also occurred post-transcriptionally. CORM-3 itself up-regulated HO-1 
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in an Nrf2 dependent fashion, however, HO-1 expression did not significantly contribute to 
the effect by CORM-3. Neither in HO-1- nor in Nrf2-siRNA treated HUVEC the efficacy of 
CORM-3 to down-regulate VCAM-1 expression was lost.  
 
As discussed already, prolonged cold ischemia is significantly associated with initial organ 
non-function and late transplant loss (54, 55). Chronic transplant vasculopathy remains a 
leading cause for chronic organ loss after transplantation (54, 56). Intimal hyperplasia and 
arterial obliteration are prominent features of chronic vasculopathy. In Chapter 8, we 
investigated the beneficial effect of CORM-3 on hypothermia-induced injury in HUVECs and 
its influence on vascular remodelling and vascular function in syngeneic rat aorta 
transplantation model. Our data showed that CORM-3 protected endothelial cells against 
hypothermia-mediated injury via liberation of CO. Cold storage induced endothelial 
denudation and intercellular gap formation in isolated rat abdomen aortas, while this was 
prevented when CORM-3 was added to the preservation solution. Similarly, vascular function 
was significantly impaired after 24 hrs of cold storage. This was largely due to impairment of 
endothelia-mediated NO production, since the relaxation response by addition of SNP was not 
affected after cold storage. In line with the observation that CORM-3 prevented endothelial 
denudation, we could demonstrate that addition of CORM-3 during cold storage also better 
preserved vascular function. Two months after aorta transplantation in syngeneic rats, neo-
intima was significantly increased in aortas that were subjected to 24 hrs of cold preservation. 
When CORM-3 was added during preservation, neo-intima formation was significantly 
abrogated.  
 
9.2 Conclusions and future perspectives 
 
Based on the finding that kidney transplants from unrelated living donors are performing 
exceedingly well despite poor HLA compatibility (57), the concept of pre-transplantation 
tissue injury as an important risk factor for long-term allograft survival has been more 
appreciated in recent years. Since cold preservation tissue damage is a major cause of pre-
transplantation injury, prevention of this type of damage is regarded as an effective approach 
to improve transplantation outcome (3-5). Damage of the vascular endothelium is a prominent 
feature of cold ischemia (58). This may facilitate inflammation through the release of 
HMGB1 and through impairment of the endothelial barrier function.  
Chapter 9: General discussion 
 
 163
To meet the growing demand of organ allografts and relative stable supply of cadaveric organ 
donors, the use of organs from so called “marginal” donors has increased dramatically. Yet, 
organs obtained from these donors might be more susceptible to cold preservation injury, 
resulting in a higher rate of delayed graft function (59) and possibly in a decrease in allograft-
survival (60). Therefore better ways to preserve organs, or as suggested from the data 
presented in this thesis, new strategies to prevent cold preservation injury are warranted.  
 
Although in the past dopamine has been frequently used in hemodynamic instable donors, in 
more recent years dopamine has been largely abandoned at the ICU because the beneficial 
effect of dopamine on renal function could not be demonstrated (61). However, our recently 
finished prospective randomized multi-centre study, together with the data presented in this 
thesis strongly favors the use of dopamine in donor management. Nevertheless, the question 
whether we should use hemodynamic active compounds to achieve a better organ quality after 
prolonged preservation is genuine and deserves more attention. Since the beneficial effect of 
dopamine on cold preservation injury is independent of its hemodynamic action, the use of 
dopamine-like compounds that are devoid of blood pressure stabilizing effects, e.g. n-
octanoyl-doapmine (NOD) would be more appropriate in hemodynamic stable donors. Also in 
non heart beating donors, the use of positive inotropic agents is not desirable. Renal allografts 
from these donors are more prone to develop delayed graft function after transplantation.  
 
Inasmuch as our in vitro data suggest that the use of NOD as donor pre-conditioning strategy 
might be more favorable than dopamine, the hydrophobic character of NOD makes its 
application more difficult. Ways to deliver NOD to donor organs are therefore of equal 
importance in future research. One possible strategy to overcome this problem is the use of 
so-called semifluorinate alkanes (SFA) emulsions. SFA’s are clinically used in eye surgery as 
temporal tamponade. Interestingly they have the propensity to act as solvent for a number of 
hydrophobic agents (62). Preliminary data from our group indicate that NOD can be dissolved 
in SFA without losing its protective effect on cold preservation injury in vitro (unpublished 
data). Moreover SFA emulsions have anti-inflammatory properties as they inhibit TNF-α 
production in whole blood assays. We could also demonstrate in a model of warm ischemia-
mediated acute renal failure that intravenous application of these emulsions significantly 
inhibited the rise in serum creatinine and that recovery of renal function was much faster 
when SFA’s were applied prior to ischemia (unpublished data). 
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Maintaining good organ quality during cold preservation can also be achieved by addition of 
CORM to the preservation solution. We have not studied the efficacy of this approach in 
vascularized organs, and thus the conclusions reach in this study must be interpreted with 
some pre-caution. 
 
In conclusion, this thesis demonstrates the detrimental influence of cold preservation and 
unveils some of the processes that might be involved in cell damage. Moreover this thesis 
provides experimental evidence on how to prevent this type of injury. In the light of the 
increasing shortage of cadaveric donors, attempts should be made in future research to keep 
transplant recipients from re-entering the waiting list as long as possible. Because chronic 
transplant loss is partly attributable to prolonged cold ischemia time, either logistical change 
to reduce cold ischemia time, i.e. local donors for local patients, or donor pre-conditioning to 

























1. Novitzky D. Selection and management of cardiac allograft donors. Curr Opin Cardiol. 11:174-182, 1996 
2. Shivalkar B, van Loon J, Wieland W, Tjandra-Mage TB, Borgers M, Plets C, Flameng W. Variable effects 
of explosive or gradual increase of intracranial pressure on myocardial structure and function. Circulation 
1993; 87:230-239,  
3. Salahudeen AK, Haider N, May W. Cold ischemia and the reduced long-term survival of cadaveric renal 
allografts. Kidney Int. 2004; 65:713-8 
4. Salahudeen AK. Consequences of cold ischemic injury of kidneys in clinical transplantation. J Investig 
Med. 2004; 52:296-8 
5. Kieran NE, Rabb H. Immune responses in kidney preservation and reperfusion injury. J Investig Med. 2004; 
52:310-4 
6. Entman ML, Smith CW. Postreperfusion inflammation: a model for reaction to injury in cardiovascular 
disease. Cardiovasc Res. 1994; 28:1301-1311  
7. Fabre JW. The role of polymorphic donor peptides in allograft recognition and rejection.  Immunol Rev. 
1996; 154:21-43 
8. Lefer AM. Role of selectins in myocardial ischemia-reperfusion injury. Ann Thorac Surg. 1995; 60:773-
777 
9. Paller MS. The cell biology of reperfusion injury in the kidney. J Investig Med. 1995; 42:632-639  
10. Schnuelle P, Berger S, de Boer J, Persijn G, van der Woude FJ. Effects of catecholamine application to 
brain dead donors on graft survival in solid organ transplantation. Transplantation 2001; 72:455-463 
11. Schnuelle P, Lorenz D, Mueller A, Trede M, van der Woude FJ. Donor catecholamine use reduces acute 
allograft rejection and improves graft survival after cadaveric renal transplantation. Kidney Int 1999; 
56:738-746 
12. Goettmann U, Notheisen A, Brinkkoetter PT, Yard BA, Waldherr R, schnuelle P, van der Woude FJ, Braun 
C. Influence of donor pre-treatment with dopamine on allogeneic kidney transplantation after prolonged 
cold storage in rats. Transplantation 2005; 79:1344-1350  
13. Schnuelle P, Yard BA, Braun C, Dominguez-Fernandez E, Schaub M, Birck R, Sturm J, Post S, van der 
Woude FJ. Impact of donor dopamine on immediate graft function after kidney transplantation. Am J 
Transplant. 2004; 4:419-426  
14. Yard B, Beck G, Schnuelle P et al. Prevention of cold-preservation injury of cultured endothelial cells by 
catecholamines and related compounds. Am J Transplant 2004; 4:22-30  
15. Brinkkoetter PT, Beck GC, Goettmann U et al. Hypothemia-induced loss of endothelial barrier function is 
restored after dopamine pre-treatment: role of p42/p44 activation. Transplantation 2006; 82:534-542 
16. De Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia-reperfusion-induced lung injury. Am J Respir 
Crit Care Med. 2003; 167 (4): 490-511. 
17. Hidalgo MA, Shah KA, Fuller BJ et al. Cold ischemia-induced damage to vascular endothelium results in 
permeability alterations in transplanted lungs. J Thorac Cardiovasc Surg 1996;112:1027 
18. Carbognani P, Spaggiari L, Rusca M et al. Pulmonary endothelial cell modifications after cold storage in 
solid organ preservation solutions. J Int Med Res 1995; 23: 200-206 
19. Pickford MA, Manek S, Green CJ et al. The pathology of rat lung isografts following 48 or 72-hour cold 
storage and subsequent reperfusion in vivo for up to 1 month. Int J Exp Pathol 1992; 73: 685-697 
20. Hall SM, Odom N, McGregor CG, et al. Transient ultrastructural injury and repair of pulmonary capillaries 
in transplantated rat lung: effect of preservation and reperfusion. Am J Respir Cell Mol Biol 1992; 7:49 
21. Wang LS, Yoshikawa K, Miyoshi A et al. The effect of ischemic time and temperature on lung preservation 
in a simple ex vivo rabbit model used for functional assessment. J Thorac Cardiovasc Surg 1989; 98: 333-
342 
22. Ware LB, Fang X, Wang Y, Sakuma T, Hall TS, Matthay MA. Selected contribution: mechanisms that may 
stimulate the resolution of alveolar oedema in the transplantated human lung. J Appl Physiol 2002; 
93(5):1869-1874. 
23. McCowin M, Hall TS, Babcock W, Solinger LL, Hall KW, Jablons D. The impact of changes in 
radiographic abnormalities in organ donors on successful lung donation. J Heart Lung transplant 2001; 
20(2):242-243 
24. Scheid CR, Honeyman TW, Fay FS. Mechanism of beta-adrenergic relaxation of smooth muscle. Nature 
1979; Jan 4;277(5691):32-6. 
25. Pessah IN. Ryanodine receptor acts as a sensor for redox stress. Pest Manag Sci 2001; 57: 941-5 
26. Koshita M, Miwa K, Oba T.  Sulfhydryl oxidation induces calcium release from fragmented sarcoplasmic 
reticulum even in the presence of glutathione. Experientia. 1993; 49(4):282-4 
27. Groschner K, Hingel S, Lintschinger B, Balzer M, Romanin C, Zhu X, Schreibmayer W. Trp proteins form 
store-operated cation channels in human vascular endothelial cells. FEBS Lett. 1998; 437(1-2):101-6 
Chapter 9: General discussion 
 
 166
28. Harder DR: Ca-induced Ca release: lessons regarding cell models. Am J Physiol Heart Circ Physiol 2004; 
287: H1885-1886 
29. Sparagna GC, Gunter KK, Sheu SS, Gunter TE: Mitochondrial calcium uptake from physiological-type 
pulses of calcium. A description of the rapid uptake mode. J Biol Chem 1995; 270: 27510-27515 
30. Kerkweg U, Li T, de Groot H, Rauen U: Cold-induced apoptosis of rat liver cells in University of 
Wisconsin solution: the central role of chelatable iron. Hepatology 2002; 35: 560-567 
31. Salahudeen AK: Cold ischemic injury of transplanted kidneys: new insights from experimental studies. Am 
J Physiol Renal Physiol 2004; 287: F181-187 
32. Sikorski EM, Hock T, Hill-Kapturczak N, Agarwal A. The story so far: Molecular regulation of the heme 
oxygenase-1 gene in renal injury. Am J Physiol Renal Physiol 2004; 286: F425-441 
33. Ben Abdennebi, H. et al. A preservation solution with polyethylene glycol and calcium: a possible 
multiorgan liquid. Transpl Int 2002; 15: 348-354 
34. Dutkowski, P. et al. Calcium prevents loss of glutathione and reduces oxidative stress upon reperfusion in 
the perfused liver. Int J Surg Investig 2000; 2: 1-7 
35. Loomans, M. E., Janusz, J. M. & Buckwalter, B. (1986) GB 2168976 
36. Takita, H., Noda, S., Mukaida, Y., Inada, K., Toji, M., Kimura, F., Nitta, T., Watanabe, K., Umekawa, K. 
& Kobayashi, H. (1985) EP 0142241 
37. Charrueau C, Blonde-Cynober F, Coudray-lucas C et al. Prevention of proteolysis in cold-stored rat liver by 
addition of amino acids to the preservation solution. J Gastroenterol Hepatol 2000; 15: 1199-204 
38. Kohli V, Gao W, Camargo CA, Jr., Clavien PA. Calpain is a mediator of preservation-reperfusion injury in 
rat liver transplantation. Proc Natl Acad Sci U S A 1997; 94 (17): 9354 
39. Goll DE, Thompson VF, Li H, Wei W, Cong J. The Calpain System. Physiol Rev 2003; 83: 731 
40. Majetschak M, Patel MB, Sorell LT, Liotta C, Li S, Pham SM. Cardiac proteasome dysfunction during cold 
ischemic storage and reperfusion in a murine heart transplantation model. Biochem Biophys Res Commun 
2008; 365(4):882-8 
41. Jani A, Ljubanovic D, Faubel S, Kim J, Mischak R, Edelstein CL. Caspase inhibition prevents the increase 
in caspase-3, -2, -8 and -9 activity and apoptosis in the cold ischemic mouse kidney. Am J Transplant 2004; 
4: 1246-54 
42. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12:991-1045 
43. Bartels-Stringer M, Kramers C, Wetzels JF, Russel FG, Groot H, Rauen U. Hypothermia causes a marked 
injury to rat proximal tubular cells that is aggravated by all currently used preservation solutions. 
Cryobiology 2003; 47:82-91 
44. Mueller S, Scaffidi P, Degryse B et al, New EMBO member’s review: the double life of HMGB1 
chromatin protein: architectural factor and extracellular signal. EMBO J 2001; 20:4337-40 
45. Dumitriu IE, BarauH P, Manfredi AA, Bianchi ME, Rovere-Querini P. HMGB1: guiding immunity from 
within. Trends Immunol 2005; 26:381-7 
46. Popovic PJ, DeMarco L, Lotze MT et al. High mobility group B1 protein suppresses the human 
plasmacytoid dendritic cell response to TLR9 agonists. J Immunol 2006; 177:8701-7  
47. Cronstein BN. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 1994; 76:5-13 
48. Eltzschig HK, Iba JC, Furuta GT, et al. Coordinated adenine nucleotide phosphohydrolysis and nucleoside 
signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med. 
2003; 198:783-96 
49. Eltzschig HK, Weissmuller T, Mager A, Eckle T. Nucleotide metabolism and cell-cell interactions. 
Methods Mol Biol. 2006; 341:73-87 
50. Wautier JL, Schmidt AM. Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 2004; Aug 
6;95(3):233-8 
51. Cines, D. B., E. S. Pollak, C. A. Buck et al. Endothelial cells in physiology and in the pathophysiology of 
vascular disorders. Blood 1998; 91: 3527-3561 
52. Rao, R. M., L. Yang, G. Garcia-Cardena, and F. W. Luscinskas. Endothelial–dependent mechanisms of 
leukocyte recruitment to the vascular wall. Circ Res 2007; 101: 234-247 
53. Alcaraz, M. J., M. I. Guillen, M. L. Ferrandiz, J. Megias, and R. Motterlini. Carbon monoxide-releasing 
molecules: a pharmacological expedient to counteract inflammation. Curr Pharm Des 2008; 14(5): 465-472 
54. Schnuelle P, Yard BA, Braun C, et al. Impact of donor dopamine on immediate graft function after kidney 
transplantation Am J Transplant 2004; 4: 419-26 
55. Gottmann U, Notheisen A, Brinkkoetter PT, et al. Influence of donor pretreatment with dopamine on 
allogeneic kidney transplantation after prolonged cold storage in rats. Transplantation 2005; 79 (10): 1344-
53 
56. Schnuelle P, Berger S, de Boer J, Persijn G, van der Woude FJ. Effects of catecholamine application to 
brain-dead donors on graft survival in solid organ transplantation. Transplantation 2001; 72: 455-63 
57. Terasaki PI, Gjertson D, Cecka JM, Takemoto S.Fit and match hypothesis for kidney transplantation. 
Transplantation 1996; 62:441-445 
Chapter 9: General discussion 
 
 167
58. Salahudeen AK. Cold ischemic injury of transplanted kidneys: new insights from experimental studies. Am 
J Physiol Renal Physiol 2004; 287: F181-187 
59. Nyhof E, Wiehl S, Steinhoff J, Krüger S, Mueller-Steinhardt M, Fricke L. Relationship between donor 
factors, immunogenic up-regulation, and outcome after kidney transplantation. Transplant Proc 2005; 
37:1605-7 
60. Parzanese I, Maccarone D, Caniglia L, Pisani F, Mazzotta C, Rizza V, Famulari A. Risk factors that can 
influence kidney transplant outcome. Transplant Proc 2006 38; 1022-3 
61. Day NP, Phu NH, Mai NT et al. Effects of dopamine and epinephrine infusions on renal hemodynamics in 
severe malaria and severe sepsis. Crit Care Med 2000; 28: 1353-62 
62. El Abed AI, Ionov R, Goldmann M. Structural and electric properties of two semifluorinated alkane 
monolayers compressed on top of a controlled hydrophobic monolayer substrate. Phys Rev E Stat Nonlin 





















































Nederlandse samenvatting  
 
Orgaantransplantatie neemt een steeds belangrijkere positie in bij de behandeling van 
terminaal orgaanfalen. Verbeteringen  van chirugische technieken, de introductie van nieuwe 
immuun supressive medicamenten alsmede de verbetering van orgaan preservatie hebben er 
toe geleid dat de transplantaat  overleving in de loop der jaren sterk verbeterd is. 
Desalnietemin is het chronische verlies van transplantaten nauwelijks afgenomen.  
 
Het merendeel van getransplanteerde organen zijn afkomstig van gestorven donoren. Deze 
hebben in vergelijking met organen van levende donoren het nadeel dat ze reeds voor 
implantatie mogelijk beschadigd zijn als gevolg van hersendood en preservatie.  De meest 
gebruikte orgaan preservatie methode vandaag de dag is de zogenaamde „static cold 
storage“ methode. Afhankelijk van de  koude preservatie tijd, neemt de kwaliteit van de 
organen af, hetgeen de functie na transplantatie negatief  beinvloedt.  
 
De studies die in dit proefschrift zijn beschreven houden zich bezig met de vraagstelling 
waarom een lange koude preservatie duur  leidt tot schade aan het endotheel, hoe deze schade 
vervolgens een ontstekings reactie  kan beinvloeden en hoe verschillende stoffen de schade 
aan het endotheel tijdens koude preservatie kunnen voorkomen. Daarbij zijn twee stoffen 
onderzocht, te weten dopamine en zogenaamde „carbon monoxide (CO) releasing molecules 
(CORM)“.  
 
De resultaten van deze studies laten zien dat bij een lange koude preservatie duur belangrijke 
intracellulaire systemen worden verstoord. Zowel dopamine als ook CORM kunnen deze 
verstoring gedeeltelijk voorkomen en het kwaliteitsverlies van organen tegen gaan. Daarnaast 
heeft CORM zogenaamde anti-inflammatoire eigenschappen, die ertoe kunnen bijdragen dat 
pathologische veranderingen in de bloedvaten na transplantie, zoals intima hyperplasie, 














Figure 4 Influence of dopamine treatment on ICAM expression. Rats were treated as 
described in Figure 1, with dopamine (A and C) or left untreated (B and D). Hereafter the 
lungs were directly reperfused and ventilated for 3 hr (A and B) or subjected to 8 hr of cold 
preservation before reperfusion and reventilation (3hr) was initiated. The results of a 
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Figure 5 Influence of dopamine treatment on tissue viability. Rats were treated with 
dopamine (A and C) or left untreated (B and D) as described in figure 1. The lungs were 
explanted and subjected to 8 hr of cold preservation. NADH staining of lung tissue was 
performed after 180 minutes of warm reperfusion. Note a more intensive NADH staining in 
dopamine treated lungs. The results of a representative experiment (n=5) is depicted. 


























































Figure 4 Ca2+ is accumulated in mitochondria during hypothermia.  HUVEC were 
incubated 2hrs prior to cold storage with 25µM DA or not. The cells were washed and 
labelled with Rhod-2 and Mitotracker-green directly before hypothermic preservation. 3hrs 
after initiation of hypothermia, the cells were analysed by confocal microscopy using the 
corresponding excitation and emission wave lengths. Specificity of Rhod-2 staining for 
mitochondrial Ca2+ was demonstrated by co-localization with Mitotracker-green and the 
absence of Rhod-2 staining when the cells were treated with CCCP to dissipate the 

























































Figure 1 HMGB1 expression in endothelial cells. Cultured HUVEC (upper two panels to the 
left) and freshly isolated PBMC (upper panel to the right) were stained for HMGB1 as 
described in the materials and methods section. Analysis of HMGB1 was performed by means 
of immune-fluorescence (upper panels to the left and to the right) and by confocal microscopy. 
Original magnification: 200x and 400x respectively. The lower panels show HMGB1 
expression in untreated HUVEC (to the right) and dopamine treated HUVEC (to the left after 
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Figure 2 Influence of CORM-3 on endothelial integrity in aorta segments subjected to cold 
preservation. Whole mount staining for CD31 (red) was performed as described in the 
Material and Method section. Nuclear staining is depicted in blue. Note that in the aorta 
segments subjected to cold preservation in the absence of CORM-3, endothelial cell 
morphology was irregular with intercellular gaps (bold arrows) appearing between adjacent 
endothelial cells. Also in the majority cells nuclear condensation and fragmentation (arrow) 
was observed (left panel). In contrast, aorta segments to which 50 µM of CORM-3 was added 
during cold preservation (middle panel) appeared to be similar to freshly isolated aorta 
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                                           B 
Figure 4 Addition of CORM-3 during cold preservation inhibits vascular remodeling.  (A) 
Syngeneic aorta transplantations were performed as described in the Materials and Methods 
section. The aortas were subjected to 24 hrs of cold preservation in the absence (CP) or 
presence (CP-CORM-3) of 50µM CORM-3. Two months after transplantation the grafts were 
harvested and macroscopically examined. Note the presence of fibrous tissue surrounding the 
graft (arrow) in the aortas subjected to cold preservation in the absence of CORM-3 (middle 
panel). This was not observed when 50 µM of CORM-3 was added during cold preservation 
(right panel). For comparison an aorta from a naïve non-transplanted rat is also depicted 
(left panel). (B) After macroscopic examination, the grafts were harvested and tissue sections 
were analysed by light microscopy using H&E staining. Representative photographs of 
transplanted grafts not subjected to cold preservation (No CP), subjected to cold preservation 
in the absence (CP) or presence of 50 µM of CORM-3 (CP-CORM-3) are depicted. Intimal 
hyperplasia is shown as the tissue in between the black arrows. Original magnification: 200x.
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